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Background: Most patients presenting with acute exacerbations of chronic obstructive pulmonary disease
(AECOPD) in primary care are prescribed antibiotics, but these may not be beneficial, and they can cause
side effects and increase the risk of subsequent resistant infections. Point-of-care tests (POCTs) could safely
reduce inappropriate antibiotic prescribing and antimicrobial resistance.
Objective: To determine whether or not the use of a C-reactive protein (CRP) POCT to guide prescribing
decisions for AECOPD reduces antibiotic consumption without having a negative impact on chronic
obstructive pulmonary disease (COPD) health status and is cost-effective.
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Design: A multicentre, parallel-arm, randomised controlled open trial with an embedded process, and a
health economic evaluation.
Setting: General practices in Wales and England. A UK NHS perspective was used for the economic analysis.
Participants: Adults (aged ≥ 40 years) with a primary care diagnosis of COPD, presenting with an
AECOPD (with at least one of increased dyspnoea, increased sputum volume and increased sputum
purulence) of between 24 hours’ and 21 days’ duration.
Intervention: CRP POCTs to guide antibiotic prescribing decisions for AECOPD, compared with usual care
(no CRP POCT), using remote online randomisation.
Main outcome measures: Patient-reported antibiotic consumption for AECOPD within 4 weeks post
randomisation and COPD health status as measured with the Clinical COPD Questionnaire (CCQ) at
2 weeks. For the economic evaluation, patient-reported resource use and the EuroQol-5 Dimensions
were included.
Results: In total, 653 participants were randomised from 86 general practices. Three withdrew consent and
one was randomised in error, leaving 324 participants in the usual-care arm and 325 participants in the CRP
POCT arm. Antibiotics were consumed for AECOPD by 212 out of 274 participants (77.4%) and 150 out of
263 participants (57.0%) in the usual-care and CRP POCT arm, respectively [adjusted odds ratio 0.31, 95%
confidence interval (CI) 0.20 to 0.47]. The CCQ analysis comprised 282 and 281 participants in the usual-care
and CRP POCT arms, respectively, and the adjusted mean CCQ score difference at 2 weeks was 0.19 points
(two-sided 90% CI –0.33 to –0.05 points). The upper limit of the CI did not contain the prespecified non-
inferiority margin of 0.3. The total cost from a NHS perspective at 4 weeks was £17.59 per patient higher in
the CRP POCT arm (95% CI –£34.80 to £69.98; p = 0.408). The mean incremental cost-effectiveness ratios
were £222 per 1% reduction in antibiotic consumption compared with usual care at 4 weeks and £15,251
per quality-adjusted life-year gained at 6 months with no significant changes in sensitivity analyses. Patients
and clinicians were generally supportive of including CRP POCT in the assessment of AECOPD.
Conclusions: A CRP POCT diagnostic strategy achieved meaningful reductions in patient-reported
antibiotic consumption without impairing COPD health status or increasing costs. There were no
associated harms and both patients and clinicians valued the diagnostic strategy.
Future work: Implementation studies that also build on our qualitative findings could help determine the
effect of this intervention over the longer term.
Trial registration: Current Controlled Trials ISRCTN24346473.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 15.
See the NIHR Journals Library website for further project information.
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Plain English summary
People with chronic obstructive pulmonary disease (COPD) often experience flare-ups known as acuteexacerbations of chronic obstructive pulmonary disease. Antibiotics are prescribed for most flare-ups,
but they do not always benefit patients and may cause harm, such as side effects or subsequent infections
that are resistant.
Rapid point-of-care tests (POCTs) can be used to help determine when antibiotics are more likely to be
needed. C-reactive protein (CRP) is a marker of inflammation that can be measured with a POCT. Patients
with flare-ups and a low CRP value are less likely to benefit from antibiotics. The PACE trial asked whether
or not measuring CRP with a POCT could lead to fewer antibiotics being consumed for flare-ups, without
having negative effects for patients.
We aimed to recruit 650 patients with a COPD flare-up from primary care. Patients were randomly
assigned to either (1) usual care with the addition of a CRP POCT, or (2) usual care without the addition
of the test. Antibiotic use over the first 4 weeks and patients’ self-assessment of their health 2 weeks
after enrolment were measured in both groups.
Patients in the CRP test group used fewer antibiotics than those managed as usual, and had improved
patient-reported outcomes. Costs were a little higher in the CRP POCT group. Interviews with patients
and clinicians found that they appreciated the CRP test being included in the decision-making process.
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Scientific summary
Background
Unnecessary antibiotic use drives antimicrobial resistance, wastes resources, may cause adverse effects
and may distract from potentially more effective interventions for individuals. Point-of-care tests (POCTs)
for acute infections are being promoted by government, by industry and in clinical guidelines to reduce
inappropriate antibiotic prescribing, help contain antimicrobial resistance and improve patient outcomes.
However, most evaluations of POCTs have examined analytic performance only, and there have been few
trials evaluating clinical effectiveness and cost-effectiveness in the context in which POCTs are intended to
be used. About 4.5% of the population over the age of 45 years live with diagnosed chronic obstructive
pulmonary disease (COPD), and about half of these people experience one or more acute exacerbations
of chronic obstructive pulmonary disease (AECOPD) that require medical treatment each year. Over 2 million
antibiotic courses are prescribed for AECOPD each year in the UK, and most of these are issued in primary
care. Although some patients with AECOPD are helped by these prescriptions, many are not, and so some
antibiotics may simply damage the microbiome. Among patients admitted to hospital, a bacterial aetiology
was identified in 30%, a viral agent was identified in 23%, both bacterial and viral agents were identified
in a further 25%, and 20% of the AECOPDs were caused by other factors. The antibiotic prescribing
recommendations for primary care management of AECOPD are generally based on clinical features alone
(Anthonisen criteria, namely increased breathlessness, increased sputum volume and increased sputum
purulence) (Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic
therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196–204).
These features are subjective and have insufficient diagnostic accuracy to predict which patients can safely
be managed without antibiotics.
C-reactive protein (CRP) is an acute phase protein that rises rapidly in infections and can be measured
easily at the point of care, and it is considered the most selective biomarker to confirm AECOPD.
A randomised controlled trial in primary care found no difference in clinical cure between patients
with AECOPD treated with antibiotics and those treated with placebo who had a CRP level of < 40 mg/l.
The availability of CRP POCT results may, therefore, help guide prescribing decisions for AECOPD to reduce
antibiotic consumption, reduce antimicrobial resistance and improve patient outcomes. However, the
clinical effectiveness and cost-effectiveness of CRP POCT have not yet been evaluated in a pragmatic
controlled trial in primary care.
Objective
We aimed to establish whether or not the addition of a CRP POCT to usual care for AECOPD in primary
care safely and cost-effectively reduces antibiotic consumption for AECOPD.
Methods
Trial design
The PACE (Primary care use of A C-reactive protein point-of-care test to help target antibiotic prescribing
to patients with acute Exacerbations of chronic obstructive pulmonary disease who are most likely to
benefit) trial was a multicentre, parallel-arm, individually randomised controlled open trial with embedded
health economics and qualitative process evaluations, conducted between September 2015 and
February 2017 in UK general medical practices.
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Intervention guidance
All participating sites were provided with information on the current best practice for managing AECOPD,
which included a brief summary of National Institute for Health and Care Excellence and the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guidance, and were provided with a desktop CRP POCT Afinion
device [Alere AfinionTM AS100 Analyzer, Alere Inc. (now Abbott Diagnostics), IL, USA]. Clinicians were given
training in the use of the POCT and guidance on interpreting the test results, which emphasised that the
decision about antibiotic prescribing should be based on a comprehensive assessment of the likely risks and
benefits, given the patient’s underlying health status and clinical features. In addition, the guidance indicated
that for patients with a CRP level of < 20 mg/l, antibiotics are unlikely to be beneficial and usually should not
be prescribed; for patients with a CRP level of 20–40mg/l, antibiotics may be beneficial, mainly if purulent
sputum is present; and for patients with a CRP level of > 40 mg/l, antibiotics are likely to be beneficial.
Eligibility, recruitment and randomisation
Men or women were eligible if they were aged ≥ 40 years, had a primary care diagnosis of COPD, presented
with an AECOPD (with at least one of increased dyspnoea, increased sputum volume and increased sputum
purulence) of between 24 hours’ and 21 days’ duration, and provided informed, written consent.
Participants were allocated to the trial arms using remote online computerised randomisation.
Data collection
Baseline data collected included the number of days the patient had AECOPD symptoms, the patient’s
medical history and clinicians’ examination findings.
A sputum sample, when obtainable, and throat swab samples were taken, and participants self-completed
the Clinical COPD Questionnaire (CCQ) and the EuroQol 5-Dimensions (EQ-5D) questionnaire prior to
randomisation. Clinicians recorded their antibiotic prescribing and other management decisions for all
participants after randomisation and assessment.
Participants were followed up with telephone calls at week 1 and week 2, and a face-to-face consultation
at 4 weeks post randomisation, during which a further throat swab and sputum sample (when available)
were taken. At 6 months, the Chronic Respiratory Disease Questionnaire Self-Administered Standardized
(CRQ-SAS) and EQ-5D questionnaires were posted to participants, who completed these and returned
them using provided stamped addressed envelopes, and we collected relevant data from electronic
medical records.
Clinicians were asked to carry out a CRP POCT as part of their assessment of participants allocated to the
intervention (CRP POCT arm). For patients allocated to usual care (control arm), clinicians were asked not
to use CRP POCT in their management of those patients’ AECOPD at any time during participation.
Outcome measures
We used two co-primary outcomes because any reduction in antibiotic consumption would have to
be considered alongside any negative impact on patient recovery. The first co-primary outcome was
patient-reported antibiotic consumption for AECOPD within 4 weeks post randomisation. The second
co-primary outcome was COPD health status (total score) measured with the CCQ at 2 weeks post
randomisation.
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Sample size
The study aimed to have sufficient power to detect a 15% reduction from an estimated 70% of patients
consuming antibiotics for AECOPD during the 4 weeks following randomisation, and sufficient power
to demonstrate that participants managed with the CRP POCT do no worse (non-inferior) than those
managed without the CRP POCT, in terms of their COPD health status measured with the CCQ 2 weeks
post randomisation. Assuming an expected difference between the arms of zero, a non-inferiority margin of
0.3 [smaller than the lowest minimal clinically important difference and a common standard deviation (SD)
of 1.1], based on a one-sided significance level of 0.05 and 90% power, the study needed 462 participants,
inflated to 580 to account for the loss to follow-up of approximately 20% of participants. It was also
anticipated that the outcomes would not be entirely independent. Therefore, we aimed to recruit at least
650 participants to maintain an overall power between 81% and 90%.
Clinical effectiveness and cost-effectiveness analyses
The main clinical effectiveness analysis was based on a modified intention-to-treat population, which
included all randomised participants who provided outcome data, regardless of protocol deviations or
intervention received. All planned analyses were described in detail in a statistical analysis plan.
A within-trial health economic analysis was undertaken from a UK NHS perspective that assessed CRP
POCT implementation costs in primary care and subsequent health-care costs within the trial follow-up
period of 6 months. A cost-effectiveness analysis based on the co-primary outcome of antibiotic
consumption at 4 weeks and a cost–utility analysis at 6 months were performed. Furthermore, a
cost–consequences analysis and a budget impact analysis were conducted and the robustness of the
results was tested in sensitivity analyses.
Process evaluation
A qualitative process evaluation was undertaken to facilitate the interpretation of results and assist with
implementation planning. Semistructured telephone interviews were carried out with 20 purposively
sampled patients and 20 primary care staff. A topic guide focused on experiences of the management of
AECOPD, the acceptability, implementation and potential mechanisms of the CRP POCT intervention and
contextual factors that could influence future implementation. Audio-recordings were transcribed verbatim
and analysed using framework analysis.
Results
Baseline characteristics
In total, 653 participants were randomised from 86 general practices between January 2015 and
February 2017. Three withdrew consent and one was randomised in error (the patient had been
randomised, but the clinician then noted that this patient was ineligible and so their baseline data were
destroyed), leaving 324 usual-care and 325 CRP POCT participants. The mean age was 68.1 (SD 9.42)
years; 51.6% of participants were men; 10.8% of participants had mild COPD (GOLD I), 54.8% of
participants had moderate COPD (GOLD II), 28.1% of participants had severe COPD (GOLD III) and
6.3% of participants had very severe COPD (GOLD IV); the mean ratio of forced expiratory volume in
1 second (FEV1) to forced vital capacity (FVC) was 0.6 (SD 0.13); the mean percentage predicted FEV1 was
59.8% (SD 20.04%); the mean number of days with symptoms prior to consultation was 6.9 (SD 5.13) days;
the mean baseline CCQ total score was 3.3 (SD 1.14) points; and the baseline health utility (EQ-5D) was
0.7 (SD 0.25). Overall, no pathogens were detected in 95 out of 386 baseline sputum samples (24.6%),
bacterial pathogens were only detected in 79 out of 386 (20.5%), viral/atypical pathogens were only
detected in 123 out of 386 cases (31.9%) and both bacterial and viral/atypical pathogens were detected
in 89 out of 386 cases (23.1%). Participants in both trial arms were well matched for these and other
characteristics at baseline.
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Primary outcome
In total, 537 out of the 649 randomised participants contributed to the primary analysis of self-reported
antibiotic consumption at 4 weeks post randomisation (82.7%), and 563 contributed to the primary
analysis of CCQ total score at 2 weeks post randomisation (86.7%). Antibiotics were consumed for
AECOPD by 212 (77.4%) usual-care participants and 150 (57.0%) CRP POCT participants [adjusted odds
ratio (AOR) 0.31, 95% confidence interval (CI) 0.20 to 0.47]. The adjusted mean CCQ score difference
at 2 weeks was –0.19 (two-sided 90% CI –0.33 to –0.05) points. The upper limit of the CI did not contain
the prespecified non-inferiority margin of 0.3.
Antibiotic prescribing at index consultation and 4-week follow-up
Antibiotic prescribing at the index consultation was ascertained for all but one participant, and 22% fewer
participants in the CRP POCT arm were prescribed antibiotics (47.7% in the usual-care arm vs. 69.7%
in the CRP POCT arm, AOR 0.31, 95% CI 0.21 to 0.45), and 21% fewer participants were prescribed
antibiotics over the 4-week follow-up (59.1% vs. 79.7%, AOR 0.30, 95% CI 0.20 to 0.46).
Antibiotic prescribing and C-reactive protein values at index consultation
A total of 97.5% (317/325) of participants allocated to the CRP POCT arm reported receiving a CRP
POCT during the recruitment consultation, and the median CRP value was 6 mg/l (interquartile range
5–18.5 mg/l); 76.0% of participants (241/317) had CRP levels of < 20 mg/l. Antibiotics were prescribed
for 33% of those patients with a CRP level of < 20 mg/l in the CRP POCT arm at the index consultation.
Secondary outcomes
There was no evidence of a difference between the arms regarding symptoms sometimes attributed as
adverse effects from antibiotics and other COPD treatments (AOR 0.79, 95% CI 0.44 to 1.39; p = 0.410),
primary or secondary care consultations during the 6 months following randomisation (AOR 1.39, 95% CI
0.46 to 4.15; p = 0.559), or pneumonia diagnoses at 4 weeks (AOR 1.57, 95% CI 0.28 to 8.84; p = 0.608)
and 6 months (AOR 0.73, 95% CI 0.29 to 1.82; p = 0.495). There was no evidence to conclude that there
were any differences between the arms for CRQ-SAS outcomes at 6 months.
No meaningful or statistically significant differences were found between the arms at 1 month in the
potential pathogens and antibiotic resistant isolates from sputum, or in resistance in commensal and
potentially pathogenic organisms isolated from throat swabs.
Adverse events
Two participants, both in the usual-care arm, died during the first 4 weeks following randomisation:
these serious adverse events were not related to the intervention or to trial participation.
Economic evaluation
Reduced antibiotic costs at the initial consultation were offset by higher total medication costs over the
following 6 months, mainly caused by a 5.4% increase in prescribing of inhaled medication in the CRP
POCT arm. COPD-related primary care contacts were lower in the intervention arm, with 2.7% fewer
general practitioner visits. Although outpatient attendances were reduced in the CRP POCT arm (4.1%
fewer appointments at 4 weeks and 6.7% fewer at 6 months), the secondary care cost for any condition
was higher for all follow-up periods as a result of increased inpatient length of stay for a small number of
intervention patients. The total incremental cost was £17.59 at 4 weeks and £126.26 at 6 months, driven
mainly by the higher inpatient cost and the cost of CRP testing. If only COPD-related health-care costs are
considered, the cost in both arms was similar, with the CRP test cost of £11.31 per test slightly offset by
savings in health-care resource use. The mean incremental cost-effectiveness ratios were £222 (95% CI
–£42.00 to £518.14) per 1% reduction in antibiotic consumption compared with usual care at 4 weeks
and £15,251 (95% CI £2959 to £22,813) per quality-adjusted life-year gained at 6 months. Patients in
the CRP POCT arm had fewer days off work, with reduced costs of productivity loss of £510.42 (95% CI
–£989.56 to –£31.28; p = 0.022) per patient reporting periods of worktime missed.
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Process evaluation
Patients participating in the qualitative evaluation felt that the CRP POCT was useful in detecting
infection and targeting treatment more appropriately, and that it seemed quick and easy to use. Clinicians
reported enhanced confidence in making management decisions and reduced decisional ambiguity
when withholding antibiotics, and felt that the CRP POCT was a useful tool for communicating with and
reassuring patients. They were keen to emphasise that the test should be used alongside, and not as a
replacement for, clinical assessment. Cartridge preparation time and the cost of the equipment presented
a significant barrier when implementing the test.
Conclusions
A CRP POCT diagnostic strategy resulted in a 20% absolute reduction in patient-reported antibiotic
consumption over 4 weeks and in clinician antibiotic prescribing at the index consultation, and no clinically
important change in patient-reported condition-specific quality of life, without evidence of an increase
in total COPD-related costs. The use of the CRP POCT strategy was broadly acceptable to patients and
clinicians. There were no associated harms identified in the trial, although clinicians indicated that the
time and costs associated with the CRP POCT needed careful consideration.
Awareness of receiving the POCT may have contributed to enhanced COPD health status; however,
this real-world effect needed to be captured. As awareness of intervention allocation may have an impact
on participant help-seeking, and, as capturing this is critical to assessments of cost-effectiveness, this was
an open trial.
C-reactive protein POCT strategies in primary care have been shown to safely and cost-effectively reduce
antibiotic prescribing for acute cough; however, only a small minority of participants in those studies had
AECOPD, and none reported effects on antibiotic consumption rather than antibiotic prescribing.
We confirmed that bacterial infection is a likely trigger for AECOPD in a minority of patients, and that
there may be potential for further safe reductions in antibiotic use for AECOPD, given that one-third of
participants with a CRP level of < 20 mg/l were nevertheless prescribed antibiotics.
This trial provides good evidence that CRP POCT testing (with the associated guidance for clinicians that
was used in this trial) to guide antibiotic prescribing decisions for AECOPD in primary care is safe and
effective. Further research, building on our qualitative findings, could help guide effective implementation.
Trial registration
This trial is registered as ISRCTN24346473.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment
programme and will be published in full in Health Technology Assessment; Vol. 24, No. 15. See the NIHR
Journals Library website for further project information.
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Chapter 1 Introduction
Background
Point-of-care tests (POCTs) for acute infections are being promoted by government, by industry and in
clinical guidelines to reduce inappropriate antibiotic prescribing, help contain antimicrobial resistance and
improve patient-reported outcomes.1–4 Whereas POCTs are frequently subjected to evaluations of analytic
performance, diagnostic strategies are often introduced into routine care before their clinical effectiveness
has been determined in rigorous clinical trials and without an understanding of their cost-effectiveness
using relevant health and service delivery outcomes.
Antibiotic use
Better targeting of antibiotics in acute exacerbations of chronic obstructive pulmonary disease (AECOPDs)
represents a major opportunity for antimicrobial stewardship and improved patient care. Over 80% of
all antibiotics are prescribed in the community,5 with high prescribing of broad-spectrum antibiotics a
particular concern. AECOPD accounts for over 2 million antibiotic prescriptions each year in the UK.6 Half
of patients with chronic obstructive pulmonary disease (COPD) experience one or more exacerbations
needing medical treatment each year.7,8 Over 70% of patients presenting with AECOPD in primary care
are prescribed an antibiotic, accounting for 4.6% of all primary care antibiotic prescriptions every year.9
COPD patients are an important group who are at risk of significant mortality, morbidity and hospitalisation
and, as such, are more likely to be prescribed broad-spectrum antibiotics.10 However, many AECOPD are
triggered by non-bacterial causes, such as viral infections and environmental factors including common
pollutants and weather. It has been estimated that approximately 70% of AECOPDs are triggered by an
infection and 30% are caused by environmental factors. Of the 70% that are triggered by an infection,
potential pathogenic bacteria are isolated in 20–58% of clinical samples, while pathogenic respiratory
viruses can be detected in approximately 50%.11–13 Among COPD patients hospitalised as a result of an
exacerbation, the causal infectious agents were identified as 29.7% bacterial, 23.4% viral and 25%
viral/bacterial.14
The overuse of antibiotics drives antimicrobial resistance15 and is facilitated by the unnecessary
consumption of antibiotics for COPD. Antimicrobial treatment in patients with COPD decreases the
infecting load but does not usually entirely eradicate organisms in the airways, increasing the risk of
resistant bacteria in COPD patients.16 Infections of antibiotic-resistant Streptococcus pneumoniae in
patients with COPD are associated with antibiotic exposure.17,18 A meta-analysis5 of seven studies of
respiratory tract bacteria that comprised 2605 participants showed that the pooled odds ratio for resistance
was 2.4 [95% confidence interval (CI) 1.4 to 3.9] and 2.4 (95% CI 1.3 to 4.5) within 2 and 12 months of
antibiotic treatment, respectively. The unnecessary use of antibiotics for AECOPD not only contributes to
the increasingly pressing public health threat of antibiotic resistance, but also poses a risk to the individual,
as it may increase the risk of subsequent antibiotic-resistant exacerbations and hasten disease progression.
The indiscriminate use of antibiotics in patients with COPD is particularly high risk because the respiratory
tracts of those affected are frequently colonised with potential pathogens.19 Using unnecessary antibiotics
also increases the risk of patient side effects, wastes money and undermines self-care.20
Current antibiotic prescribing recommendations for general practitioners (GPs) are generally based on
symptoms alone.21 In 1987, Anthonisen et al.22 defined three types of exacerbation based on the presence of
one, two or three of the following features: increased dyspnoea, increased sputum production and increased
sputum purulence. Exacerbations with all three of these features were defined as type 1 exacerbations,
those with two of these features were defined as type 2 exacerbations, and those with only one feature,
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in combination with an upper respiratory tract infection within the previous 5 days, a fever without another
cause, increased wheezing, increased cough or a > 20% increase in respiratory rate or heart rate compared
with baseline, were called type 3 exacerbations. Anthonisen et al.22 demonstrated an association between
these exacerbation types and benefit from antibiotics, and these features became widely adopted as a guide
to when to prescribe antibiotics. However, the features are subjective and are insufficiently diagnostically
accurate to enable clinicians to predict patients who can safely be managed without antibiotics. A Cochrane
systematic review23 of the use of antibiotics for managing exacerbations of COPD comprised 16 trials
(n = 2068 participants) and reported that there was insufficient evidence of effectiveness to guide antibiotic
prescribing decisions in primary care. Our placebo controlled trial of antibiotics for AECOPD in primary care
indicated that benefit from antibiotics for AECOPD was limited largely to those who had a raised C-reactive
protein (CRP) level (CRP level refers to CRP concentration measured in serum).24 More effective strategies
are required to ensure that antibiotics are used most effectively for managing AECOPD, so that antibiotic
treatment can be targeted at those most likely to benefit and effective non-antibiotic treatment can be
targeted at those who are unlikely to benefit from antibiotics.
C-reactive protein
C-reactive protein is an acute-phase protein found in blood. The serum level of CRP increases rapidly
during infections, particularly in severe bacterial infections. A prospective evaluation of 36 biomarkers25
found that CRP level was the most selective biomarker to confirm an AECOPD and, in combination with
Anthonisen criteria, produced an area under the curve of 0.88 (95% CI 0.82 to 0.93), indicating that the
biomarker had good diagnostic accuracy. High levels of serum CRP is correlated with sputum purulence
and raised serum leucocyte counts, and the serum level of CRP is higher in the presence of bacterial
infection.24,26 CRP levels rise in patients with AECOPD and is correlated with the number of Anthonisen
criteria present and the degree of airflow limitation in hospitalised patients.27,28 As CRP levels are more
likely to be raised when there is bacterial infection, the treatment effect of antibiotics increases with higher
values of CRP.29
In our previous study30 examining predictors of treatment with antibiotics and systemic corticosteroids
for acute exacerbations of asthma and COPD, we found that > 50% of COPD patients experiencing
an AECOPD had a CRP level of < 8 mg/l, and that chest examination findings, a raised CRP value and
decreased oxygen saturation were stronger predictors of prescribing antibiotics and systemic corticosteroids
than respiratory symptoms. We found marginal benefit from antibiotic treatment in patients with AECOPD
who had only one or two Anthonisen criteria, and using Anthonisen criteria to predict benefit from
antibiotic treatment produced an area under the curve of 0.708 (95% CI 0.616 to 0.801). Adding CRP
increased this to an area under the curve of 0.842 (95% CI 0.760 to 0.924).31 Based on these data, we
anticipated that using a CRP test alongside clinical assessment might make it possible to safely reduce the
antibiotic prescription rate for this condition to around 45%.
C-reactive protein POCTs are widely available and are already commonly used to help guide antibiotic
prescribing decisions, including for lower respiratory tract infections (LRTIs) and AECOPD in primary care in
a number of European countries (mostly Scandinavian).32 In two trials33,34 evaluating the use of a CRP POCT
to help target antibiotic treatment for LRTIs in primary care, antibiotics were prescribed to 53% and 48%
of patients in each trial’s usual-care group, respectively, and to 31% and 33% of patients managed by
clinicians using a CRP POCT (with training). However, only small numbers had COPD (< 10% in one study33
and < 20% with asthma or COPD in the other34). CRP POCT was cost-effective in reducing antibiotic
prescribing for LRTIs when there was no or low willingness to pay for the tests.35,36 Now that better and
more rapid CRP POCTs are available,37 there is potential for this technology to be widely used for a variety
of acute infections in primary care to better guide antibiotic prescribing and, in doing so, to help reduce
unnecessary antibiotic consumption and thus contain antibiotic resistance.
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The PACE randomised controlled trial: overall aim
The clinical effectiveness and cost-effectiveness of using a CRP POCT in addition to usual clinical assessment
to guide antibiotic prescribing for AECOPD has not been evaluated in a well-powered, pragmatic, individually
randomised controlled trial (RCT) in primary care. The PACE (Primary care use of A C-reactive protein point
of care test to help target antibiotic prescribing to patients with acute Exacerbations of chronic obstructive
pulmonary disease who are most likely to benefit) trial, therefore, aimed to determine whether or not
using a CRP POCT in addition to usual care to guide prescribing decisions for AECOPD reduces antibiotic
consumption without having a negative impact on COPD health status.
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Chapter 2 Clinical effectiveness methods
Some material in this report has been reproduced from Bates et al.38 This article is distributed underthe terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated. No changes to the content of the material were made; sentences/
paragraphs were rephrased.
Summary of trial design
The PACE trial was a multicentre, parallel-arm, open, individually randomised (1 : 1) controlled trial of
the clinical effectiveness and cost-effectiveness of CRP POCT in addition to usual care to guide antibiotic
treatment decisions for AECOPD on safely reducing patient antibiotic consumption. The study involved
general practices that were part of primary care research networks in the UK. Participants presenting with
AECOPD to participating practices were randomised to clinical management based on usual care alone
(control arm) or to usual care with the addition of a CRP POCT (intervention arm) to guide antibiotic
prescribing. This was an open, pragmatic trial with no blinding of participants or clinicians, as we aimed
to assess the effects of the intervention in comparison with current usual practice.
Clinical effectiveness objectives
Primary objective
The primary objective was to determine whether or not the addition of a CRP POCT (with training on test
use and advice on interpretation) to usual care for managing AECOPD leads to a reduction in antibiotic
consumption for AECOPD without having a negative impact on COPD health status, compared with usual
care alone.
Secondary objectives
The secondary objectives were to assess the effect of using a CRP POCT for AECOPD in primary care on:
l all-cause antibiotic consumption during the first 4 weeks
l antibiotic prescribing at the index consultation
l use of other COPD treatments, including oral steroids, during the first 4 weeks
l primary and secondary care consultations [including out of hours, accident and emergency (A&E) visits
and hospitalisations] during the subsequent 6 months
l incidence of pneumonia during the first 4 weeks and from the 4-week follow-up to 6 months
l adverse effects from antibiotics and other medication prescribed for AECOPD during the first 4 weeks
l COPD health status, as measured using the Clinical COPD Questionnaire (CCQ), at weeks 1, 2 and 4
l health utility, as measured using the EuroQol 5-Dimensions (EQ-5D) at 1, 2 and 4 weeks and at 6 months
l disease-specific health-related quality of life (HRQoL) and Chronic Respiratory Disease Questionnaire
Self-Administered Standardized (CRQ-SAS) at 6 months
l prevalence of potentially pathogenic bacteria cultured from sputum at 4 weeks and the proportion of
bacteria that are resistant
l prevalence of commensal organisms cultured from throat swabs at 4 weeks and the proportion of bacteria
that are resistant.
Changes made to the objectives are outlined in Appendix 1, Table 30.
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The objectives of the qualitative process evaluation and the health economic evaluation are outlined in
Chapters 4 and 5, respectively.
Internal pilot
An internal pilot study was carried out in 15 general practices in Wales from January 2015 to August 2015.
The aim of the pilot study was to assess the recruitment potential, adherence to the intervention allocation
and the proportion of participants in whom both primary outcomes could be measured. The prespecified
criteria for the success of the internal pilot were at least 1.5 participants recruited per open site per month
(excluding the first 2 months), 80% of participants reporting receiving a finger-prick blood test concordant
with their allocated intervention arm, and 80% of recruited participants for whom we could ascertain both
components of the co-primary outcome. The pilot phase met these criteria, enabling progression to the main
study. In addition to monitoring recruitment against projected targets, a qualitative study was embedded
within the pilot phase to identify barriers to and facilitators of recruitment from the perspectives of primary
care staff (n = 9) and patients (n = 10), and to pilot the qualitative topic guides. The following changes were
made at the end of the pilot phase to facilitate recruitment:
l Patient information was streamlined, and clarification was provided on when to make an appointment
and on rescue packs.
l The inclusion criteria were modified slightly (see Appendix 1, Table 31).
l The baseline case report forms (CRFs) were simplified.
l Guidance was provided to practices on which tasks could be delegated to members of the primary care
team other than the treating clinician.
l Owing to the more sensitive instrument becoming available at the time, the EuroQol-5 Dimensions,
three-level version (EQ-5D-3L), used during the internal pilot, was replaced with the EuroQol-5
Dimensions, five-level version (EQ-5D-5L).
Participants
During the main study (September 2015–February 2017), a total of 96 general practices in England and
Wales were opened to recruitment at some point. Not all of these sites were able to recruit; not all were
open during the whole study period and some sites were closed and new sites opened.
Participants were eligible if they had had an AECOPD for at least 24 hours but no longer than 21 days
and did not meet any of the exclusion criteria, and they were recruited opportunistically while consulting
in routine primary care. The eligibility criteria used in the pilot phase (see Appendix 1, Table 32) were
modified slightly for the main trial (see Appendix 1, Table 33). The changes, which were made to facilitate
recruitment, are summarised in Table 31 (see Appendix 1).
Patients’ informed consent to participate in the trial was obtained by the responsible clinician or an
appropriately trained member of the practice team or a researcher. After this consent was obtained,
data and sample collection were undertaken before the participants were remotely randomised to either
the intervention or usual-care arm. Participant flow in the trial is summarised in Figure 1.
Trial interventions
Intervention arm (C-reactive protein point-of-care test)
Participants randomised to the intervention arm had a CRP POCT measurement to help guide initial
antibiotic prescribing decisions for their AECOPD. This was used in addition to usual clinical assessment.
Clinicians were asked to use the CRP POCT during all primary care AECOPD consultations that occurred
during the 4 weeks following randomisation for those participants randomised to the intervention arm.
CLINICAL EFFECTIVENESS METHODS
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Participating general practices were provided with a desktop CRP POCT Afinion device [Alere AfinionTM
AS100 Analyzer, Alere Inc. (now Abbott Diagnostics), IL, USA] and CRP cartridges, and trained to use the
device. This POCT required 1.5 µl of capillary blood (from a finger prick) and took < 4 minutes to provide a
quantitative result. Other validated CE (Conformité Européene)-marked POCT devices and CRP cartridges
giving a quantitative result within the range of the Alere Afinion POCT and requiring a similar volume of
Practice identifies patients with COPD: flagged in medical
record
• Patient sent information about the study
• Contacts surgery
• Avoids starting ‘rescue medication’ if appropriate
• Treated in line with clinical
   assessment according to current best
   practice (based on NICE guidance) +
   results of CRP POCT: to guide
   antibiotic therapy decision in line with
   training and guidance provided
• Management decisions recorded in
   baseline CRF
• Follow-up arranged
• Management decisions recorded 
   in baseline CRF
• Follow-up arranged
• Obtains appropriate and timely appointment (e.g. end of
   surgery)
Patient develops AECOPD
Clinical assessment of medical history, symptoms and signs
Eligibility assessment to be completed only by the treating 
clinician
 
Obtain informed consent
Randomisation
Intervention
CRP is measured using the POCT at initial
consultation and in any additional
AECOPD consultations during the 4-week
follow-up period
Control
CRP test not used at any point
during the 4-week follow-up 
period
Baseline data and
samples
Treated in accordance with
clinical assessment according to
current best practice (based on
NICE guidance)
Weeks 1 and 2 follow-up by telephone
Week 4 follow-up in surgery
6-month time point: patient medical note review. CRQ-SAS and EQ-5D 
completed and returned to research team
FIGURE 1 Participant flow diagram. NICE, National Institute for Health and Care Excellence. Reproduced from Bates
et al.38 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution
(CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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blood from a finger prick were also eligible to be used in the study when a practice preferred to use a CRP
POCT they were already using and that was quality controlled. Only two practices used a device other than
the Alere Afinion. Clinicians in participating general practices (e.g. GPs, nurse practitioners, practice nurses
and health-care assistants) were provided with study-specific training, which included guidance for the
clinical prescribers on interpreting CRP results in the context of AECOPD (Box 1).
BOX 1 Guidance for interpreting CRP results
C-reactive protein guidance
The decision to prescribe antibiotics or not has to be based on a comprehensive assessment of the likely risks
and benefits given:
l the patient’s underlying health status (COPD severity, comorbidities, frailty)
l clinical features of the current exacerbation.
Measurement of CRP can aid decision-making but is not meant to replace clinical assessment.
Patients with the following features are likely to be at an increased risk of complications:
l severe COPD (GOLD grade 3)
l past history of severe exacerbations (requiring hospitalisation)
l significant comorbidities (e.g. heart failure, poorly controlled diabetes, lung cancer).
Sputum purulence is currently the best clinical predictor of bacterial infection. However:
l patient reported sputum colour is generally not reliable
l purulence can be increased in viral infections as well as in bacterial infections
l try to obtain a sputum sample to objectively assess sputum purulence when possible.
Ask the patient how much the colour of their sputum has changed from its usual colour. This is particularly
pertinent when it is not possible to objectively assess their sputum.
C-reactive protein measurement
CRP level of < 20mg/l
Antibiotics are unlikely to be beneficial and usually should not be prescribed.
CRP level of 20–40mg/l
Antibiotics may be beneficial, mainly if purulent sputum is present. You may decide to prescribe antibiotics
after taking into account the patient’s underlying health status and the features of the current exacerbation.
C-reactive protein guidance
CRP level of > 40mg/l
Antibiotics are likely to be beneficial. Consider prescribing antibiotics unless the patient is assessed as being at a
lower risk of complications and unlikely to have a bacterial infection (no increased sputum purulence and no
features suggesting severe exacerbation).
GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Reproduced from Bates et al.38 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build
upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/.
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The guidance was based on a review of evidence including data from our recently published placebo-controlled
trial of antibiotics for patients with acute exacerbations of mild to moderate COPD.24 A cut-off point of 48 mg/l
of CRP had previously been shown to distinguish pneumonia from non-consolidative exacerbations,39 and in
our trial group we found that benefit from antibiotics was largely confined to those with a CRP level of
> 40mg/l.24 We emphasised that CRP can take up to 24 hours to rise in a AECOPD, so duration of illness
should be taken into account when interpreting the result. Our guidance, therefore, took a conservative
approach and included cut-off points of < 20 mg/l, 20–40 mg/l and ≥ 40 mg/l, and placed greater emphasis
on not prescribing antibiotics for those participants with a low level of CRP.
Control arm (usual care)
Participants allocated to usual care did not have a CRP POCT as part of the management of their AECOPD
at any time during their participation and were managed according to usual care alone. All participating
sites were provided with information on current best practice for managing AECOPD, which included a
brief summary of National Institute for Health and Care Excellence (NICE) and Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidance delivered via the study-specific site initiation guidance, training
and the PACE trial website (see Report Supplementary Material 1). No other specific guidance or instructions
were given to clinicians in relation to the management of participants randomised to the usual-care arm.
Data collection
A summary of data collection is provided in Table 1. All data, including sensitive and personal data, were
handled in accordance with the Data Protection Act 199840 and the subsequent General Data Protection
Regulation 2016.41 Paper CRFs were completed at all time points and then entered into the database by
a member of the trial team. The database was built with internal validations and range checks. Queries
arising during data entry were referred back to the site. Self-evident correction rules were developed
during the trial in response to common errors of CRF completion. Central data monitoring was conducted
throughout the trial, and a 10% quality control of all manually entered data was undertaken periodically.
Following data cleaning, the data sets were extracted from the database, checked to ensure consistency
with the paper CRFs and then provided to the statistician for analysis. All data will be retained for 15 years
post trial closure in line with Cardiff University’s procedures.
Baseline appointment
Baseline data collected included the number of days the participant reported experiencing AECOPD
symptoms, medical history and clinical examination results (e.g. temperature, pulse, oxygen saturation,
evidence of tachypnoea, crackles, wheezes, diminished vesicular sounds and evidence of consolidation).
The clinicians responsible for managing the participant recorded the participants’ clinical findings.
The collection of additional data could be conducted by a suitably trained member of the practice team.
A sputum sample (when participants were able to produce sputum) and a throat swab sample (using a
charcoal swab) were obtained from participants at the baseline appointment (prior to randomisation)
for bacterial and biological analyses. The recruiting clinicians recorded the colour of the participant’s sputum
according to a BronkoTest© (London, UK) chart.42 The BronkoTest is a colour chart that can be used by
patients and clinicians to assess the colour of sputum to more effectively manage exacerbations of COPD.
It is based on choosing one of five colours, and has been shown to correlate with the presence of bacterial
pathogens in sputum.43 If it was not possible to obtain sputum, participants were asked to estimate the
current colour of their sputum based on a BronkoTest chart. These samples were appropriately packaged
and sent to a local microbiology laboratory using first-class Royal Mail (London, UK) safe boxes at
ambient temperature.
Participants were asked to self-complete the CCQ44 and the EuroQol 5-Dimensions (EQ-5D) questionnaire45–48
at their baseline appointment (prior to randomisation). The EQ-5D-3L was used for the 1-, 2- and 4-week
follow-up assessments for the first 60 participants recruited; thereafter (and for all 6-month follow-ups),
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TABLE 1 Baseline and follow-up data collected
Assessment
Time point
Baseline
appointment
1 week
(telephone call)
2 weeks
(telephone call)
4 weeks
(face to face) 6 months
Assessment of eligibility ✗
Written informed consent ✗
Contact details ✗
Medication history ✗
Temperature ✗
Oxygen saturation ✗
Antibiotic prescribing ✗ ✗ (NS)
Antibiotics prescribed in the
12 months prior to study
inclusion
✗ (NS)
Spirometry results (prior to
inclusion or within 6 months post
inclusion if no pre-inclusion
results are available)
✗ (NS)
Most recent eosinophil count
prior to inclusion
✗ (NS)
Other prescribed medications for
current illness
✗
CRP levela ✗
CCQ ✗ ✗ ✗ ✗
EQ-5D ✗ ✗ ✗ ✗ ✗ (P)
Sputum sample and throat swab ✗ ✗
4-week return visit date ✗
Antibiotics use ✗ ✗ ✗ ✗ (NS)
Other medications for AECOPD ✗ ✗ ✗
Adverse effects ✗ ✗ ✗
Adherence to use of POCT ✗ ✗ ✗ ✗
Smoking history ✗
Time off paid work ✗
Diagnosis of pneumonia
(since baseline appointment)
✗
Health-care contact and use ✗ ✗ (NS)
Mortalityb ✗ ✗ (NS)
CRQ-SAS ✗ (P)
NS, notes search; P, post.
a Only for patients randomised to the POCT arm.
b Deaths during the 4-week follow-up period only will be reported as serious adverse events.
Reproduced from Bates et al.38 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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the EQ-5D-5L was used. CRP test results were recorded for those randomised to the intervention arm.
Antibiotics prescribing and other management decisions were recorded for all participants following
randomisation (as well as the outcome of the test result for those allocated to the intervention arm).
Follow-up data collection
Follow-up included telephone calls at 1 and 2 weeks, and a face-to-face consultation at 4 weeks post
randomisation. In addition, the CRQ-SAS49 and the EQ-5D-5L were posted to participants for them to
complete and return, using the provided and stamped addressed envelopes, to the study team at
6 months.
1- and 2-week telephone follow-up
A member of the trial team telephoned participants at weeks 1 and 2 to collect outcome data (see Table 1).
Time windows for these data collection points were set at – 1/+ 2 working days for the 1-week follow-up
and – 1/+ 7 working days for the 2-week follow-up.
4-week face-to-face visit
A 4-week face-to-face appointment at the general practice was arranged at the time of the baseline
appointment. Appointments were conducted by a member of the clinical team in the general practice,
or by a research nurse working for the local Clinical Research Network (CRN). The time window of the
4-week data collection was set at –3/+14 working days. Table 1 reports the data captured at this time
point. In addition, any further CRP tests carried out since the baseline appointment were recorded. Sputum
and throat swab samples were obtained when possible, and the colour of the sputum was assessed against
a BronkoTest chart. If it was not possible to obtain sputum, participants were asked to estimate the current
colour of their sputum based on a BronkoTest chart. These samples were sent to a local microbiology
laboratory, as at baseline. If a successful appointment did not take place at week 4, the study team
contacted the participant by telephone to obtain a minimum data set, including antibiotic consumption
during the third and fourth week after randomisation, health-care resource use, diagnosis of pneumonia
and completion of the CCQ and EQ-5D questionnaires. Minimum data set questions for the 1- and
2-week follow-up telephone calls were completed at the 4-week assessment if these had not already
been completed.
Collection of relevant data from electronic medical records at 6 months
The data ascertained at the 6-month notes reviews are presented in Table 1.
Patient self-reported Chronic Respiratory Disease Questionnaire Self-Administered
Standardized and EuroQol 5-Dimensions, five-level version at 6 months
Participants were sent a copy of the CRQ-SAS and EQ-5D-5L at 6 months post randomisation. The trial
team telephoned participants 1 and 2 weeks after the due date to remind them to complete and return
the questionnaire by post, or to offer to complete these instruments over the telephone.
Adverse events
Hospitalisation was considered an expected event in this patient population and this information was
collected and reported as part of routine follow-up. All other events fulfilling the definition of a serious
adverse event (SAE), including death, that occurred between the time of consent and the 4-week follow-up,
were reported to the co-ordinating research centre within 24 hours of the site becoming aware of the event.
Microbiological assessment
Sputum (if available) and throat swab samples were obtained at the baseline appointment visit and at the
face-to-face visit at week 4. Samples obtained were sent to the Specialist Antimicrobial Chemotherapy
Unit, Public Health Wales, at the University Hospital of Wales.
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Not all participants were able to produce a sputum sample on request and, therefore, we expected a lower
return rate for these samples than for the throat swab samples at both baseline and week 4.
Sputum sample appearance (including colour and consistency) was noted at the laboratory, and all sputum
samples were processed using the laboratory’s standard operating procedures. Potential pathogenic bacteria
(including S. pneumoniae, Haemophilus influenzae/H. parainfluenzae, Moraxella catarrhalis, Pseudomonas
species, Enterobacteriaceae and Staphylococcus aureus) were identified from sputum samples using
matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry, and semiquantitative counts
were recorded. Antimicrobial susceptibilities were performed on relevant bacterial species from sputum
samples by disc diffusion using European Committee on Antimicrobial Susceptibility Testing (EUCAST)
methodology and break points. Throat swabs (charcoal) were added to tryptone soya broth (BO0351Y,
Oxoid, Basingstoke, UK) and 50 µl was spiral plated onto a range of non-selective plates and selective plates
for identification purposes [e.g. Columbia blood agar with optochin discs, chocolate agar with bacitracin,
Pseudomonas agar with cetrimide, fucidin and cephaloridine plus Iso-SensitestTM agar (CM0471, Oxoid,
Basingstoke, UK) with 5% defibrinated horse blood (TCS Biosciences, Buckingham, UK)] without and with
the following antimicrobials: penicillin, third-generation cephalosporins, doxycycline, levofloxacin and
clarithromycin at concentrations consistent with EUCAST break points. Total bacterial counts of commensal
organisms were recorded on non-selective and selective agars; proportional quantification of resistant
isolates was determined from the selective media. All isolated pathogens, sputum samples and the remaining
broth from throat swabs were stored at –80 °C.
Nucleic acid was extracted from sputum samples using the Nuclisens® easyMAG® system (bioMérieux,
Basingstoke, UK) and then analysed with the Luminex NxTAG® Respiratory Pathogen Panel (Luminex,
Hertogenbosch, the Netherlands) for a variety of viral and bacterial pathogens.
Outcome measures
The co-primary outcome measure comprised:
1. Antibiotic consumption for AECOPD at any point during the 4 weeks post randomisation. Antibiotic
consumption (rather than prescribing or dispensing) is the driver of antimicrobial resistance and was,
therefore, selected as the outcome measure. With regard to the timing of this primary outcome, antibiotics
consumed within 4 weeks of presenting with an AECOPD are likely to be related to the AECOPD and,
therefore, using this time frame is more conservative in terms of demonstrating a reduction in antibiotic
use related to the intervention. Data on antibiotic consumption were captured by participant self-report
during the telephone interviews at weeks 1 and 2, and at the face-to-face interview at week 4. This was
a binary outcome with a cut-off point of any consumption/no consumption.
2. COPD health status as measured with the CCQ via telephone interview at 2 weeks. The CCQ is a
patient-centred health status measure that has been well validated, is widely used in patients with COPD
and has a well-described minimal clinically important difference.50 The CCQ is a brief questionnaire and,
therefore, less burdensome to patients, and it is possible to use it with a recall period of 24 hours. CCQ
scores range from 0 to 6 points, and the minimal clinically important difference is 0.4. CCQ was selected
as a co-primary outcome to evaluate whether or not the intervention resulted in a meaningful reduction
in antibiotic consumption (compared with usual care) without making COPD health status worse.
A 4-week time window was selected for the antibiotic consumption outcome to measure consumption of
antibiotics prescribed at the initial consultation, and also antibiotics that were prescribed for the AECOPD
in question but were initiated or prescribed at a later date. The CCQ outcome was measured at 2 weeks
post randomisation as this is the time when most patients would be expected to have recovered and,
therefore, the point at which a difference would be most indicative of delayed recovery.
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Sample size
The study aimed to have sufficient power to detect a 15% reduction from an estimated 70% of patients
who consume antibiotics for the AECOPD during the 4 weeks following randomisation.9 Trials using CRP
testing to reduce antibiotic prescribing for LRTI have resulted in absolute reductions in antibiotic prescribing
in the region of 13–22%.33,34,51 Even relatively small changes in prescribing are likely to have beneficial effects
on bacterial resistance at a population level.15 Detecting a difference in proportions between 0.70 and
0.55 at the 5% alpha and with 90% power required a total of 434 participants, inflated to 544 participants
to account for the loss to follow-up of approximately 20% of participants. In addition, we aimed to have
sufficient power to demonstrate that participants managed with the CRP POCT are no worse (non-inferior),
compared with those managed without the CRP POCT, in terms of their COPD health status measured
with the CCQ 2 weeks post randomisation. Assuming an expected difference between the arms of zero,
a non-inferiority margin of 0.3 (this is lower than the lowest minimal clinically important difference of 0.4)
and a common standard deviation (SD) of 1.1,50 based on a one-sided alpha of 5% and 90% power,
the study needed 462 participants, inflated to 580 participants to account for the loss to follow-up of
approximately 20% of participants.
Formulating our overall hypothesis using the intersection–union test,52 we aimed to carry out our individual
sub-hypothesis tests at the 5% level and, if both were significant, conclude overall significance at the 5%
level. Power will be affected by the level of correlation between the two outcomes and their corresponding
effect sizes. The impact on overall power is at its greatest when there is zero correlation between outcomes
and the effect sizes are identical (when this is the case, the overall power is the product of the powers for
testing each individual sub-hypothesis).53,54 Overall power decreases with increasing correlation between the
outcomes and with greater difference in effect sizes. We did not expect our effect sizes to be similar, as our
co-primary outcomes are two very different constructs (i.e. not two patient-reported outcome measures
that are likely to yield similar effect sizes). We also anticipated that the outcomes would not be entirely
independent (in those participants who do in fact require antibiotics, antibiotic consumption is likely to be
related to COPD health status). We therefore aimed to recruit at least 650 participants to maintain an overall
power between 81% and 90%.
Randomisation
Participants were remotely randomised, after giving their consent, using an online computerised
randomisation system created by the Centre for Trials Research at Cardiff University. This was operational
24 hours a day. In addition, a telephone back-up was available from 8.30 a.m. to 6.30 p.m. if the online
system failed or if the general practice had problems accessing the online site.
Participants were randomised in a 1 : 1 ratio to receive either usual care alone (control) or usual care with the
addition of CRP POCT (intervention). Randomisation used minimisation, with a random element set at 80%
to improve the integrity of the randomisation process. Anthonisen criteria (categorised as type 1, 2 or 3)
were used as a minimisation variable to achieve balance with respect to COPD exacerbation severity. Remote
allocation allowed the maintenance of allocation concealment from both the participant and the recruiting
clinician up to the point of intervention, as this was an open study.
Statistical methods
Participant characteristics and clinical measures were summarised using frequencies and percentages,
means and SDs or medians and interquartile ranges (IQRs), as appropriate. There was no planned interim
analysis. All analyses have been presented as estimates of treatment effects (adjusted mean differences or
odds ratios, as appropriate), with associated 95% CIs and p-values. The main trial analysis was based
primarily on a modified intention-to-treat (MITT) population, which included all randomised participants
who provided outcome data, regardless of protocol deviations or intervention received. Missing outcome
data were imputed using multiple imputation to obtain a secondary analysis of the primary outcomes
based on the full intention-to-treat (ITT) population. A complier average causal effect (CACE) analysis,
which accounted for departures from randomised treatment while maintaining a comparison of groups as
randomised, was also conducted on the primary CCQ analysis.55 The conclusions drawn on the primary
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CCQ analysis were based on both the MITT and the CACE analyses [i.e. the upper limit of the one-sided
95% CI (equivalent to the two-sided 90% CI) had to exclude 0.3 in both analyses for non-inferiority to
be concluded].
All planned analyses were conducted using Stata (version 13.0; StataCorp, College Station, TX, USA)
described in detail in a statistical analysis plan, which was finalised prior to database lock.
Primary analysis
Our first primary analysis was to compare the odds of consuming an antibiotic for an acute exacerbation
during the 4 weeks following randomisation, in each trial arm, using logistic regression. Our second primary
analysis was to compare the mean CCQ score between each trial arm using linear regression, with baseline
CCQ scores included as a covariate and a one-sided 95% CI constructed to assess non-inferiority. We fitted
two-level regression models (using the mixed and melogit commands) to account for clustering of participants
within practices. Modelling assumptions were tested, with appropriate adjustments made in the presence
of any violations. Missing primary outcome data were anticipated to be minimal, but were accounted for
in sensitivity analyses using multiple imputation (using the mi commands), where we assumed that primary
outcome data are missing at random given observed measurements. Further sensitivity analyses considered
the impact that departures from the missing at random assumption may have on any conclusions that could
be drawn (using the rctmiss command).
Our second primary analysis, testing the non-inferiority of management with CRP versus no CRP with
respect to the CCQ, was based on our prespecified margin of 0.3. We prespecified that if the observed
difference in CCQ was between 0.3 and 0.4 (0.4 is the minimal clinically important difference for the
outcome), we would further reflect on differences found in antibiotic consumption and secondary
outcomes (e.g. antibiotic resistance, EQ-5D) between the two trial arms before drawing any conclusions.
Secondary analysis
Secondary outcomes were analysed in a similar manner to the primary outcomes, with linear, logistic,
Poisson and negative binomial regression models fitted as appropriate (for the last two, the mepoisson
and menbreg commands were used). The majority of regression models accounted for clustering effects of
participants within practices. The analysis of CCQ domains and EQ-5D (both health utility and health status
variables) over time involved fitting a three-level model, with responses nested within participants within
practices. The antibiotic resistant organism outcomes (for both sputum and throat swabs at 4 weeks) were
compared between the arms using binomial regression (using the binreg command).
Subgroup analysis
Differential intervention effects on the primary outcomes were assessed by fitting interaction terms in the
primary models between trial arm and the following:
l COPD severity (GOLD I/II/III/IV), from spirometry results (prior to inclusion or within 6 months post
inclusion if no pre-inclusion results are available)
l the severity of COPD exacerbation (Anthonisen criteria type 1/2/3)
l the presence of a potentially pathogenic bacteria cultured from a sputum sample at baseline.
Sensitivity analysis
We determined whether or not the primary analyses were robust to the following sensitivity analyses:
l modifying the inclusion criteria following the internal pilot
l excluding participants on the basis of protocol violations
l accounting for antibiotic consumption over time (rather than considering it as one single binary variable).
CLINICAL EFFECTIVENESS METHODS
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Patient and public involvement
The PACE trial patient and public involvement (PPI) representatives were both co-applicants and advisors
on PACE and members of the Trial Management Group. They were recruited through Cynnwys Pobl
(Involving People, Wales) and had relevant training and experience of contributing to national and local
committees seeking to improve care for COPD sufferers. Sadly, one of our PPI representatives passed
away before the end of the study. During the development of the PACE trial proposal, PPI representatives
attended development team meetings, discussed the proposed research with a COPD patient group and
contributed to the design of the trial. They paid special attention to plans for approaching/recruiting
participants and providing participant-facing study materials, ensuring that participating patients felt safe
in the knowledge that, should their acute exacerbation indicate the need for antibiotics, these would be
prescribed. They were also involved in reviewing and discussing our primary outcome in relation to the best
method of assessing quality of life and recovery in AECOPD. As members of our Trial Management Group,
they continued to play a pivotal role in the design and conduct of the study, and our remaining PPI
representative assisted with the dissemination of this research.
Ethics approval and governance
Ethics approval for the trial was given on 15 September 2014 by the Research Ethics Committee (REC)
for Wales (Wales REC 6), recognised by the United Kingdom Ethics Committee Authority (REC reference
14/WA/1106). All sites received research and development approval from the appropriate Health Boards
and Clinical Commissioning Groups before commencing trial procedures. The trial was registered on
20 August 2014 with the International Standard Randomised Controlled Trial Registration Number
ISRCTN24346473. Cardiff University acted as a sponsor for the trial.
A summary of the changes made to the original protocol is given in Appendix 1, Table 35 (all outcome
measures and changes to the outcome measures are shown in Appendix 1, Table 30).
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Chapter 3 Clinical effectiveness results
Recruitment and participant flow
Ninety-six general practices across five research network hubs were open to recruitment at some point
during the study period between January 2015 and February 2017. Ten of these practices did not recruit
any participants.
It should be noted that completing screening logs is challenging for busy general practices, especially for
patients with acute medical conditions. Not all of the clinicians working at each site participated in the study,
worked full-time or were available to recruit each time they were on service. Fifty-six practices returned
one or more screening logs, but, of these, only nine returned screening logs had data that were considered
reliable (i.e. were regularly returned and consistently included details of participants’ approach in addition to
those recruited). Using data from these reliable returns, we estimate that 1988 patients were approached in
total, with 1319 patients being eligible for inclusion in the study (approximately 66% of those approached).
Six hundred and fifty-three participants were recruited from 86 general practices.
Table 2 provides a breakdown of the number of sites and participants from each recruitment centre.
Overall, practices recruited a median of five participants, with the number per practice ranging from 1 to
40 participants.
Three randomised participants withdrew from the study, including withdrawal of their consent for their
data to be used, and one participant was randomised in error (with the recruiting clinician destroying their
data). All subsequent analyses are based on a maximum of 649 participants. Figure 2 provides details of
recruitment and retention throughout the study.
TABLE 2 Participant recruitment and site participation across recruitment centres
Recruitment centre
Number of
participants
Number of sites
(general practices)
Number of participants per practice
Mean Median
Minimum to
maximum
Cardiff and South Wales 328 33 9.9 7.0 1 to 40
London 84 20 4.2 2.5 1 to 15
Oxford and Thames Valley 149 19 7.8 6.0 2 to 33
Norfolk 77 9 8.6 7.0 2 to 25
North-west coast 15 5 3.0 3.0 1 to 4
Overall 653 86 7.6 5.0 1 to 40
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Baseline data
Participants in both arms were well matched at baseline. The key baseline characteristics, including
participant demographics and presentation features, are provided in Tables 3–5.
Sputum bacteriological and virological profiles at baseline
At baseline, sputum sample bacteriology data were available for 195 usual-care participants and 202 CRP
POCT participants (60.2% and 62.2% of randomised participants, respectively). Of the samples with
potential pathogenic bacteria, 103 organisms were cultured from usual-care participants and 113 were in
sputa from participants allocated to CRP POCT. There were 23 distinct potential pathogenic species identified
in total. Potential pathogen profiles were similar between the arms (Figure 3). Baseline antibiotic sensitivity
data for the three most frequently cultured potentially pathogenic species are presented in Table 6.
Potentially assessed for eligibility
(n = 1988)a
• Included in primary antibiotic consumption 
   analysis, n = 263  
• Included in primary CCQ analysis, n = 281
Provided data at:
• Week 1, n = 282
• Week 2, n = 290
• Week 4, n = 282
• 6-month notes review, n = 305
• 6-month postal questionnaire, n = 231 
Allocated to CRP POCT arm
(n = 325)
• Received CRP POCT, n = 317
• Did not receive allocated intervention,
   n = 8
• Machine error, n = 8
Provided data at:
• Week 1, n = 285
• Week 2, n = 285
• Week 4, n = 283
• 6-month notes review, n = 304
• 6-month postal questionnaire, n = 219
Allocated to control arm
(n = 324)
• Did not receive CRP POCT, n = 321
• Received CRP POCT, n = 3
• Received CRP POCT during the 4 weeks 
   post randomisation, n = 3
• Included in primary antibiotic consumption
   analysis, n = 274
• Included in primary CCQ analysis, n = 282
Allocation
Analysis
Follow-up
Randomised
(n = 653)
Enrolment
Excluded 
(n = 4)
• Withdrew consent to use data, n = 3
• Randomised in error and data destroyed,
   n = 1
Potentially eligible
(n = 1319)a
FIGURE 2 The Consolidated Standards of Reporting Trials (CONSORT) flow diagram. a, Number of participants
assessed for eligibility based on screening log data from 9 out of 86 practices that returned reliable screening log
data (i.e. were regularly returned and consistently included details of participants’ approach in addition to those
recruited). From these practices, 208 patients were approached (an average of 23 patients approached per practice),
138 patients (66.3%) were eligible and 109 patients were recruited. Potentially assessed for eligibility calculation:
(208/9) × 86= 1988. Potentially eligible calculation: (138/9) × 86= 1319. The main reasons for patients’ ineligibility
were that they had recently used, or were currently using, antibiotics (28/70), or that they had already participated
in the PACE trial (13/70). The main reasons because of which eligible patients were not recruited were because
the patient declined (18/29) or because there was a lack of clinical time to recruit (9/29). Data are drawn from
Butler et al.56
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TABLE 3 Participant characteristics at baseline (1 of 2)
Variable
Trial arm
OverallUsual care CRP POCT
n Mean (SD) Median (IQR)
Minimum to
maximum n Mean (SD) Median (IQR)
Minimum to
maximum n Mean (SD) Median (IQR)
Minimum to
maximum
Age (years) 324 68.3 (9.31) 68.5
(62.0 to 75.0)
40 to 92 325 67.8 (9.53) 68.0
(62.0 to 75.0)
41 to 90 649 68.1 (9.42) 68.0
(62.0 to 75.0)
40 to 92
Number of days with
symptoms prior to
consultation
324 7.1 (5.06) 6.0
(3.0 to 10.0)
1 to 21 325 6.8 (5.2) 5.0
(3.0 to 9.0)
1 to 28 649 6.9 (5.13) 5.0
(3.0 to 10.0)
1 to 28
Pack years (for current
smokers)
92 47.8 (30.47) 41.6
(27.5 to 56.3)
5 to 165 95 41.0 (30.66) 36.0
(22.2 to 49.3)
3 to 162 187 44.4 (30.67) 40.0
(24.6 to 53.5)
3 to 165
CCQ symptoms score
(points)
319 3.8 (1.09) 3.8
(3.0 to 4.5)
1.25 to 6.0 320 3.7 (1.14) 3.8
(3.0 to 4.5)
0.5 to 6.0 639 3.8 (1.11) 3.8
(3.0 to 4.5)
0.5 to 6.0
CCQ functional state
score (points)
319 3.0 (1.45) 3.0
(2.0 to 4.0)
0.0 to 6.0 319 2.9 (1.54) 3.0
(1.8 to 4.0)
0.0 to 6.0 638 2.9 (1.49) 3.0
(1.8 to 4.0)
0.0 to 6.0
CCQ mental state score
(points)
316 2.9 (1.60) 3.0
(1.5 to 4.0)
0.0 to 6.0 317 2.9 (1.64) 3.0
(1.5 to 4.0)
0.0 to 6.0 633 2.9 (1.62) 3.0
(1.5 to 4.0)
0.0 to 6.0
CCQ total score (points) 316 3.3 (1.11) 3.3
(2.4 to 4.2)
0.7 to 5.8 314 3.2 (1.16) 3.3
(2.4 to 4.1)
0.3 to 6.0 630 3.3 (1.14) 3.3
(2.4 to 4.1)
0.3 to 6.0
Overall health (EQ-5D) 289 48.3 (21.33) 50.0
(30.0 to 60.0)
0 to 100 288 48.6 (19.89) 50.0
(40.0 to 60.0)
0 to 98 577 48.5 (20.61) 50.0
(35.0 to 60.0)
0 to 100
Health utility (EQ-5D) 314 0.6 (0.27) 0.6
(0.5 to 0.8)
–0.4 to 1.0 316 0.6 (0.29) 0.7
(0.5 to 0.8)
–0.6 to 1.0 630 0.6 (0.28) 0.7
(0.5 to 0.8)
–0.6 to 1.0
Data are drawn from Butler et al.56
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TABLE 4 Participant characteristics at baseline (2 of 2)
Variable
Trial arm, frequency (%)
Overall, frequency (%)Usual care CRP POCT
Male 173 (53.4) 162 (49.8) 335 (51.6)
Female 151 (46.6) 163 (50.2) 314 (48.4)
Heart failure 15 (4.6) 16 (4.9) 31 (4.8)
Coronary heart disease 59 (18.2) 55 (16.9) 114 (17.6)
Diabetes 54 (16.7) 50 (15.4) 104 (16.0)
Chronic kidney disease 32 (9.9) 27 (8.3) 59 (9.1)
Hypertension 143 (44.1) 124 (38.2) 267 (41.1)
Other chronic disease 70 (24.1) 85 (28.5) 155 (26.3)
Non-smoker 22 (7.9) 20 (7.1) 42 (7.5)
Ex-smoker 163 (58.4) 165 (58.7) 328 (58.6)
Current smoker 94 (33.7) 96 (34.2) 190 (33.9)
1/3 Anthonisen criteria 81 (25.0) 76 (23.4) 157 (24.2)
2/3 Anthonisen criteria 98 (30.2) 100 (30.8) 198 (30.5)
3/3 Anthonisen criteria 145 (44.8) 149 (45.8) 294 (45.3)
Current sputum colour according to BronkoTest (clinician-assessed if sputum obtained during consultation)
1 (light/non-purulent) 48 (25.3) 59 (30.6) 107 (27.9)
2 (non-purulent) 47 (24.7) 39 (20.2) 86 (22.5)
3 (purulent) 36 (18.9) 50 (25.9) 86 (22.5)
4 (purulent) 53 (27.9) 37 (19.2) 90 (23.5)
5 (dark/purulent) 6 (3.2) 8 (4.1) 14 (3.7)
Current sputum colour according to BronkoTest (participant-assessed if sputum not obtained during consultation)
1 (light/non-purulent) 14 (11.9) 14 (12.0) 28 (11.9)
2 (non-purulent) 18 (15.3) 22 (18.8) 40 (17.0)
3 (purulent) 28 (23.7) 22 (18.8) 50 (21.3)
4 (purulent) 23 (19.5) 27 (23.1) 50 (21.3)
5 (dark/purulent) 13 (11.0) 13 (11.1) 26 (11.1)
Unable to produce sputum 22 (18.6) 19 (16.2) 41 (17.4)
Sputum colour according to BronkoTest when not exacerbating (participant-assessed)
1 (light/non-purulent) 126 (44.5) 130 (46.6) 256 (45.6)
2 (non-purulent) 74 (26.1) 88 (31.5) 162 (28.8)
3 (purulent) 32 (11.3) 23 (8.2) 55 (9.8)
4 (purulent) 12 (4.2) 9 (3.2) 21 (3.7)
5 (dark/purulent) 5 (1.8) 2 (0.7) 7 (1.2)
Unable to produce sputum 34 (12.0) 27 (9.7) 61 (10.9)
CLINICAL EFFECTIVENESS RESULTS
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TABLE 4 Participant characteristics at baseline (2 of 2) (continued )
Variable
Trial arm, frequency (%)
Overall, frequency (%)Usual care CRP POCT
Crackles 162 (50.0) 158 (48.6) 320 (49.3)
Wheeze 167 (51.5) 171 (52.6) 338 (52.1)
Diminished vesicular sounds 82 (25.5) 71 (21.8) 153 (23.6)
Evidence of consolidation 8 (2.5) 11 (3.4) 19 (2.9)
Prescribed oral antibiotics in the past 12 months 198 (65.6) 205 (67.4) 403 (66.5)
Using regular inhalers prior to recruitment 290 (96.0) 289 (95.1) 579 (95.5)
Mobility
No problems 64 (20.3) 79 (24.7) 143 (22.5)
Problems 252 (79.7) 241 (75.3) 493 (77.5)
Self-care
No problems 172 (54.4) 202 (63.5) 374 (59.0)
Problems 144 (45.6) 116 (36.5) 260 (41.0)
Usual activities
No problems 67 (21.2) 74 (23.1) 141 (22.2)
Problems 249 (78.8) 246 (76.9) 495 (77.8)
Pain/discomfort
No problems 102 (32.4) 93 (29.2) 195 (30.8)
Problems 213 (67.6) 225 (70.8) 438 (69.2)
Anxiety/depression
No problems 162 (51.3) 156 (48.8) 318 (50.0)
Problems 154 (48.7) 164 (51.2) 318 (50.0)
No bacterial growth in sputum/not analysed
No growth 28 (14.4) 23 (11.4) 51 (12.8)
Insufficient sample 2 (1.0) 4 (2.0) 6 (1.5)
Sputum not processed 0 (0.0) 1 (0.5) 1 (0.3)
Potential bacterial pathogens in sputum
Pure growth of pathogen 22 (11.3) 23 (11.4) 45 (11.3)
Mixed growth including pathogens 60 (30.8) 65 (32.2) 125 (31.5)
No potential bacterial pathogens in sputum
Normal respiratory flora 83 (42.6) 85 (42.1) 168 (42.3)
Mixed growth of non-pathogens 0 (0.0) 1 (0.5) 1 (0.3)
Data are drawn from Butler et al.56
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TABLE 5 Participant lung function parameters at baseline
Variable
Trial arm
OverallUsual care CRP POCT
n Mean (SD) Median (IQR)
Minimum to
maximum n Mean (SD) Median (IQR)
Minimum to
maximum n Mean (SD) Median (IQR)
Minimum to
maximum
Ratio of FEV1 to FVC 224 0.6 (0.13) 0.6
(0.5 to 0.7)
0.23 to 0.85 205 0.6 (0.12) 0.6
(0.5 to 0.7)
0.30 to 0.85 429 0.6 (0.13) 0.6
(0.5 to 0.7)
0.23 to 0.85
% predicted FEV1 282 60.4 (20.73) 59.2
(45.0 to 74.0)
11.4 to 150.4 277 59.2 (19.33) 58.9
(45.0 to 71.6)
9.9 to 125.4 559 59.8 (20.04) 59.0
(45.0 to 73.0)
9.9 to 150.4
Ratio of FEV1 to FVC of
< 0.7 (% of those with
a calculable ratio),
frequency (%)
181 80.8 172 83.9 353 82.3
Ratio of FEV1 to FVC of
≥ 0.7 (% of those with
a calculable ratio),
frequency (%)
43 19.2 33 16.1 76 17.7
Mild COPD (GOLD I),
frequency (%)
20 11.1 18 10.5 38 10.8
Moderate COPD
(GOLD II), frequency (%)
100 55.6 93 54.1 193 54.8
Severe COPD (GOLD III),
frequency (%)
47 26.1 52 30.2 99 28.1
Very severe COPD
(GOLD IV), frequency (%)
13 7.2 9 5.2 22 6.3
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
Data are drawn from Butler et al.56
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H. influenzae
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M. catarrhalis
S. pneumoniae
Pseudomonas aeruginosa
Stenotrophomonas maltophilia
Serratia marcescens
S. aureus
K. pneumoniae
Proteus mirabilis
Klebsiella oxytoca
Escherichia coli
Serratia liquefaciens
Enterobacter cloacae
Citrobacter freundii
Acinetobacter haemolyticus
Acinetobacter johnsonii
Acinetobacter radioresistens
Acinetobacter species
Citrobacter koseri
Kosakonia cowanii
K. aerogenes
Raoultella species
Serratia species
FIGURE 3 Potential bacterial pathogens from sputum samples at baseline. Usual care data based on 103 potential bacterial pathogens from 82 participants. CRP POCT data
based on 113 potential bacterial pathogens from 88 participants.
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Both bacteriology and virology data from sputum samples at baseline were available for 190 usual-care
participants and 196 CRP POCT participants. There was little difference between the arms regarding the
general microbiological profile of sputum samples. Overall, no pathogens were detected in 95 out of 386
sputum samples (24.6%), bacterial pathogens only (i.e. no viral/atypical pathogens) were detected in 79
out of 386 cases (20.5%), viral/atypical pathogens only were detected in 123 out of 386 cases (31.9%),
and both bacterial and viral/atypical pathogens were detected in 89 out of 386 cases (23.1%). Of those
with viral/atypical pathogens, 137 viruses/atypical organisms were detected in samples obtained from
usual-care participants and 117 in those allocated to CRP POCT. Ten distinct species were detected in
total. Pathogen profiles were similar between the arms (Figure 4).
In total, 97.5% (317/325) of participants allocated to the CRP POCT arm reported receiving a CRP POCT
during the recruitment consultation. For the remaining eight participants, a CRP POCT could not be carried
out because of a machine error. Of the participants allocated to the usual-care arm, 13.6% (44/324)
reported receiving a finger-prick blood test at some point within the 4 weeks following randomisation.
However, 84% (37/44) of these reports of finger-prick blood testing were verified (by checking machine
logs and 6-month notes reviews, and querying with the recruiting practice) as not being CRP tests. CRP
testing was confirmed in three instances (all at the initial consultation) and unverified (i.e. no additional
data to confirm or deny) in four instances. Therefore, the percentage of usual-care participants who
received a CRP POCT was between 0.9% (3/324) and 2.2% (7/324).
TABLE 6 Antibiotic resistance in the most common potential pathogens cultured from sputum samples at baseline
Bacteriaa Antibiotic
Trial arm
OverallUsual care CRP POCT
Tested
(n)
Resistant,
n (%)
Tested
(n)
Resistant,
n (%)
Tested
(n)
Resistant,
n (%)
H. influenzae (n = 45) Ampicillin 20 5 (25.0) 24 10 (41.7) 44 15 (34.1)
Cefotaxime 20 0 (0.0) 24 0 (0.0) 44 0 (0.0)
Ceftazidime 20 20 (100.0) 25 25 (100.0) 45 45 (100.0)
Co-amoxiclav 20 5 (25.0) 24 7 (29.2) 44 12 (27.3)
Erythromycin 20 20 (100.0) 25 25 (100.0) 45 45 (100.0)
Tetracycline 20 0 (0.0) 24 0 (0.0) 44 0 (0.0)
M. catarrhalis (n = 44) Ampicillin 22 22 (100.0) 21 21 (100.0) 43 43 (100.0)
Cefotaxime 22 1 (4.5) 22 1 (4.5) 44 2 (4.5)
Ceftazidime 0 0 0
Co-amoxiclav 22 0 (0.0) 22 0 (0.0) 44 0 (0.0)
Erythromycin 22 3 (13.6) 22 1 (4.5) 44 4 (9.1)
Tetracycline 22 0 (0.0) 22 0 (0.0) 44 0 (0.0)
S. pneumoniae (n = 36) Ampicillin 15 5 (33.3) 10 1 (10.0) 25 6 (24.0)
Cefotaxime 0 0 0
Ceftazidime 17 17 (100.0) 15 15 (100.0) 32 32 (100.0)
Co-amoxiclav 15 5 (33.3) 10 1 (10.0) 25 6 (24.0)
Erythromycin 18 5 (27.8) 18 2 (11.1) 36 7 (19.4)
Tetracycline 18 3 (16.7) 18 3 (16.7) 36 6 (16.7)
a The n refers to the frequency of the corresponding potentially pathogenic species being cultured from sputum samples
at baseline. H. influenzae is naturally resistant to ceftazidime and erythromycin. M. catarrhalis is naturally resistant to
ampicillin. S. pneumoniae is naturally resistant to ceftazidime.
Antimicrobial discs were used for susceptibility testing of all sputum samples. All discs were supplied by Oxoid (Basingstoke, UK).
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FIGURE 4 Viral and atypical pathogens from sputum samples at baseline. Usual-care data based on 137 viral/atypical pathogens from 109 participants. CRP POCT data based on
117 viral/atypical pathogens from 103 participants. Confirmation of CRP POCT testing.
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Distribution of C-reactive protein values
For the 317 participants allocated to the CRP POCT arm and for those who were tested with a CRP POCT
at the index consultation, the median CRP value was 6 mg/l (IQR 5–18.5 mg/l). Of those participants,
76.0% (241/317) had CRP values of < 20 mg/l, 12% (38/317) had CRP values in the intermediate category
(20–40 mg/l) and 12% (38/317) had CRP values in the highest range (> 40 mg/l) (Figure 5).
Outcomes and estimation
Co-primary outcomes
Of the 649 participants randomised, 537 contributed to the primary analysis of antibiotic consumption (82.7%)
and 563 contributed to the primary analysis of CCQ total score at 2 weeks post randomisation (86.7%).
The odds of consuming an antibiotic for AECOPD during the first 4 weeks following randomisation were
69% lower in participants allocated to the CRP POCT arm than in those in the usual-care arm (Table 7).
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FIGURE 5 Dot plot of CRP levels. Censored observations are fixed at censored value (i.e. < 5 and > 200 are set to
5 and 200, respectively). The dashed lines are at y = 20 and y = 40 to distinguish between the three categories
provided to clinicians as part of the intervention.
TABLE 7 Between-arm comparison of antibiotic consumption for AECOPD during the 4 weeks post randomisation
Outcome measure Time point
Trial arm
AORa
(95% CI) p-value ICC
Usual care CRP POCT
n
Frequency
(%) n
Frequency
(%)
Antibiotic consumption
for AECOPD
During the 4 weeks
post randomisation
274 212 (77.4) 263 150 (57.0) 0.31
(0.20 to 0.47)
< 0.001 0.17
AOR, adjusted odds ratio; ICC, intraclass correlation coefficient.
a Ratio is CRP POCT/usual care. Adjusted for Anthonisen criteria. Clustering of participants within practices accounted for
by fitting a two-level logistic regression model (analysis based on 537 participants within 82 practices). ICC calculated
using π2/3 estimator.
CLINICAL EFFECTIVENESS RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
The adjusted mean difference in CCQ score was 0.19 (two-sided 90% CI –0.33 to –0.05) points lower in
the CRP POCT arm than in the usual-care arm. The two-sided 90% CI for both CACE analyses ranged
from –0.34 to –0.07 points. The upper limit of both CIs did not include the prespecified non-inferiority
margin of 0.3, suggesting that a CRP-assisted management strategy is no worse than usual management
(without a CRP POCT) according to COPD health status at 2 weeks (Table 8).
As the null hypotheses were rejected for both co-primary outcomes, our overall (composite) primary
hypothesis can also be rejected, and we can conclude that we found evidence that a CRP-assisted
management strategy results in reduced antibiotic use for patients presenting to primary care with
AECOPD without having a negative impact on COPD health status at 2 weeks.
Secondary outcomes
The percentage of participants included in the analysis of secondary outcomes, based on data collected in
the 4 weeks following randomisation, ranged from 74.0% (480/649) for the total number of days that
antibiotics were consumed during the first 4 weeks outcome to 99.8% (648/649) for the antibiotic
prescribing at the index consultation outcome. The percentage of participants included in the secondary
outcome analysis of the CRQ-SAS domains, which were collected at 6 months via postal questionnaires,
ranged between 61.5% for the dyspnoea domain (399/649) and 68.0% for the emotional function
domain (441/649).
Medication use
Antibiotics were prescribed to 79 out of 241 participants with a CRP of < 20 mg/l (32.8%), 32 out of
38 participants with a CRP level between 20 and 40 mg/l (84.2%) and 36 out of 38 participants with a
CRP level of > 40 mg/l (94.7%).
We found that the odds of consuming antibiotics for any reason during the 4 weeks following randomisation,
receiving an antibiotic prescription at the initial consultation or receiving an antibiotic prescription during the
4 weeks following randomisation were lower in participants allocated to the CRP POCT arm than in those
allocated to usual care. We found no evidence of any difference between the arms regarding the use of other
COPD treatments during the 4 weeks following randomisation (Table 9). The between-arm analyses of the total
number of days that antibiotics were consumed for AECOPD/any reason during the first 4 weeks following
randomisation produced intervention effects consistent with the binary consumed/not consumed outcomes.
TABLE 8 Between-arm comparison of CCQ at 2 weeks post randomisation
Analysis
set
Outcome
measure Time point
Trial arm
Adjusted mean
differencea (90% CI) ICC
Usual care CRP POCT
n Mean (SE) n Mean (SE)
MITT CCQ (points) Two weeks post
randomisation
282 2.8 (0.07) 281 2.6 (0.07) –0.19 (–0.33 to –0.05) 0.04
CACE 1 –0.20 (–0.34 to –0.07)
CACE 2 –0.20 (–0.34 to –0.07)
ICC, intraclass correlation coefficient; SE, standard error.
a Difference is CRP POCT minus usual care. Adjusted for Anthonisen criteria and baseline CCQ total score. Clustering of
participants within practices accounted for by fitting a two-level linear regression model (analysis based on 563 participants
within 83 practices). CACE 1 assumes that usual-care participants who have self-reported as having received a CRP POCT
but have no further data to verify this have received it. CACE 2 assumes that those participants have not received a CRP
POCT. CACE estimated using two-stage instrumental variables regression with cluster robust SEs used to account for
clustering of participants within practices.
Data are drawn from Butler et al.56
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Potential medication side effects, consultations with primary/secondary care
and pneumonia diagnoses
Symptoms commonly attributed as adverse effects from antibiotics and other COPD treatments were
reported by 264 out of 289 participants in the usual-care arm (91.3%) and 255 out of 285 participants
in the CRP POCT arm (89.5%) during the 4 weeks following randomisation [adjusted odds ratio (AOR)
0.79, 95% CI 0.44 to 1.39; p = 0.410]. There was no evidence of a difference between the arms regarding
primary/secondary care consultations for any reason during the 6 months following randomisation (AOR 1.39,
95% CI 0.46 to 4.15; p = 0.559), or pneumonia diagnoses at 4 weeks (AOR 1.57, 95% CI 0.28 to 8.84;
p = 0.608) or 6 months following randomisation (AOR 0.73, 95% CI 0.29 to 1.82; p = 0.495).
Patient-reported outcome measures
Table 10 describes the analyses of COPD health status (as measured with the CCQ) over time. For the total
score, as well as the individual domains, there is a discernible reduction (improvement) in scores over the
follow-up time periods. The adjusted mean difference (AMD) (averaged across follow-up time points) was
lower (better) in the CRP POCT arm than in the usual-care arm for the total score (AMD –0.20, 95% CI
–0.34 to –0.06; p = 0.005), symptom domain (AMD –0.19, 95% CI –0.34 to –0.05; p = 0.010) and
function state (AMD 0.29, 95% CI –0.45 to –0.12; p = 0.001). There was no evidence of a difference for
the mental state domain (AMD –0.08, 95% CI –0.27 to 0.10; p = 0.372). There was also no evidence of
any differential intervention effect over time.
Table 11 describes the analysis of general health utility and health status over time (measured with the
EQ-5D). For health utility, there was no evidence of any difference between arms averaged across follow-up
time points (AMD 0.03, 95% CI –0.04 to 0.09; p = 0.384). Although there was some evidence of a difference
in health utility across time in general (i.e. averaged across usual-care arm participants and CRP POCT arm
participants), there was no evidence to suggest any differential intervention effect over time. There was a
difference between arms in terms of general health status, with participants allocated to the CRP POCT arm
reporting a health status score > 3 points higher than that of usual-care arm participants (AMD 3.12, 95% CI
0.50 to 5.74; p = 0.019). Health status generally improved over the follow-up time points, but, similar to the
health utility measure, there was no evidence to suggest any differential intervention effect over time.
Table 12 describes the analysis of the COPD HRQoL at 6 months post randomisation (as measured by the
four domains of the CRQ-SAS). There was no evidence to conclude any differences between arms for
these outcomes. The AMDs were all small (ranging from –0.09 for the mastery domain to 0.15 for the
emotional function domain), with no CIs containing values that would be considered to be clinically
important (the literature suggests a minimally clinically important difference of between 0.4 and 0.5).
TABLE 9 Between-arm comparisons of secondary outcome measures related to medication prescription or use
Outcome measure Time point
Trial arm
AORa
(95% CI) p-value ICC
Usual care CRP POCT
n
Frequency
(%) n
Frequency
(%)
Antibiotic consumption
for any reason
During the 4 weeks post
randomisation
278 220 (79.1) 267 158 (59.2) 0.31
(0.20 to 0.48)
< 0.001 0.15
Antibiotic prescribing During index consultation 323 225 (69.7) 325 155 (47.7) 0.31
(0.21 to 0.45)
< 0.001 0.21
Antibiotic prescribing During the 4 weeks post
randomisation
316 252 (79.7) 313 185 (59.1) 0.30
(0.20 to 0.46)
< 0.001 0.21
Use of other COPD
treatments
During the 4 weeks post
randomisation
290 268 (92.4) 290 263 (90.7) 0.79
(0.43 to 1.46)
0.453 0.14
AOR, adjusted odds ratio; ICC, intraclass correlation coefficient.
a Ratio is CRP POCT/usual care. Adjusted for Anthonisen criteria. Clustering of participants within practices was accounted
for by fitting a two-level logistic regression model. ICC was calculated using π2/3 estimator.
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TABLE 10 Between-arm comparisons of CCQ scores over time
Outcome measure
Time point
(weeks)
Trial arm, mean (SE) Time point,a coefficient (95% CI) Intervention effectb
Usual care CRP POCT Week 2 Week 4 p-value Coefficient (95% CI) p-value
CCQ total score (points) 1 2.8 (0.07) 2.6 (0.07) –0.08 (–0.15 to –0.01) –0.21 (–0.29 to –0.14) < 0.001 –0.20 (–0.34 to –0.06) 0.005
2 2.8 (0.06) 2.6 (0.07)
4 2.6 (0.07) 2.4 (0.07)
CCQ symptom domain score (points) 1 3.2 (0.07) 3.0 (0.07) –0.04 (–0.13 to 0.05) –0.22 (–0.31 to –0.13) < 0.001 –0.19 (–0.34 to –0.05) 0.010
2 3.2 (0.07) 3.0 (0.07)
4 3.0 (0.07) 2.8 (0.07)
CCQ function state score (points) 1 2.6 (0.08) 2.3 (0.08) –0.11 (–0.19 to –0.02) –0.14 (–0.23 to –0.05) 0.006 –0.29 (–0.45 to –0.12) 0.001
2 2.5 (0.08) 2.2 (0.08)
4 2.5 (0.08) 2.2 (0.08)
CCQ mental state score (points) 1 2.6 (0.09) 2.5 (0.09) –0.14 (–0.24 to –0.03) –0.39 (–0.49 to –0.28) < 0.001 –0.08 (–0.27 to 0.10) 0.372
2 2.4 (0.09) 2.4 (0.09)
4 2.2 (0.09) 2.1 (0.09)
SE, standard error.
a Reference category is week 1.
b Adjusted mean difference (CRP POCT minus usual care) averaged across time points. Model adjusts for Anthonisen criteria and the corresponding CCQ score at baseline as a covariate.
Clustering of responses within participants within practices is accounted for by fitting a three-level linear regression model (analysis based on up to 1675 responses among 608 participants
within 83 practices).
D
O
I:10.3310/hta24150
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2020
VO
L.24
N
O
.15
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2020.This
w
ork
w
as
produced
by
Francis
et
al.under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,the
fullreport)m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:N
IH
R
Journals
Library,N
ationalInstitute
for
H
ealth
Research,Evaluation,Trials
and
Studies
C
oordinating
C
entre,A
lpha
H
ouse,U
niversity
of
Southam
pton
Science
Park,Southam
pton
SO
16
7N
S,U
K
.
29
TABLE 11 Between-arm comparisons of EQ-5D scores over time
Outcome measure
Time
point
Trial arm, mean (SE) Time point,a coefficient (95% CI) Intervention effectb
Usual care CRP POCT Week 2 Week 4 Month 6 p-value
Coefficient
(95% CI) p-value
EQ-5D index value Week 1 0.6 (0.01) 0.6 (0.01) 0.04 (0.00 to 0.08) 0.14 (0.11 to 0.18) –0.05 (–0.09 to –0.01) < 0.001 0.03 (–0.04 to 0.09) 0.384
Week 2 0.6 (0.01) 0.6 (0.01)
Week 4 0.6 (0.01) 0.7 (0.01)
Month 6 0.6 (0.01) 0.6 (0.01)
EQ-5D health status Week 1 54.7 (1.24) 57.8 (1.26) 2.94 (1.13 to 4.75) 5.26 (3.40 to 7.11) 5.15 (3.16 to 7.14) < 0.001 3.12 (0.50 to 5.74) 0.019
Week 2 57.6 (1.24) 60.7 (1.25)
Week 4 59.9 (1.25) 63.0 (1.27)
Month 6 59.8 (1.31) 62.9 (1.32)
SE, standard error.
a Reference category is week 1.
b Adjusted mean difference (CRP POCT minus usual care) averaged across time points. Model adjusts for Anthonisen criteria and the corresponding EQ-5D score at baseline as a covariate.
Index values transformed by adding 0.6 to the original value (to make all responses positive) and then squaring. Clustering of responses within participants within practices is accounted
for by fitting a three-level linear regression model (analysis of index values based on 2060 responses from 602 participants in 84 practices; analysis of health status values based on
1874 responses from 548 participants in 80 practices).
TABLE 12 Between-arm comparison of CRQ-SAS domains at 6 months post randomisation
Outcome measure Time point
Trial arm
AMDa (95% CI) p-value ICC
Usual care CRP POCT
n Mean (SE) n Mean (SE)
CRQ-SAS dyspnoea domain Six months post randomisation 193 4.2 (0.10) 206 4.3 (0.10) 0.06 (–0.20 to 0.33) 0.636 0.01
CRQ-SAS fatigue domain Six months post randomisation 215 3.5 (0.11) 221 3.6 (0.11) 0.13 (–0.12 to 0.38) 0.295 0.11
CRQ-SAS emotional function domain Six months post randomisation 216 4.3 (0.08) 225 4.4 (0.08) 0.15 (–0.04 to 0.34) 0.129 0.11
CRQ-SAS mastery domain Six months post randomisation 214 4.3 (0.03) 221 4.2 (0.03) –0.09 (–0.18 to 0.01) 0.065 0.00
ICC, intraclass correlation coefficient; SE, standard error.
a Difference is CRP POCT minus usual care. Adjusted for Anthonisen criteria. Clustering of participants within practices is accounted for by fitting a two-level linear regression model
(analysis based on a maximum of 441 participants within 80 practices).
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Sputum microbiology profile and outcomes at 4 weeks
post randomisation
Sputum microbiological outcome analyses included 360 out of 649 samples for the comparison of the
proportion with potentially pathogenic bacteria cultured from sputum at 4 weeks (55.5%) and 122 out
of 649 samples for the comparison of the percentage of tested antibiotics to which at least one cultured,
potentially pathogenic bacteria was resistant (18.8% of randomised participants; this analysis included only
those with potentially pathogenic bacteria in sputum at 4 weeks).
At 4 weeks, sputum sample bacteriology data were available for 187 usual-care arm participants and 175 CRP
POCT arm participants (57.7% and 53.8% of randomised participants, respectively). Among those with sputum
bacteriology data, there was little difference between the arms regarding the microbiological profile. Potential
pathogens (either pure or mixed) were found in 67 out of 187 samples from usual-care arm participants and in
62 out of 175 samples from CRP POCT arm participants (35.9% and 35.4%, respectively). Normal respiratory
flora alone (i.e. no potential pathogens) was found in 42 out of 187 samples from usual-care arm participants
and in 41 out of 175 samples from CRP POCT arm participants (22.5% and 23.4%, respectively).
Both bacteriology and virology data from sputum samples at 4 weeks were available for 178 usual-care
arm participants and 167 CRP POCT arm participants (54.9% and 51.4%, respectively). There was little
difference between the arms regarding the general microbiological profile of sputum samples. In 154
out of 345 participants, neither potential bacterial nor viral/atypical pathogens were detected (44.6%).
Although just over one-fifth of participants provided a sample from which only a potential bacterial
pathogen was detected (79/345, 22.9%), the majority of participants provided a sample from which a
potential viral/atypical pathogen was detected alone (66/345, 19.1%) or in combination with a potential
bacterial pathogen (46/345, 13.3%).
There was no evidence of any differences between the arms in terms of the presence of potentially
pathogenic bacteria cultured from sputum at 4 weeks (AOR 0.97, 95% CI 0.63 to 1.50; p = 0.905) nor in
the percentage of tested antibiotics to which at least one potentially pathogenic bacteria (cultured from
sputum at 4 weeks) was resistant (Table 13).
Baseline throat swab sample data were available for 309 usual-care arm participants and 320 CRP POCT
arm participants (95.4% and 98.8% of randomised participants, respectively). Resistance to antibiotics in
commensal bacteria detected from throat swabs, expressed as the percentage of total bacteria load that
grew on each antibiotic plate, was similar between arms (Table 14).
At 4 weeks, throat swab sample data were available for 270 usual-care arm participants and 267 CRP POCT
arm participants (83.3% and 83.1% of randomised participants, respectively). Analysis of throat swabs at
4 weeks was based on 537 out of 649 participants (82.7%). There was no evidence of any differences
between the arms in the percentage of the total bacterial load from throat swabs that grew on any of
the five antibiotic plates (i.e. penicillin, levofloxacin, clarithromycin, doxycycline and extended-spectrum
beta-lactamases) at 4 weeks (Table 15).
Sensitivity analyses
The conclusions drawn on the co-primary analyses were robust to all plausible assumptions made regarding
missing outcome data, accounting for the modification of eligibility criteria following the internal pilot and
excluding participants on the basis of protocol violations (see Appendix 2, Tables 36–43 and Figure 16).
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TABLE 13 Between-arm comparisons of sputum microbiology outcome (percentage of antibiotics to which at least one cultured, potentially pathogenic bacteria from sputum
was resistant at 4 weeks)
Outcome measure Time point
Trial arm
Adjusted risk
(proportion)
differencea
(95% CI) p-value
Usual care CRP POCT
n
Mean (SE)
number of
antibiotics
tested
Mean (SE)
number of
isolates
non-susceptible
to an antibiotic
Mean
(SE) % n
Mean (SE)
number of
antibiotics
tested
Mean (SE)
number of
isolates
non-susceptible
to an antibiotic
Mean
(SE) %
Percentage of tested
antibiotics to which at
least one cultured,
potentially pathogenic
bacteria (from sputum)
was resistant
Four weeks post
randomisation
64 17.2 (0.99) 8.0 (0.59) 47.1 (2.81) 58 17.5 (1.06) 8.7 (0.76) 48.1 (3.10) 0.04
(–0.03 to 0.11)
0.293
SE, standard error.
a Difference is CRP POCT minus usual care. Adjusted for Anthonisen criteria. Cluster robust SEs used to account for clustering of participants within practices.
TABLE 14 Resistance to antibiotics in commensal bacteria detected from throat swabs at baseline (expressed as percentage of total bacterial load that grew on each
antibiotic plate)
Variable
Trial arm
OverallUsual care CRP POCT
n Mean (SD) Median (IQR)
Minimum to
maximum n Mean (SD) Median (IQR)
Minimum to
maximum n Mean (SD) Median (IQR)
Minimum to
maximum
Penicillin 309 48.0 (37.92) 39.5 (10.9 to 87.5) 0 to 100 320 50.8 (37.30) 50.0 (12.3 to 90.0) 0 to 100 629 49.4 (37.60) 45.8 (11.4 to 88.9) 0 to 100
Levofloxacin 309 16.0 (25.28) 3.8 (0.4 to 18.1) 0 to 100 320 18.3 (28.05) 3.3 (0.2 to 25.0) 0 to 100 629 17.1 (26.73) 3.6 (0.3 to 20.3) 0 to 100
Clarithromycin 309 43.6 (36.72) 34.2 (8.6 to 78.6) 0 to 100 320 47.2 (36.74) 40.0 (11.6 to 85.9) 0 to 100 629 45.4 (36.75) 36.8 (10.6 to 80.8) 0 to 100
Doxycycline 309 30.9 (33.09) 16.7 (2.6 to 51.7) 0 to 100 320 31.9 (33.36) 20.3 (2.6 to 55.2) 0 to 100 629 31.4 (33.20) 18.6 (2.6 to 54.1) 0 to 100
ESBL 309 2.2 (11.62) 0.0 (0.0 to 0.0) 0 to 100 320 5.4 (20.5) 0.0 (0.0 to 0.0) 0 to 100 629 3.8 (16.81) 0.0 (0.0 to 0.0) 0 to 100
ESBL, extended-spectrum beta-lactamases.
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Modelling medication use over time showed that antibiotic consumption displayed the greatest between-arm
difference between the index consultation and 1 week post randomisation (the time during which most
antibiotics were prescribed), and consumption decreased over the 4-week follow-up period in both arms
(see Appendix 2, Tables 44 and 45 and Figure 17). The use of other COPD treatments decreased at a similar
rate in both arms over the 4-week follow-up period (see Appendix 2, Table 46 and Figure 18).
The mean number of primary care consultations during the 6 months following randomisation was 6.3
[standard error (SE) 0.28] for participants allocated to the usual-care arm and 6.6 (SE 0.29) for participants
allocated to the CRP POCT arm. The adjusted incidence rate ratio was 1.04 (95% CI 0.92 to 1.18; p = 0.504).
The mean number of secondary care consultations during the 6 months following randomisation was 1.7
(SE 0.12) for participants allocated to the usual-care arm and 1.6 (SE 0.11) for participants allocated to the
CRP POCT arm. The adjusted incidence rate ratio was 0.96 (95% CI 0.79 to 1.17; p = 0.719). The mean
number of primary and secondary care consultations combined was, therefore, a combination of the two
separate consultation variables and similarly indicated insufficient evidence of a difference between the
arms (see Appendix 2, Figures 19 and 20 and Table 47).
Subgroup analyses
Table 16 provides model estimates for prespecified subgroup analyses conducted for the primary antibiotic
consumption outcome.
There was no evidence of a differential intervention effect for participants who provided a sputum sample
containing potentially pathogenic bacteria at baseline.
Although there was also insufficient evidence to conclude a differential intervention effect according to
COPD severity, there were some descriptive differences between the arms. Antibiotic consumption was
consistently different between the arms for participants with GOLD I, GOLD II and GOLD IV COPD.
However, 28 out of 40 (70.0%) usual-care arm participants with GOLD III COPD consumed antibiotics for
AECOPD, compared with 30 out of 44 (68.2%) CRP POCT arm participants with GOLD III COPD.
TABLE 15 Between-arm comparisons of throat swab bacteriology outcomes (percentage of total bacteria load from
throat swabs that grew on the antibiotic plate at 4 weeks)
Outcome measure Time point
Trial arm
Adjusted risk
(proportion)
differencea
(95% CI) p-value
Usual care CRP POCT
n
Mean
(SE) % n
Mean
(SE) %
Penicillin 4 weeks post
randomisation
270 54.0 (2.24) 267 55.8 (2.18) 0.02 (–0.04 to 0.08) 0.566
Levofloxacin 16.5 (1.55) 16.6 (1.59) 0.00 (–0.04 to 0.04) 0.958
Clarithromycin 48.9 (2.31) 47.4 (2.21) –0.01 (–0.09 to 0.06) 0.703
Doxycycline 35.8 (2.19) 33.3 (2.14) –0.02 (–0.09 to 0.04) 0.468
ESBL 4.7 (1.17) 3.6 (0.96) –0.01 (–0.04 to 0.02) 0.512
ESBL, extended-spectrum beta-lactamases; SE, standard error.
a Difference is CRP POCT minus usual care. Adjusted for Anthonisen criteria. Cluster robust SEs used to account for
clustering of participants within practices.
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TABLE 16 Subgroup analyses for antibiotic consumption for AECOPD within 4 weeks post randomisation
(primary outcome)
Subgroup analysis Variable AORa (95% CI) p-value
COPD severity (GOLD
category) (n = 335)
Usual care Reference category for trial arm main effect (i.e. effect of
trial arm for GOLD I subgroup)
0.119
CRP POCT 0.29 (0.06 to 1.38)
GOLD I Reference category for COPD severity main effect
(i.e. effect of GOLD subgroup for participants allocated
to usual-care arm)
0.816
GOLD II 1.39 (0.42 to 4.64)
GOLD III 0.91 (0.24 to 3.37)
GOLD IV 1.18 (0.19 to 7.13)
CRP POCT × GOLD I Reference category for trial arm × COPD severity
interaction
0.146
CRP POCT × GOLD II 1.19 (0.21 to 6.73)
CRP POCT × GOLD III 4.04 (0.62 to 26.54)
CRP POCT × GOLD IV 0.39 (0.03 to 6.07)
Severity of COPD
exacerbation (Anthonisen
criteria) (n = 537)
Usual care Reference category for trial arm main effect (i.e. effect of
trial arm for 1/3 features subgroup)
0.506
CRP POCT 1.30 (0.60 to 2.81)
1/3 features Reference category for severity of COPD exacerbation
main effect (i.e. effect of severity of COPD exacerbation
for participants allocated to usual-care arm)
< 0.001
2/3 features 4.73 (2.13 to 10.48)
3/3 features 9.34 (4.13 to 21.13)
CRP POCT × 1/3
features
Reference category for trial arm × severity of COPD
exacerbation interaction
< 0.001
CRP POCT × 2/3
features
0.12 (0.04 to 0.35)
CRP POCT × 3/3
features
0.14 (0.05 to 0.39)
Presence of potentially
pathogenic bacteria
cultured from sputum at
baseline (n = 337)
Usual care Reference category for trial arm main effect (i.e. effect of
trial arm for no potential pathogenic bacteria subgroup)
< 0.001
CRP POCT 0.20 (0.09 to 0.43)
No potential
pathogenic bacteria
Reference category for presence of potentially
pathogenic bacteria cultured from sputum at baseline
main effect (i.e. effect of presence of potential
pathogenic bacteria for participants allocated to
usual-care arm)
0.773
Potential pathogenic
bacteria
1.14 (0.48 to 2.72)
CRP POCT × no
potential pathogenic
bacteria
Reference category for trial arm presence of potential
pathogenic bacteria interaction
0.553
CRP POCT × potential
pathogenic bacteria
1.42 (0.45 to 4.49)
a Models adjust for Anthonisen criteria (when it is not the subgroup of interest).
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There was some evidence to suggest a differential intervention effect for antibiotic consumption by the
severity of the COPD exacerbation (according to the Anthonisen criteria). Figure 6 illustrates this differential
effect, indicating that antibiotic consumption was similar between the arms for participants who met one
out of the three Anthonisen criteria and differences were only observed for participants with two or more
of the symptoms.
There was no evidence of any differential intervention effects for the primary CCQ outcome for any of the
other prespecified subgroups (see Appendix 2, Table 48).
Adverse events
Serious adverse events were collected during the first 4 weeks following randomisation. During this period,
two SAEs were reported. These were both events where study participants had died. Both participants
were in the usual-care arm, and the SAEs were not deemed to be related to the intervention or to trial
participation.
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FIGURE 6 Differential effect of the intervention on the use of antibiotics during the first 4 weeks. Reproduced
from The New England Journal of Medicine. Butler et al., C-reactive protein testing to guide antibiotic prescribing
for COPD exacerbations, 381, 111–20.56 Copyright © 2019 Massachusetts Medical Society. Reprinted with permission
from Massachusetts Medical Society.
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Chapter 4 Qualitative process evaluation
Aim
The aim of the qualitative process evaluation was to facilitate the interpretation of outcome results and
assist with implementation planning.57,58
Methods
Setting and participants
Purposive sampling was used, with the aim of capturing a range of views and enabling saturation to be reached
in framework analysis.59 A sampling framework was used, with the aim of interviewing up to 20 patients in
the CRP POCT trial arm and up to 20 members of the primary care teams who had carried out the CRP POCT
with patients and/or used the CRP POCT result during consultations with patients. A sampling framework was
used to ensure that views were captured from patients and members of the primary care teams in each of
the regions where the PACE study took place (Wales, Oxford, London and Norfolk), and from approximately
equal numbers of patients who had and had not been prescribed antibiotics at their initial consultation.
Procedure
Semistructured interviews were carried out over the telephone by a qualitative researcher. Topic guides
(see Report Supplementary Material 2) focused on experiences of the management of AECOPD, the
acceptability, implementation and potential mechanisms of the CRP POCT intervention and contextual
factors that could influence future implementation.
Analysis
Interviews were audio-recorded and transcribed verbatim. NVivo 11 (QSR International, Warrington, UK)
qualitative analysis software was used to assist coding. Data were analysed using framework analysis. This is
a systematic approach to a thematic qualitative analysis that allows for easy comparisons between and within
cases, facilitates sharing and discussion of data and allows for clear linking/access from developed themes to
original data.60–62 Framework analysis involves five stages: (1) familiarisation with the data, (2) development
of a thematic framework, (3) applying thematic codes to all of the data (indexing), (4) retrieving and
summarising coded data in a chart and (5) interpreting the data by drawing inferences and pulling together
relevant themes.63 Framework analysis is particularly useful when there are a number of clear research aims
that have guided the questions, while allowing new themes to emerge from the data that are relevant to
the research question.60–62 This approach was used for the qualitative data gathered during the main trial
phase, as opposed to a more traditional thematic analysis, to facilitate the identification of consensus and
discrepancies in the themes emerging in different key groups (e.g. patients prescribed antibiotics vs. those
who were not, GPs vs. other members of the primary care team) that would enable us to understand how
contextual factors might interact with the acceptability and implementation of the CRP POCT.
During analysis, the qualitative researchers met regularly to discuss the coding, frameworks and themes as
these developed. Data analysis was iterative, with the majority of analysis (familiarisation, development of
framework and charting) taking place before the trial outcomes were known, in line with the Medical
Research Council guidance on process evaluation.58 The definition of data saturation used in this study was
the point at which the ability to obtain additional new information had been attained and when further
coding was not feasible.64 Using the frameworks, the qualitative researchers (RP and HS) assessed whether
or not the last five interviews with primary care staff and patients provided new information that would
add to the theory being developed with regard to the mechanisms of impact for the intervention. On this
basis, the judgement was made that data saturation had been achieved.
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Results
Semistructured interviews were carried out with 20 patients and 20 primary care staff between October
2015 and March 2017. The interview participant characteristics are shown in Table 17.
The key themes identified through the framework analysis are summarised in Table 18.
Pseudonyms have been used alongside quotations from patients to protect anonymity. CRP readings and
whether or not antibiotics were prescribed during the initial consultation (at the time of recruitment) are
provided as the context for patient quotations.
Acceptability
All prescribers felt that the CRP POCT provided a useful piece of information, although several felt that this
affected their decision only when there was some uncertainty about whether or not antibiotics were needed.
Prescribers emphasised the importance of using clinical findings to guide antibiotic prescribing decisions,
and recognised that CRP POCT testing provided additional information and was not a replacement for
clinical skills:
I’m not daft enough to think that this test was a right/no thing, a yes/no thing and I know that clinical
suspicion and judgment and history is far more important.
General practitioner 2
It’s shown that we’re not always right when we listen in, you know. There is a possibility that this may
just be a viral crackle, as opposed to bacterial, but again it’s very difficult without the reassurance of
the, the CRP, to let the patient go away.
Nurse practitioner 3
TABLE 17 Characteristics of qualitative evaluation participants
Participants N Characteristics (n)
Patients
Prescribed antibiotics at
index consultation
Not prescribed antibiotics
at index consultation
CRP level of < 20mg/l 14 4 10
CRP level of > 20mg/l 6 5 1
Total 20 9 11
Primary care staff
Made prescribing decisions
guided by CRP POCT result Carried out the CRP POCT
GPs 12 12 7
Nurse practitioners 5 5 5
Non-prescribers
Made prescribing decisions
guided by CRP POCT result Carried out the CRP POCT
Practice nurse 1 0 1
Research assistant 1 0 1
Pharmacist 1 0 1
Total 20 17 15
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Clinicians emphasised the importance of providing ‘safety-netting’ advice to patients if antibiotics were not
prescribed, for example letting them know when they should reconsult or start medication that they had at
home to reduce the risk of adverse clinical outcomes:
So other patients were you sort of think, well yes you have an exacerbation of your COPD, but I’m
not sure if it’s an infective one. It could be that you are just getting more symptoms. So I would
have a discussion with them about starting steroids straight away, but actually delaying antibiotics for
maybe 1 or 2 days and obviously giving them lots of safety advice and permission for them to start
the antibiotics before then if they get a temperature, if they get increased sputum, and they feel that
things are worsening, because obviously these are our frail, often frail and elderly patients who end up
bouncing into hospital and that’s the last thing that they want and that we want.
Nurse practitioner 2
TABLE 18 Summary of key themes from the framework analysis of qualitative data
Main theme Subtheme Key points
Acceptability of the
CRP POCT
General views of
the CRP POCT
Patients and primary care staff generally thought that the CRP POCT
was a useful addition to the consultation that would help guide antibiotic
prescribing decisions. Primary care clinicians emphasised the importance
of using the CRP POCT in addition to, not in place of, a thorough clinical
assessment
Implementation of the
CRP POCT
Technical aspects
of the test
Primary care staff felt that the need for test cartridges to be refrigerated
during storage and returned to room temperature before use, and the
need for regular calibration of the machine, were barriers to using the
CRP POCT in primary care
Time Primary care staff acknowledged the impact on consultation length that
the use of the CRP POCT had, but felt that it was worthwhile
Roll-out in routine
practice
Patients and primary care staff were positive about the use of the CRP
POCT in routine NHS care for the management of AECOPD. There were
differences of opinion about whether the CRP POCT would be used for
all patients with AECOPD, or for only those patients for whom there was
uncertainty about the need for antibiotics based on clinical examination.
The cost of the CRP POCT machine and cartridges was seen as a potential
barrier to its use in NHS primary care services
Mechanisms of impact
of the CRP POCT
Objective sign of
illness
Patients and primary care staff felt that the CRP POCT provided an
objective sign of illness that could help guide treatment. Prescribers felt
that this increased their confidence in their antibiotic prescribing decisions
Patient education
tool
Primary care staff felt that the test was useful in educating patients about
antibiotic use and antimicrobial resistance. Patients, however, had a
limited understanding of these issues
Reinforcing
prescribers’
decisions
Primary care staff perceived the CRP POCT result as being useful in
reinforcing their decision about antibiotic prescribing when communicating
with patients. Patients were generally passive in these consultations and did
not report being involved with antibiotic treatment decisions. Continuity of
care was viewed to be important by patients and clinicians in determining
the quality of communication with regard to antibiotic prescribing decisions
for AECOPD
Contextual factors Attitudes towards
antibiotics
Patient attitudes with regard to antibiotic use for AECOPD were varied,
but many did not want to take antibiotics for AECOPD unless they were
required. Primary care staff were aware of the need to reduce antibiotic
use for AECOPD and acknowledged that patient attitudes varied and
could influence prescribing decisions
COPD routine care
pathway
Anxiety around undertreatment through withholding antibiotics (including
clinical outcomes and risk of litigation), and the use of ‘rescue packs’ that
usually contain steroid and antibiotic medication that patients can start at
home, could influence and be influenced by the use of the CRP POCT
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One clinician described a case in which a CRP reading had been unexpectedly high and the effect that this
had had on his perception of the value of CRP POCT testing:
I told my partner, who had seen this gentleman first this morning and I told him how high the CRP
was. He was, he was as shocked as I was. Now it may be that this man has another reason for having
a high CRP, you know, there may be something else going on other than infection and we’re going to
follow that up. But, but I would say that it would be, you know, the point-of-care testing would be an
excellent thing to have in the surgery, because it can, you know, it can give you some information
which, which you would not have on a clinical examination.
General practitioner 3
One of the aspects of the CRP POCT that primary care staff liked was that they felt that the test reassured
patients, particularly when the CRP reading was low, and that the test demonstrated to the patient that a
thorough examination had taken place:
They [patients] feel reassured that no antibiotics have been given and the doctor’s actually checked that
this was not necessary before he said ‘no’ to the antibiotics, rather than just saying ‘no you don’t need it’.
General practitioner 1
Patients felt that the CRP POCT was useful in rapidly deducing the severity of illness and/or the need
for antibiotics:
I think it’s a great idea to measure really sort of how ill you are and whether you really need more
treatment or not.
Participant 1, CRP < 20 mg/l, no antibiotics
Patients were generally confident that the CRP POCT would help their doctors decide whether or not they
needed antibiotics, but some felt that the test result was not consistent with their subjective experience:
I wasn’t happy to be honest, because, simply because they said the test that was OK, and an ever
slight inflammation which they took because of this blood test she found and she gave me 5 days of
the steroids, but after the 5 days I was back to square one.
Participant 2, CRP < 20 mg/l, no antibiotics
Implementation of the C-reactive protein point-of-care test
Technical aspects of the test
Patients did not report any difficulties from a practical or technical perspective with clinicians’ use of the
CRP POCT, and they were satisfied with the way in which the CRP POCT was used. Primary care staff
reported that they were able to use the CRP POCT with all patients randomised to the intervention arm,
and that, in general, it was easy to use.
However, the need to refrigerate cartridges and allow time for them to return to room temperature before
use and the need to regularly carry out control testing were both seen as burdensome and potential
barriers to implementation. Some primary care staff felt that the CRP POCT would require an operational
overhaul to make it simpler and faster to use during routine care:
I think that, you know, in theory that [using the CRP POCT in routine care] could be very good, but the
only thing I would say is that because it’s so cumbersome within the consultation clinicians won’t use
it, I’m just being honest with you, it takes, you know, 10 minutes to go and sort the machine and
calibrate it, you know, how easy is that going to be?
General practitioner 7
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The portability of the device was also identified as an important factor in the future development of the
CRP POCT equipment:
I think it would be nicer if it was, you know in an ideal world, if it was a hand-held machine, so you
could take it with you on a, on a home visit for instance, would be a useful.
General practitioner 5
Time
Patients reported that use of the test was ‘quick’ and that it did not cause any delays. The primary care
staff described an ‘investment’ of time required to use the CRP POCT, and that using the machine did
make consultations slightly longer. However, they felt that this was worthwhile:
I think where there was a great degree of uncertainty about what the right thing was to do, yeah
there are definitely times when you’d be willing to invest that extra bit of time to do it.
General practitioner 4
Views about roll-out in routine practice
Patients and primary care staff had a positive view about whether or not the CRP POCT should be
introduced into routine NHS care for patients with AECOPD:
I think it’s an important test and if we, it’s something I’d certainly want to explore in the future after
the trial is finished, getting a CRP machine for the practice.
General practitioner 5
I think they’re [GPs] doing their best, and I do think that the pinprick test is absolutely amazing and
I should . . . I would like it to be done as a regular thing if you get a flare-up.
Participant 3, CRP < 20 mg/l, not prescribed antibiotics
Primary care staff discussed the advantages of using the test in routine care, mainly in terms of antibiotic
stewardship and achieving better consistency in prescribing decisions:
So I think it may help to standardise the treatments that we offer, I definitely think it’s a good idea,
I think it’s something that we should be doing more of, because I think we probably would end up
prescribing less antibiotics because of it.
Nurse practitioner 2
Patients discussed the benefits of the test mainly in terms of reducing antibiotic use and saving money.
Patients felt that the CRP POCT could ‘help’ doctors with their decisions and did not report any anxiety
about having the test. Patients also recognised saving money and reducing antibiotic misuse as possible
societal benefits of using the CRP POCT:
Helping decide if you need antibiotics or not, and I should imagine it would save money in the long
run as well.
Participant 4, CRP < 20 mg/l, no antibiotics
Some clinicians said that they would use the CRP POCT for all patients presenting with AECOPD to
‘increase their data’. This was understood to mean that they would use it as a learning tool to improve
their ability to detect patients who are likely to need antibiotic treatment. Others felt that they would not
use the CRP POCT for all patients, particularly when they felt confident in making a decision based on their
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clinical judgement. Primary care staff felt that the CRP POCT would be introduced across a range of
conditions in routine practice, rather than being used exclusively for patients with AECOPD:
I can really see that near point testing of CRP is a brilliant idea and I am sure that it is going to expand
to lots of other things. I think patients really like it because it makes sense to them.
General practitioner 6
Primary care staff felt that the cost of the CRP POCT machine and cartridges was prohibitive under current
funding arrangements, and that it would not be widely adopted unless additional funding was provided to
cover these costs.
Mechanisms of impact of the C-reactive protein point-of-care test
Three themes emerged relating to perceptions about how using the CRP POCT might achieve the desired
aims: the CRP POCT as an objective sign of illness, the CRP POCT as a patient education tool and the use
of the CRP POCT to reinforce the prescriber’s decision.
The C-reactive protein point-of-care test as an objective sign of illness
Prescribers reported that the objectivity of the CRP POCT reading was used to support clinical
decision-making and reduce decisional uncertainty:
I think the clinical decision was, was probably there anyway without needing the CRP test, but
obviously there are some instances where, you know, if you’re not too sure, then obviously that CRP
test could’ve maybe made that difference as to whether you gave the antibiotics or not.
Non-prescriber 2
Being able to share the reading with patients helped to make the treatment decision-making process more
transparent, whereas some other aspects of the clinical examinations were more subjective and/or less
visible. One of the clinicians described why they felt that patients liked to have objective tests carried out:
Because I think if it’s just you face to face and you have no objective evidence, it’s just your opinion
and they sometimes question that.
General practitioner 8
Primary care staff felt that this enhanced their confidence and reassured both prescribers and patients
about their decision with regard to antibiotic treatment:
I found writing down ‘CRP normal’, I found that that was a very powerful of reassuring me and the
patient actually, it seemed to place a great deal of, you know, faith on, on blood testing.
General practitioner 2
Patients reported being able to effectively communicate the more visible symptoms of their AECOPD to
their clinician. However, the less visible subjective signs of their AECOPD were more difficult to detect and
communicate. Patients viewed the CRP POCT as a useful way of objectively measuring the severity of
their illness:
I thought it [the CRP POCT] was excellent because it was just proving what I already knew if you know
what I mean.
Participant 5, CRP 20–40 mg/l, prescribed antibiotics
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The C-reactive protein point-of-care test as a patient education tool
Clinicians reported that they used the test result to help explain whether or not they thought that the patient’s
AECOPD was likely to be caused by a bacterial infection and whether or not antibiotics were likely to be
needed. They felt that patients had greater involvement in the consultation through the discussion of the
test outcome, and that it provided them with an opportunity to educate patients about antibiotic overuse:
It allows you to talk a little bit about antibiotics, you can then, you can, we can then add and refer
people to an information sheet about the duration of common symptoms for example.
General practitioner 9
From the patient perspective, there was a reasonable level of understanding of the purpose of the CRP
POCT, which they typically discussed in discrete terms [presence/absence of infection (or inflammation) and
requirement/no requirement of antibiotics]:
Yes, it was to see if I had an infection on my chest and the count of it was I think five, so they decided
I didn’t have an infection but that the steroids would help me, which they did.
Participant 3, CRP < 20 mg/l, no antibiotics
Although this particular patient recalled her CRP result, most patients showed little evidence of remembering
the actual number generated by the test or awareness of how their result compared with that of other
patients. In some cases patients were also uncertain about the type of infection the CRP POCT was detecting:
They need to confirm, which is what I thought this test and that was doing, that it is, it is a proper
viral infection.
Participant 6, CRP 20–40 mg/l, prescribed antibiotics
Use of the C-reactive protein point-of-care test to reinforce prescribers’ decisions
Primary care staff felt that the CRP POCT could help make the reasoning behind antibiotic prescribing
decisions more transparent and less ‘secretive’ by providing patients with an objective measure. However,
there were very few examples of the CRP POCT facilitating shared decision-making between the patient
and the prescriber. The CRP POCT reading was generally used to articulate and justify prescribing decisions,
rather than to actively involve patients in these decisions:
It gives something to justify to the patient that it’s not just your clinical judgement on the signs and
things that you have actually done a test and that has, you know, given even more back up that the
fact that you confidently don’t need antibiotics.
General practitioner 6
From the patient perspective, prescribers were viewed very much as being the decision-makers with regard
to antibiotic treatment, and the addition of the CRP POCT appeared to reinforce this power dynamic.
Patients were generally very accepting of what the doctor or nurse told them with regard to whether or
not they needed antibiotics:
I would say my doctors give me sound advice about what to do, because at the end of the day I know
they are very busy people and their range of knowledge is quite astounding, and at the end of the day
I’m relying on him to give me the correct information to make an educated decision.
Participant 7, CRP < 20 mg/l, prescribed antibiotics
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Patients felt that it was right that the doctors made the decisions about antibiotic prescribing:
Well I don’t think it comes under what the patients want, it’s the patient is ill enough to need
antibiotics, you know then they should be given, other than that I don’t think they should be given,
if the patient isn’t ill enough for them.
Participant 8, CRP < 20 mg/l, no antibiotics
When patients reported that they felt involved in decisions about antibiotics, they described this in terms of
their agreeing with the doctor’s decision or because they felt that the doctors had explained their decision
to them, rather than being actively involved in the decision-making process per se.
Patients felt that communication was better when clinicians knew them and were familiar with their case,
and that a clinician’s knowledge of their patient could influence their decisions about antibiotic prescribing:
I suppose everyone is an individual, their own fears and state of mind have to be considered, whether
they’re a hypochondriac or . . . there is a lot to it and I think the doctor would sort of be able to judge
his patient if he knew them.
Participant 3, CRP < 20 mg/l, no antibiotics
Primary care staff also felt that their knowledge of the patient and their history was important, and that
antibiotics were more likely to be overprescribed when doctors did not know their patients:
And that [the CRP POCT] would be even more important in practices where you’ve got like supermarket
medicine going on where you’ve got hundreds of doctors seeing patients once and never seeing them
again where there is not the trust that you get with that sort of relationship.
General practitioner 8
Contextual factors
Attitudes towards antibiotics
There was a high level of awareness among primary care staff of the need to reduce antibiotic prescribing
and they acknowledged that there was a general tendency to overprescribe antibiotics. Patient anxiety,
a strong patient preference for antibiotics and individual circumstances (e.g. the recent death of a spouse)
were cited by primary care staff as possible reasons for still prescribing antibiotics despite a low CRP POCT
result, indicating that non-medical factors continue to influence antibiotic prescribing even when an
objective measure of the likely severity of infection is available.
Primary care staff had mixed views about the level of awareness of the potential risks of overuse of
antibiotics among their patients; some felt that patients had a good awareness and were open to reducing
their use, whereas other patients were ‘surprised’ to learn of the potential downsides of using antibiotics if
they were not required. Clinicians frequently discussed the usefulness of the CRP POCT as an educational
tool within this social context and talked about a range of wider interventions and resources that aim to
alter antibiotic prescribing practices:
I think there are really good resources out there for GPs who do want to improve their consulting skills
and to having a few ideas about how to open this discussion and to reframe the discussion around
antibiotics with patients, um so one of the things that we want to do is get everyone to do those
tutorials, sort of just have a few extra tools in their, in their doctor’s bag, you know for being able to
help that discussion with patients around reducing antibiotic use.
General practitioner 9
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Patients’ priority was to resolve their symptoms, and there were mixed feelings about when antibiotics
should be prescribed. Mostly, patients recognised how valuable antibiotics were when they were needed,
but did not want to take them if they were not required:
It’s not good taking antibiotics just for a minor complaint, you know, you should have it being really
bad with your chest before taking antibiotics.
Participant 8, CRP < 20 mg/l, no antibiotics
Some felt that they should take antibiotics for AECOPD regardless (as a precautionary or preventative
measure), others felt that people with COPD should take long-term antibiotics in winter and others saw using
antibiotics as a last resort. Although the majority of patients reported no adverse effects from previous use of
antibiotics, some reported having experienced drawbacks to their use, including allergic reactions, thrush and
stomach upsets. A few patients perceived that the antibiotics that they had used had become less effective
over time. Some patients reported that they had little or no understanding of antibiotic resistance and the
need for antibiotic stewardship, whereas others appreciated the need not to overuse antibiotics:
So of course, they [doctors] are a bit concerned about giving me tablets, if I get too used to them and
they don’t work.
Participant 9, CRP < 20 mg/l, no antibiotics
Patients felt that they had little understanding of how their doctor or nurse made decisions about whether
or not antibiotics were required. Most often, patients thought that doctors predominantly based their
decision on chest sounds:
Well in general they you know listen to my chest and do my blood pressure and that sort of thing,
so they usually just do the chest, and decide then whether they think I’m rattling enough to need
antibiotics or not.
Participant 1, CRP < 20 mg/l, no antibiotics
Patients discussed antibiotic resistance in terms of their body becoming resistant or ‘immune’ to the medication,
blood becoming resistant or the immune system becoming damaged. A small minority of patients discussed the
risk of overuse of antibiotics in terms of the bacteria becoming ‘immune’ to the medication. However, several
patients reported that they were not aware of any disadvantages to antibiotic use:
There’s no drawbacks at all [to antibiotic use].
Participant 10, CRP < 20 mg/l, no antibiotics
Chronic obstructive pulmonary disease routine care pathway
Clinicians felt that the risk of undertreatment was a driver of antibiotic prescribing for AECOPD:
There’s so much pressure not to refer patients to hospital, so if you, the view is, if you treat them
early, you know, when their symptoms are relatively mild, maybe we’ll be able to stop someone going
to hospital unnecessarily.
General practitioner 9
Fear of litigation and how the use of the CRP can help provide objective evidence was also discussed:
I can only speak for myself, but every patient I see, when I’m writing down, I’m thinking that
somebody’s going to be suing me as a result of it, which is very sad but it’s just the way the world’s
going, and I think every GP is probably very similar, and I know that if I write down ‘CRP less than 5’
then anyone taking me to court over that is going to have one hell of a hard time of it to prove that
that patient was ill at that point.
General practitioner 2
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Patients in some practices were issued with ‘rescue packs’ containing antibiotics and oral steroids that they
could use at home to manage AECOPDs. Patients had mixed views about the use of rescue packs, with
some preferring to see a doctor before starting antibiotics and others preferring to start their medication
without the need to see a doctor:
I’d just rather skip the appointment because you know if you’re bad or not don’t you? You know
what I mean, so if, if I knew I was really ill and I had them in the drawer then I would just take them
because I knows what it is now.
Participant 11, CRP > 40 mg/l, prescribed antibiotics
Clinicians also had some ambivalence about rescue packs, expressing the view that these were appropriate
only for patients who were able to recognise the symptoms that indicated that antibiotics were required.
They felt that there were advantages to rescue packs in terms of encouraging self-management and
timely treatment:
It [having a rescue pack] improves their confidence, I think in theory it could stop people exacerbating
so badly that they end up being admitted to secondary care.
General practitioner 5
Not all practices issued rescue packs to patients, and some did this only when it had been advised by
secondary care. The potential for overusing antibiotics and passing on difficult decisions about when to
start treatment to the patients were seen as possible disadvantages of using rescue packs:
Some patients might find it quite difficult to understand exactly when a leaflet [about use of the
rescue pack] is given to them or even when they’re explained about the leaflet and when to use the
antibiotics, we are leaving the patients to make their own clinical decisions.
General practitioner 1
One clinician suggested that a CRP test that could be easily administered by patients at home could help
patients make decisions about when they should start their antibiotics in the future.
Qualitative evaluation summary
Patients and clinicians participating in the PACE trial’s qualitative evaluation perceived the CRP POCT as a
useful tool to help guide the management of AECOPD in primary care. They described it as providing an
objective sign of the severity of illness, increasing confidence and providing reassurance, being a useful
tool for patient education, and being helpful in reinforcing the prescriber’s decision when communicating
with patients. Previous qualitative studies in adults with acute cough have also indicated that CRP POCTs
are an acceptable intervention from the perspectives of patients and clinicians, with the main perceived
mechanisms of the intervention being reducing clinical uncertainty, increasing prescribing confidence and
enhancing communication,65–67 and our findings were highly consistent with this.
Although CRP POCTs are widely used in a number of European countries for managing LRTIs, they have
not yet become routinely used in the NHS.68 Concerns about funding for the CRP POCT machine and
cartridges, and the time needed to use the CRP POCT, were identified as potential barriers to adoption
in NHS primary care services. Similar issues have been identified with regard to the routine use of CRP
POCTs in the management of LRTIs in NHS primary care services.68 The primary care staff interviewed in
the current study generally felt that the additional time required to complete the test was worth the
investment, and felt that the test may help practitioners be less risk-averse when deciding to manage
an AECOPD without antibiotics. However, they felt that the costs of the CRP POCT testing equipment
and cartridges would be prohibitive under current funding arrangements for NHS primary care services,
and this would need to be addressed before it was implemented in routine practice.
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There is a lack of evidence for risk stratification based on current clinical assessments in guiding antibiotic
prescribing for AECOPD.69 Our qualitative findings indicated that, in line with this, prescribers felt that
the CRP POCT provided useful information in addition to their usual clinical assessment to guide their
antibiotic prescribing decisions for AECOPD. They emphasised that the CRP POCT result would not replace
other clinical factors in their decision-making but that, rather, it added a piece of objective information
for them to consider. Clinicians reported that they would be most likely to use the CRP POCT in routine
care in cases when there was clinical uncertainty, which is consistent with the views of clinicians on when
the test would be used in the management of LRTIs.67 In a study67 of primary care clinicians’ views on
the potential use of CRP POCTs for LRTIs, clinicians discussed difficulties with interpreting results or being
distracted from clinical reasoning as potential disadvantages of the test. The clinicians interviewed in the
current study who had used the CRP POCT in consultations did not report experiencing any difficulties in
interpreting the test or any negative impact on their clinical judgement.
Contextual factors can influence, and be influenced by, the introduction of an intervention aiming to alter
antibiotic consumption for AECOPD, including patient attitudes towards antibiotics and clinician perception
of patient preferences,70,71 and broader issues in relation to the care pathways for COPD, such as continuity
of care, patient engagement, resources and communication.72,73 The current study indicated that, in
addition to informing clinicians’ decisions about the need for antibiotics, the CRP POCT was used as a
tool to educate patients, reinforce clinicians’ antibiotic prescribing decisions and facilitate communication.
Patients, however, reported that they were not engaging with the decisions being made about antibiotic
treatment for their AECOPD. Although they did not report being dissatisfied with this consultation
dynamic, their lack of involvement was reflected in their low levels of understanding of the potential
disadvantages of using antibiotics and of the purpose of the CRP POCT.
Primary care clinicians’ antibiotic prescribing behaviour for acute cough in adults is influenced by their
perceptions of patient expectations, but their perceptions do not always match with patient views.71 Patients
report lower levels of satisfaction with their consultation if they have an expectation of receiving antibiotics that
is not met.71 Being able to effectively elicit patient views is, therefore, an important skill for clinicians managing
acute cough.71 A study33 of the use of CRP POCT to guide antibiotic prescribing for acute respiratory tract
infections in primary care indicated that both the CRP POCT and clinician training in communication skills were
effective in reducing antibiotic prescribing, but the greatest reduction was seen when the CRP POCT and
communication skills training interventions were combined. Patients with acute cough whose clinician had
received communication skills training or had used a CRP POCT were satisfied with their consultation even when
they had not received an antibiotic.66 Patients felt positive about the clinician communication skills training,
reporting that they felt that their concerns had been understood.66 Training for prescribers in integrating
the CRP POCT into consultations for AECOPD in a patient-centred way may, therefore, enhance its effects.
Patient education is likely to be an important aspect of the successful implementation of the CRP POCT,
to ensure that patients understand why the test is needed, have confidence in its use and are sufficiently
informed about their treatment options so that they can become more engaged with the decisions that
are made about their health care. This is particularly relevant to the population of patients with COPD,
as older adults and those from socioeconomically deprived backgrounds are more often affected by this
disease,74 and low health literacy is more prevalent in these demographic groups.75,76 Ensuring that there
is continuity of care and that a consistent approach to antibiotic prescribing for AECOPD is adopted could
also increase the quality of communication about the appropriate use of antibiotics in the management of
AECOPD and facilitate the implementation of the CRP POCT in routine care.
Conclusions
Patients and clinicians perceived the addition of the CRP POCT to consultations for AECOPD as acceptable
and useful. Implementation planning should include consideration of funding arrangements, training for
clinicians, patient education, provision of continuity of care and promotion of a consistent approach to
prescribing as ways of facilitating implementation and enhancing the effects of the CRP POCT intervention.
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Chapter 5 Health economics
Introduction
This chapter presents the methods and results of the economic evaluation conducted alongside the PACE
trial. A within-trial health economic analysis was undertaken from a health service perspective (the UK
NHS), reflecting the trial follow-up period of 6 months and addressing the secondary trial objective of
assessing the costs and cost-effectiveness of using CRP POCT to guide antibiotic prescribing for AECOPD
in primary care. Wider costs resulting from patient absences from work were also considered but were
reported separately. The health economic evaluation included a cost-effectiveness analysis, a cost–utility
analysis (CUA) and a cost–consequences analysis. A trial-based budget impact analysis was undertaken to
estimate the likely impact of using CRP POCT in the management of antibiotic prescribing for AECOPD in
primary care on NHS budgets.
Methods
Before the analysis commenced, a health economic analysis plan was produced, which was reviewed by
the trial team and incorporated in the statistical analysis plan. The health economic team followed this
analysis plan during the conduct of the economic evaluation without deviation.
Costs included in the health economic analysis
The health economic analysis considered the following:
l cost of the CRP POCT implementation in primary care (including staff time for training, testing and
travel, and costs of CRP POCT kits and consumables)
l costs of medications prescribed (including antibiotics, oral corticosteroids and inhaled medications)
l cost of health-care resource use (primary and secondary care).
As the analyses were undertaken from a NHS perspective, the cost associated with productivity loss due to
time off work was assessed but not included in the formal evaluation.
Costs are based on all available cases (for the most complete overview), the MITT population for antibiotic
consumption and EQ-5D (for the cost-effectiveness analysis and CUA base cases) and the ITT population
(using multiple imputation) for the secondary analysis. All costs are expressed in 2015/16 Great British
pounds, inflated and converted appropriately where required.77 Neither costs nor outcomes were
discounted, as the duration of the trial follow-up period did not exceed 1 year.
C-reactive protein point-of-care test costs
Resource use resulting from CRP POCT implementation (including materials, consumables, staff time and
training) was estimated through interviews and direct communications with general practice staff involved
in the trial, the CRP POCT manufacturer and the trial team, and by using data collected during the trial
(e.g. frequency of repeat testing). Unit costs of materials and consumables were obtained directly from the
manufacturer and online wholesale catalogues. Staff costs were estimated using published unit costs.78
Any assumptions were based on clinical expert opinion from the PACE trial team and the impact on the
results was tested as part of the sensitivity analysis.
The number of CRP tests performed during the trial was recorded for every participant at baseline and
within the first 4 weeks of follow-up.
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Cost of medication prescribed for the treatment of acute exacerbations of
chronic obstructive pulmonary disease
New prescriptions of medications for treating COPD were recorded routinely during the trial immediately
following randomisation and for the 6-month review period. This comprised prescriptions for antibiotics,
oral steroids and inhaled medication (including short- and long-acting beta-2 agonists, short- and long-
acting muscarinic agonists, inhaled corticosteroids and combination inhalers). Unit costs were taken from
the Monthly Index of Medical Specialities79 and the British National Formulary.80 All medication unit costs
used in the costing of the economic evaluation can be found in Tables 49 and 50 in Appendix 3.
Prescriptions were costed individually based on prescribed dose, treatment duration and number of doses per
day. For antibiotics and oral steroids, in cases when information on prescribed dose, duration or frequency
was missing, the most common prescription of the specific medication was assumed. In cases when no
antibiotic or steroid name was reported and when it could not be extrapolated from other information
(e.g. dose or duration), the most commonly prescribed antibiotic (500 mg of amoxicillin, 21 tablets) and oral
steroid (5 mg of prednisolone, 56 tablets) were assumed. For inhaled medication, it was assumed that, if the
medication was increased at the index consultation, a new prescription was issued at the same time. If no
information on the type of inhaled medication was available, it was assumed that salbutamol metered dose
inhaler (100 mg) was given, using the mean cost of all of its licensed formulations.
The costs of antibiotics, oral steroids and inhaled medications were calculated at the initial consultation,
for the 6-month review period and as a total (initial consultation and 6 months combined). It was assumed,
for the purpose of the cost-effectiveness analysis, that one-sixth of all medication prescriptions recorded in
the 6-month review period would have occurred in the first 4 weeks. This assumption was tested in a
sensitivity analysis.
Cost of health-care resource use
Health-care resource use (including primary care consultations, A&E visits, outpatient appointments and
inpatient stays) was collected using data from an adapted Client Service Receipt Inventory (CSRI), integrated
in the 4-week CRF and 6-month note review, to assess the differences in the profile of health-care use as a
result of the intervention compared with control. If one or more items in the health-care consultations part of
the CRF (i.e. the CSRI) were completed (values of ≥ 0), the CSRI was assumed to have been fully completed
and any missing items were imputed with zeros. If the CRF was marked as ‘not done’ or was otherwise fully
incomplete, data were considered missing and costs were based on all available cases for the base case,
using multiple imputation to account for missing data in the secondary analyses.
Costs were assigned using published unit costs.78,81 Outpatient visits and inpatient stays were costed individually
according to the reasons for health-care contact, length of stay and specialty/department visited recorded in the
trial CRFs. All unit costs used can be found in Table 51 in Appendix 3. The health-care costs in both trial arms
were summated and the mean difference per patient in costs (including 95% CIs) was calculated.
Every patient had one initial index consultation (baseline appointment) during which they were randomised,
which was excluded from the 4-week and 6-month follow-up health-care costs but included in the final
health economic analysis.
Cost of work lost as a result of acute exacerbations of chronic obstructive
pulmonary disease
Participants provided the number of days they had taken off paid employment as a result of AECOPD at
the 4-week follow-up time point. Using the Human Capital Approach,82 days taken off work were costed
using a cost of £97.77 per day based on average UK weekly gross earnings for the whole economy during
the trial period.83
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Cost-effectiveness analysis
The cost-effectiveness analysis expressed the incremental cost required to reduce the number of people
consuming at least one dose of antibiotics by 1%. The base-case analysis was based on the MITT
population for the co-primary outcome of antibiotic consumption at 4 weeks. The total costs at 4 weeks
(including costs at the initial consultation) for the MITT population only were considered. The results of
the comparative analysis of incremental costs and effects can be summarised in terms of incremental
cost-effectiveness ratios (ICERs). An ICER can be represented as:
ICER =
C1 − C0
E1 − E0
=
ΔC
ΔE
, (1)
where C1 and E1 are the costs and effects of the intervention arm and C0 and E0 are the costs and effects of
the control arm, with ΔC and ΔE the incremental costs and effects of the intervention compared with control.
The ICER is reported to determine the cost-effectiveness of the intervention compared with competing
alternatives and to aid decision-making. No established willingness-to-pay threshold for the cost-effectiveness
of reducing antibiotic consumption is available. Furthermore, cost-effectiveness is a spectrum rather than a
dichotomy, with the maximum threshold increasing depending on the circumstances. The reported ICERs
from our analysis are presented to assist the decision-making process and are not an absolute statement on
whether or not the intervention can be deemed cost-effective.
Cost–utility analysis
A within-trial CUA was undertaken to assess the incremental costs per quality-adjusted life-year (QALY)
gained as a result of using CRP POCT compared with control at 6 months. Individual-level utility scores
were obtained at each assessment point using the EQ-5D-5L questionnaire mapped back to the UK
EQ-5D-3L valuation set, as currently recommended,84 and summated for the CRP POCT and control arms.
During the internal pilot, the EQ-5D-3L version of the questionnaire was used and health states were
transformed using UK EQ-5D-3L valuation sets. QALYs for each patient were calculated based on the
utility scores at baseline and 6 months using the area under the curve approach and linear interpolation.
The total costs at 6 months (including baseline) for the EQ-5D MITT population were used to calculate
the incremental cost per QALY gained. The EQ-5D MITT population comprised all patients who had a
complete baseline questionnaire and any one complete follow-up questionnaire.
Quality-adjusted life-years incorporate quantity of life (additional life-years) and quality of life in one
measure. Thus, by dividing the difference in costs by the difference in QALYs, the cost per QALY can be
calculated for each comparison. Generally, NICE considers an intervention cost-effective if one of the
following applies:
l The intervention is less costly and more clinically effective than all other relevant alternatives. In this
case, no ICER is calculated as the strategy in question dominates the alternatives.
l The intervention has an ICER of < £20,000 per QALY compared with the next best alternative. This
means that an investment of up to £20,000 to achieve an additional QALY is considered cost-effective.
The ICER resulting from the CUA was compared with the willingness-to-pay threshold of £20,000 per
QALY gained as standardised by NICE. No conditions for non-inferiority were applied in this analysis. The
results are reported as ICERs showing the extra cost of producing one extra QALY or the extra savings
achieved by sacrificing one additional QALY.
Sensitivity analyses
Sensitivity analyses were undertaken to test the robustness of the results of both cost-effectiveness analysis
and CUA, considering the uncertainty in input parameters, such as costs and outcomes, and in different
scenarios. Deterministic, univariate sensitivity analyses changed test, medication and health-care costs and
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outcomes individually within plausible ranges. Scenario analyses tested different assumptions and
recalculated the ICER using COPD-related costs only. Furthermore, a probabilistic sensitivity analysis used
non-parametric bootstrapping to address joint parameter uncertainty and assess the impact on the ICER
during 1000 simulations that were undertaken using random sampling of the distributions of costs and
outcomes, with results presented on cost-effectiveness planes and as cost-effectiveness acceptability
curves. The cost-effectiveness plane is a scatterplot of the point estimates obtained as a result of the 1000
simulations depicted in four quadrants, representing the probability of the intervention being more or less
costly and more or less effective than the control. A cost-effectiveness acceptability curve is a curve that
describes the probability of the intervention being cost-effective at different willingness-to-pay thresholds
based on the probabilistic sensitivity analysis.
We also undertook a secondary analysis in the ITT population using multiple imputation to account for missing
data. The problems concerning missing data are particularly relevant to health economic analysis, as the
main outcomes are cumulative measures collected during the trial. Missing items relating to health-care
service usage may underestimate the total costs, and missing outcome data may be correlated with effects,
as those individuals without information may be systematically different from those for whom all information
is observed.85 As such, using only complete-case assessments and available cases analysis could result in
meaningful data being excluded.85 We therefore adopted a multiple imputation approach as the appropriate
technique to provide a comprehensive investigation of the impact of missing data on the estimations of
cost-effectiveness.86 Multiple imputation was performed using chained equations and predictive mean
matching on all variables except categorical (yes/no) parameters, where multiple imputation using logistic
regression was deemed appropriate given values of 0 and 1 only. Predictive mean matching for continuous
variables was preferred to other methods as imputed values are taken from the set of observed values,
avoiding any values outside plausible ranges (e.g. utility values of > 1 and costs of < £0). A total of
20 imputations were added. The results were combined using Rubin’s rules.87
Cost–consequences analysis
A cost–consequences analysis presents all relevant primary and secondary outcomes alongside the costs in
tabular form (without combining them into ICERs) to leave decision-makers the option to form their own
view of relative importance.
Budget impact analysis
A trial-based budget impact analysis was undertaken and extrapolated to the UK population to estimate
the likely impact of using CRP POCT on NHS budgets through implementation costs and changes in
health-care usage. The budget impact analysis was informed by trial data supplemented by the best
available published evidence when required and conducted according to recommended good practice.88
A simple budget impact model was constructed in Microsoft Excel® 2010 (Microsoft Corporation,
Redmond, WA, USA). The number of eligible patients was calculated using prevalence and yearly incidence
figures and accounting for age-specific and COPD mortality. Prevalence, incidence and mortality data for
COPD in the UK were obtained from published sources89 and age-specific general population mortality
was derived from statistics available on deaths in England and Wales in 2016.90 It is estimated that, since
2012,89 the yearly incidence of COPD in the UK has been steady, at around 115,000 new diagnoses,
and the budget impact analysis, therefore, assumes the incidence to be constant over the first 5 years
after CRP testing is introduced in primary care. It also assumes that all diagnosed patients experience
one AECOPD per year and are eligible for CRP testing. The expected uptake rate is assumed to be 10%
in year 1, rising to 50% depending on the installation of the required analysers in general practices.
The costs of testing and subsequent health-care resource use were taken from the trial costings.
Sensitivity analyses were undertaken to estimate the range of a potential budget impact considering
parameter uncertainty within plausible ranges.
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Results
Four participants were excluded from all analyses (three withdrew consent to use their data and one was
randomised in error).
C-reactive protein point-of-care test costs
The total cost of a CRP POCT was estimated to be £11.31 per test (Table 19). This cost comprises £5.40
for materials and consumables (including quality control tests), £0.13 for capital expenditure, £0.10 for
staff training and £5.38 for staff required for sample processing, testing and reporting. During the trial
baseline CRP testing, 10 out of 333 tests were invalid or resulted in an error message, requiring repeat
testing. Therefore, a cost of £0.29 was added to each test to account for material and staff costs required
for repeat testing.
TABLE 19 Cost components and total testing cost of CRP POCT in primary care
Cost component List price (£) Resource use
Cost per
test (£) Notes
Material costs
Alere Afinion CRP test
cartridgea
58.00 1 3.87 No discounts given, 15 cartridges per pack
Alcohol wipeb 2.00 1 0.02 100 wipes per pack
Prick needlec 7.50 1 0.08 100 lancets per pack
Gauze pads/swabsd 15.30 1 0.06 250 pads per pack
Glovese 9.19 2 0.18 100 per pack
Quality control testing kitsa 36.00 0.13 1.20 Four per pack. One high level and one low
level control required per 15 tests
Repeat samples because of
invalid resultsf
58.00 0.03 0.13 10/333 tests at baseline gave an error (3.0%)
Capital costs
Alere Afinion AS100 Analyzera 1200.00 0.00011 0.13 7-year life span (five samples per day
assumed, 260 working days per year)
= 9100 samples
Maintenance contracta None 0.00 No maintenance required
Set-up and training
Initial set-up, calibration and
configurationa
0.00 Done by supplier before training
Travel and trainer cost 0.00 Done at GP surgery, included in purchase
price
GP opportunity costg 134.00/hour 45 minutes 100.50 GMS activity including qualifications and
excluding direct care staff
Nurse opportunity cost
g
43.00/hour 45 minutes 32.25 Including qualifications
Testing
Analyser switch-on and
self-testa,g
43.00/hour 1 minute 0.14 Nurse assumed, 1 minute needed,
five tests per day assumed
Sample processing (including
taking sample, labelling,
preparation and test start)
by GP
g
199.00/hour 1.15 minutes 3.81 Patient contact excluding direct care staff,
1 minute and 9 seconds average processing
time,a assumed 70% of cases
continued
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Three participants in the control arm received CRP tests at baseline in error and eight participants in the
CRP POCT arm did not have test results as a result of machine errors. Four participants in the control arm
self-reported a CRP test at baseline, with no other records to clarify.
Considering all available cases (n = 649), the total cost of CRP testing at baseline in the CRP POCT arm
(n = 325) was £3697.54, with a mean of £11.38 per participant (SD £1.25 per participant). Assuming that
the four unresolved patients did not receive a CRP test, the total cost in the control arm (n = 324) was
£33.92, with a mean of £0.10 per patient (SD £1.09 per patient), increasing to £79.16 (mean £0.24 per
patient, SD £1.64 per patient) if it is assumed that the four unresolved cases did receive a CRP test.
In the first 4 weeks after randomisation, 18 patients in the CRP POCT arm received 20 CRP tests. This
increases the total cost of CRP testing at the 4-week follow-up point (including baseline) to £3923.69 in
the CRP POCT arm (mean cost per patient £12.08, SD £3.23).
Cost of medication prescribed for treatment of acute exacerbations of
chronic obstructive pulmonary disease
A breakdown summary of the mean costs for all recorded medication prescriptions is shown in Table 20.
The total medication costs for the CRP POCT and control arms are presented in Appendix 3, Table 52.
Antibiotics
Considering all available cases (n = 649), 155 patients in the CRP POCT arm (47.7%) were prescribed antibiotics
at their baseline general practitioner (GP) consultation following CRP testing, compared with 225 patients
in the control arm (69.4%). This resulted in a cost saving of £0.28 (95% CI –£0.39 to –£0.17) per patient
at baseline (see Table 20). The most commonly prescribed antibiotic was amoxicillin (59.5%), followed by
doxycycline (24.0%), clarithromycin (12.8%), co-amoxiclav (1.9%), erythromycin (1.3%) and cefalexin (0.5%).
In the 6-month review period (n = 606), 173 patients in the CRP POCT arm (56.9% of 304 patients) were
issued 403 antibiotic prescriptions, and 191 people in the control arm (63.2% of 302 patients) had
received 404 antibiotic prescriptions. Of these, 80.6% were attributed to COPD and lung conditions
(including rescue packs) in the CRP POCT arm and 79.7% were attributed to COPD and lung conditions
(including rescue packs) in the control arm. Other most common indications for which antibiotics were
issued were urinary tract infections, skin infections, wound infections and infected ulcers. In total, 12.8%
TABLE 19 Cost components and total testing cost of CRP POCT in primary care (continued )
Cost component List price (£) Resource use
Cost per
test (£) Notes
Sample processing (including
taking sample, labelling,
preparation and test start)
by nurse
43.00/hour 1.15 minutes 0.82 Including qualifications, 1 minute and
9 seconds average processing time,a
assumed 30% of cases
Results check and reporting
(GP)
199.00/hour 0.7 minutes 2.32
Dealing with testing errors and
retesting
199.00/hour 0.03 0.16 10/333 tests at baseline required retesting
Total test cost 11.31
GP, general practitioner.
a Source: Alere Inc. (Adam Martin, 21 July 2017, personal communication).
b Source: Medisupplies.91
c Source: Amazon.92
d Source: Medisupplies.93
e Source: Scientific Laboratory Supplies.94
f Source: PACE trial.
g Source: Personal Social Services Research Unit, 2016.78
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fewer patients received any antibiotic prescriptions in the 6 months following the baseline GP consultation
in the CRP POCT arm, the patients who were issued prescriptions had, on average, 0.21 prescriptions
more than patients in the control arm (2.33 vs. 2.12). Furthermore, the prescriptions issued were for more
expensive antibiotic formulations (mean of £1.66 per prescription, compared with £1.53 in the control arm),
resulting in a £0.15 increase in cost of antibiotics per patient in the CRP POCT arm (p = 0.251).
Overall, when initial consultation and 6-month review period prescriptions were combined, the mean cost of
antibiotics in the CRP POCT arm was reduced by £0.13 (95% CI –£0.72 to £0.46) per patient (p = 0.135).
Oral corticosteroids
All oral corticosteroids prescribed at baseline were prednisolone formulations. In the CRP POCT arm,
178 patients (54.9% of 324) received oral steroids compared with 179 patients (55.6% of 322) in the
control arm. Patients who were issued prescriptions for oral steroids received, on average, 1.00 prescription
in the control arm and 1.02 prescriptions in the CRP POCT arm, resulting in a marginal cost increase of £0.02
per patient in the CRP POCT group (see Table 20).
During the 6-month follow-up period, 130 patients in the CRP POCT arm (42.8% of 304) received
279 prescriptions for oral steroids, of which 91.4% were issued for COPD and related respiratory disease.
In the control arm, 146 patients (48.3% of 302) were issued 271 steroid prescriptions, of which 95.9%
were related to COPD and respiratory conditions. Although 5.5% fewer people received any oral steroid
prescriptions in the CRP POCT arm, they were issued 0.29 more prescriptions for oral steroids per patient
(2.15 vs. 1.86 in the control arm). However, the average cost of oral steroid prescriptions per patient was
lower in the CRP POCT arm (£1.20 vs. £1.40 in the control arm), partially driven by the higher cost of
dexamethasone for one patient in the control arm. The cost of oral steroids during the 6-month review
period was, therefore, £0.16 per patient (95% CI –£0.55 to £0.23; p = 0.491) lower in the CRP POCT arm.
Overall, when baseline and 6-month review period prescriptions were combined, oral steroid cost was
reduced by £0.12 (95% CI –£0.52 to £0.28; p = 0.482) per patient receiving the intervention.
TABLE 20 Cost of antibiotics, oral steroids, inhaled medications and all medications at baseline and 6-month
follow-up
Medication
Trial arm, mean (SD)
Difference (95% CI) p-value
CRP POCT
(n= 325)
Usual care
(n= 324)
Antibiotics
Cost at index consultation (£), per patient 0.63 (0.69) 0.91 (0.72) –0.28 (–0.39 to –0.17) 0.029
Cost at 6-month review (£), per patient 2.20 (4.69) 2.05 (2.78) 0.15 (–0.46 to 0.77) 0.251
Oral steroids
Cost at index consultation (£), per patient 0.75 (0.77) 0.74 (0.73) 0.02 (–0.10 to 0.13) 0.862
Cost at 6-month review (£), per patient 1.10 (1.92) 1.26 (2.88) –0.16 (–0.55 to 0.23) 0.491
Inhaled medications
Cost at index consultation (£), per patient 3.14 (8.82) 3.10 (8.41) 0.05 (–1.33 to 1.42) 0.889
Cost at 6-month review (£), per patient 10.05 (18.65) 7.74 (16.20) 2.30 (–0.49 to 5.09) 0.109
Total medication cost
Cost at index consultation (£), per patient 4.51 (8.74) 4.70 (8.39) –0.21 (–1.57 to 1.16) 0.905
Cost at 6-month review (£), per patient 13.35 (19.55) 11.05 (17.00) 2.30 (–0.62 to 5.22) 0.341
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Inhaled medications
In the CRP POCT arm, 71 patients (21.9% of 324) were prescribed new inhaled medications or had
their existing prescription increased at baseline, resulting in 87 prescriptions (1.23 per patient receiving
any inhaled medication prescriptions). This was similar to the 73 patients (22.7% of 321) in the control
arm who were issued 86 prescriptions for inhaled medications (1.18 per patient receiving any inhaled
medication prescriptions). The marginally higher cost of £0.05 per patient (see Table 20) reflects the cost
of one additional prescription in the CRP POCT arm.
During the 6-month follow-up period, 93 CRP POCT arm patients (30.6% of 304) received 124 prescriptions
for inhaled medications (1.33 per patient receiving any prescriptions). This was 5.4% more than in the
control arm, in which 76 patients (25.2% of 302) were issued 94 inhaler prescriptions (1.24 per patient
receiving a prescription). Owing to the increased use of inhalers in the CRP POCT arm and the higher
acquisition cost (on average approximately £22 per prescription), the total cost of inhaled medications
during the 6-month review period was £2.30 higher per patient (95% CI –£0.49 to £5.09 per patient).
Overall, when baseline and 6-month review period prescriptions were combined, inhaler cost was £2.21
(95% CI –£0.75 to £5.18; p = 0.228) per patient higher in the CRP POCT arm than in the control arm.
Cost of health-care resource use
The costs reported represent the mean cost per patient. The total health-care costs for CRP POCT and
control arms are summarised in Appendix 3, Tables 53 and 54.
Primary care costs
In the first 4 weeks following randomisation, 27.6% of people in the CRP POCT arm (76/275 available cases)
saw their GP at the surgery for any reason an average of 1.45 times. This represents a difference of 7.7%
compared with the control arm, in which 35.4% of patients (99/280 available cases) had an average of
1.42 GP visits at their surgery, and results in a cost difference for GP visits at the surgery in the CRP POCT
arm of –£3.73 per person (95% CI –£8.38 to –£0.92 per person; p = 0.07).
Patients in the CRP POCT arm accrued slightly higher total costs for nurse consultations and other health-care
contacts (NHS Direct) than those in the control arm. However, this was more than offset by savings from fewer
GP contacts, with an overall cost difference of –£4.58 (95% CI –£13.55 to £4.39; p = 0.132) per patient for all
primary care use in the CRP POCT arm, which was mainly driven by savings in GP visits at the surgery and GP
telephone consultations (Table 21).
During the 6-month review period (which includes the first 4 weeks but excludes the baseline), 259 people
saw their GP at the surgery for any reason in both arms (85.7% of available cases in the control arm and
85.2% of available cases in the CRP POCT arm). Patients in the CRP POCT arm saw their GP for any condition
on average 3.8 times. This was slightly more frequently than the 3.7 times in the control arm, resulting in
a cost increase of £3.21 per patient (see Table 21). Considering all primary care contacts, costs for patients
in the CRP POCT arm were £5.16 (95% CI –£18.14 to £28.47; p = 0.882) per person more than for control
arm patients.
However, when analysing primary care contacts related to COPD only (Table 22), fewer patients had GP
home visits, nurse home visits and GP telephone consultations in the CRP POCT arm than in the control
arm. Furthermore, GP surgery consultations for COPD were 2.7% less frequent (58.6% vs. 61.3%), with
slightly fewer visits per patient (2.18 visits in CRP POCT arm compared with 2.27 visits in the control arm),
resulting in an overall difference in primary care cost due to COPD in the CRP POCT arm of £6.35 per
patient (95% CI –£18.98 to £6.27; p = 0.515).
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TABLE 21 Cost of primary care resources used in the 4-week follow-up and 6-month review periods
Health-care resource
Trial arm
Difference (95% CI) p-value
CRP POCT
(n= 275)
Usual care
(n= 280)
Primary care: cost per patient in 4-week follow-up period
GP visits at the surgery (£) (SD) 14.40 (26.64) 18.13 (29.08) –3.73 (–8.38 to –0.92) 0.070
Nurse visits at the surgery (£) (SD) 2.79 (7.43) 2.47 (5.55) 0.32 (–0.77 to 1.41) 0.950
GP visits at home (£) (SD) 1.24 (10.20) 1.52 (13.38) –0.28 (–2.27 to 1.70) 0.984
Nurse visits at home (£) (SD) 0.09 (1.43) 0.17 (2.01) –0.08 (–0.37 to 0.21) 0.574
GP telephone consultations (£) (SD) 2.98 (10.55) 4.01 (14.19) –1.02 (–3.11 to 1.07) 0.579
Nurse telephone consultations (£) (SD) 0.22 (1.20) 0.19 (1.26) 0.03 (–0.18 to 0.23) 0.592
Other health-care contacts (£) (SD) 1.86 (26.47) 1.67 (26.20) 0.19 (–4.20 to 4.58) 0.303
Total cost of primary care use (£) per
patient (SD)
23.57 (52.34) 28.16 (55.16) –4.58 (–13.55 to 4.39) 0.132
Primary care: cost per patient in 6-month review period
GP visits at the surgery (£), (SD) 117.59 (102.44) 114.32 (93.48) 3.27 (–12.37 to 18.92) 0.969
Nurse visits at the surgery (£), (SD) 18.04 (24.84) 16.72 (29.44) 1.32 (–3.02 to 5.67) 0.120
GP visits at home (£), (SD) 6.99 (42.83) 9.57 (40.45) –2.58 (–9.23 to 4.07) 0.364
Nurse visits at home (£), (SD) 1.80 (20.51) 1.42 (13.76) 0.38 (–2.41 to 3.17) 0.521
GP telephone consultations (£), (SD) 27.90 (51.32) 25.28 (46.39) 2.62 (–5.18 to 10.43) 0.540
Nurse telephone consultations (£), (SD) 1.39 (3.66) 1.31 (4.16) 0.08 (–0.55 to 0.70) 0.818
Other health-care contacts (£), (SD) 0.28 (1.78) 0.22 (1.80) 0.06 (–0.22 to 0.35) 0.413
Total cost of primary care use (£) per
patient (SD)
174.00 (153.48) 168.83 (138.20) 5.16 (–18.14 to 28.47) 0.882
TABLE 22 Cost of primary care resources used in the 6-month review period related to COPD
Health-care resource
Trial arm (£), mean (SD)
Difference (£) (95% CI) p-value
CRP POCT
(n= 304)
Usual care
(n= 302)
Primary care related to COPD: cost per patient
GP visits at the surgery 45.95 (55.06) 50.07 (59.78) –4.12 (–13.29 to 5.05) 0.489
Nurse visits at the surgery 7.31 (10.44) 6.67 (11.83) 0.64 (–1.14 to 2.42) 0.115
GP visits at home 3.08 (18.66) 4.50 (22.53) –1.43 (–4.73 to 1.87) 0.376
Nurse visits at home 0.00 (0.00) 1.10 (13.12) –1.10 (–2.41 to 0.37) 0.044
GP telephone consultations 10.89 (25.96) 11.23 (28.26) –0.34 (–4.67 to 3.99) 0.735
Nurse telephone consultations 0.82 (2.63) 0.76 (2.79) 0.06 (–0.37 to 0.49) 0.441
Other health-care contacts 0.09 (0.94) 0.16 (1.63) –0.06 (–0.28 to 0.15) 0.987
Total cost of primary care use per patient 68.13 (72.34) 74.49 (85.37) –6.35 (–18.98 to 6.27) 0.515
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Secondary care costs
Secondary care resource use is summarised in Table 23. A summary of secondary care costs can be found
in Table 24.
In the first 4 weeks of follow-up, the secondary care costs were £13.74 (95% CI –£45.87 to £73.35;
p = 0.842) per person higher in the CRP POCT arm, mainly as a result of an increased number of
inpatient stays.
In the 6-month review period, the total secondary care cost was £112.40 (95% CI –£106.67 to £331.46;
p = 0.523) per person higher in the CRP POCT arm (see Table 24), mainly caused by, on average, 3.03 days
(95% CI –0.08 to 6.14 days; p = 0.342) longer inpatient hospital stays in the CRP POCT arm (7.78 days
vs. 4.75 days in the control arm). This was attributed to a higher number of stays exceeding 10 days in
the CRP POCT arm (eight stays of > 10 days, of which three were COPD/respiratory related) than in the
control arm (three stays of > 10 days, all of which were COPD/respiratory related), including two patients
who experienced prolonged inpatient stays (> 20 days) as a consequence of a stroke and a fall.
Considering only COPD-related causes, the total secondary care cost was marginally lower in the CRP
POCT arm despite the mean length of hospital stay being 1.68 days longer (95% CI –1.92 to 5.28 days;
p = 0.617) than in the control arm (6.42 days vs. 4.74 days).
Total costs at 4 weeks and 6 months
The total costs from a NHS perspective at the 4-week follow-up time point (including baseline costs)
were £143.93 (SD £348.96) and £126.34 (SD £329.37) in the CRP POCT and control arms, respectively,
resulting in a difference of £17.59 per patient (95% CI –£34.80 to £69.98 per patient; p = 0.408) with
higher costs in the CRP POCT arm. This was a result of the CRP testing costs and higher inpatient costs
in the CRP POCT arm that could not be offset by savings in primary care (Figure 7).
In the 6-month review period (including baseline), the mean cost per patient for any condition in the CRP
POCT arm was £732.31 (SD £1660.08) and £606.04 (SD £1009.32) in the control arm, representing a
cost increase of £126.26 per patient (95% CI –£85.92 to £338.45 per patient; p = 0.680). This was mainly
driven by higher inpatient costs, slightly increased primary care costs and the cost of CRP testing (Figure 8).
TABLE 23 Secondary care resources used per patient in the trial follow-up period
Health-care resource
Trial arm, n (mean, SD)
CRP POCT (n= 275) Usual care (n= 280)
Secondary care resource use in the 4-week follow-up period
A&E visits 13 (0.05, 0.21) 9 (0.03, 0.18)
Outpatient visits 35 (0.11, 0.41) 42 (0.13, 0.37)
Inpatient stays 7 (0.02, 0.15) 4 (0.01, 0.11)
Secondary care resource use in the 6-month review period n = 305 n = 302
A&E visits 82 (0.25, 0.69) 76 (0.23, 0.61)
Outpatient visits 380 (1.17, 1.55) 393 (1.21, 1.60)
Inpatient stays 35 (0.11, 0.44) 34 (0.10, 0.38)
Secondary care resource use in the 6-month review period related to COPD only
Total A&E visits related to COPD, n (% of all visits) 35 (42.7) 33 (43.4)
Total outpatient visits related to COPD, n (% of all visits) 8 (21.1) 11 (26.2)
Total inpatient stays related to COPD, n (% of all visits) 17 (48.6) 21 (61.8)
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FIGURE 7 Costs accrued in the first 4 weeks of follow-up (including baseline but excluding medication costs
between baseline and 4 weeks because of a lack of data).
TABLE 24 Cost of secondary care resources used per patient in the trial follow-up period
Health-care resource
Trial arm (£), mean (SD)
Difference (£) (95% CI) p-valueCRP POCT (n= 275) Usual care (n= 280)
Secondary care cost per patient during the 4-week follow-up period
A&E visits 6.92 (31.44) 5.12 (29.27) 1.80 (–3.26 to 6.86) 0.366
Outpatient visits 14.45 (53.23) 20.98 (76.26) –6.53 (–17.50 to 4.44) 0.138
Inpatient stays 52.32 (343.41) 31.44 (310.45) 20.88 (–33.68 to 75.44) 0.346
Other secondary care use 8.05 (42.51) 10.51 (62.00) –2.46 (–11.34 to 6.41) 0.246
Total cost of secondary care
use per patient
81.80 (369.35) 68.05 (345.38) 13.74 (–45.87 to 73.35) 0.842
Secondary care cost per patient in the 6-month review period for any reason
n = 305 n = 302
A&E visits 37.03 (98.02) 34.66 (86.56) 2.37 (–12.38 to 17.12) 0.713
Outpatient visits 151.99 (208.14) 157.51 (205.98) –5.53 (–38.54 to 27.49) 0.782
Inpatient stays 347.69 (1581.94) 232.91 (983.98) 115.55 (–90.35 to 322.46) 0.802
Total cost of secondary care
use per patient
536.71 (1673.02) 424.32 (983.98) 112.40 (–106.67 to 331.46) 0.523
Secondary care cost per patient in the 6-month review period for COPD-related reasons only
A&E visits 16.26 (61.07) 14.60 (55.35) 1.66 (–7.63 to 10.95) 0.903
Outpatient visits 24.06 (77.74) 36.84 (105.53) –12.79 (–27.55 to 1.98) 0.115
Inpatient stays 134.16 (855.00) 123.57 (625.23) 10.59 (–108.90 to 130.09) 0.568
Total cost of secondary care
use per patient
174.48 (911.54) 175.01 (669.57) –0.53 (–128.13 to 127.07) 0.271
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However, considering only health-care resource use related to COPD, the total cost was similar in both arms
(Figure 9), with £294.14 per patient in the CRP POCT arm and £287.33 per patient in the control arm,
resulting in a cost difference of £6.81 per patient (95% CI –£116.49 to £130.11 per patient; p = 0.986).
Cost of work lost due to acute exacerbations of chronic obstructive
pulmonary disease
In the CRP POCT arm, 274 patients provided information on whether or not they took time off paid
employment because of COPD. At the 4-week follow-up point, 30.7% were in paid employment at the
time of reporting. Of these, 19.0% reported sickness leave and took an average of 4.3 days off work
because of illness (a total of 69 days off work). This amounted to a cost of £421.62 per person.
By comparison, 280 people provided information in the control arm, of whom 27.5% were in paid
employment at the time of reporting. Of these, 19.5% took a total of 143 days off work, which equals
9.5 days per person. This results in a cost of £932.04 per person in work lost.
Cost-effectiveness analysis
The mean cost for the MITT population (n = 537) at the 4-week follow-up point (including baseline) was
£161.77 (SD £385.58) in the CRP POCT arm (n = 274) and £116.68 (SD £223.46) in the control arm
(n = 263). This represents an incremental cost of £45.09 per person (95% CI £8.07 to £98.26 per person;
p = 0.020) in the CRP POCT arm. Considering that 77.4% of patients in the control arm consumed antibiotics
compared with 57.0% of patients in the CRP POCT arm (see Chapter 3), the mean ICER is £222 (95% CI
–£42.00 to £518.14) per 1% absolute reduction in antibiotic consumption. For the base case, the four
unresolved control patients who reported a CRP POCT test are assumed to not have received a test.
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FIGURE 8 Costs accrued for any condition in the 6-month review period (including baseline costs).
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FIGURE 9 Total costs during study period for CRP POCT and control arm, respectively. Costs associated with COPD
and other respiratory conditions only (including baseline costs).
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Sensitivity analyses
The results of the sensitivity analyses can be found in Table 25. In all analyses, ICERs ranged between £120
and £234 per 1% reduction in antibiotic consumption. ICERs were generally robust but were most affected
by changes in health-care costs and the exclusion of health-care costs not related to COPD.
Probabilistic sensitivity analysis gave a point estimate of the ICER of £196, with the majority of results
more costly but also more effective in the CRP POCT arm, with some iterations where CRP POCT dominates
control (i.e. less costly and more effective; Figures 10 and 11).
TABLE 25 Results of the deterministic sensitivity analyses and scenario analyses on the primary base-case
cost-effectiveness analysis results
Parameter Change(s) ICER (£)
Deterministic one-way sensitivity analysis
CRP POCT costs Remove GP training cost. Assume machine used for other tests in
routine practice. Assume testing carried out predominantly by nurses,
change cost ±20%
211 to 234
Medication costs Change costs ±20% 222 (marginal
change)
Health-care costs Change costs ±20% 190 to 255
Antibiotic consumption Change antibiotic consumption by ±20% 212 to 319
Scenario analysis
CRP POCT costs Four unresolved control cases assumed to have received CRP test
at baseline
222
Medication cost in 4-week
follow-up period
No medication cost considered. Medication cost increased to
one-third of 6-month review costs
220 to 224
Health-care costs COPD-related health-care costs only considered 120
Incremental effect
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FIGURE 10 Cost-effectiveness plane (MITT analysis) for the base case (incremental cost per percentage reduction in
antibiotic consumption).
DOI: 10.3310/hta24150 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 15
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Francis et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
61
Cost–utility analysis
The total cost at 6 months (including baseline) for the EQ-5D MITT population was £759.35 (SD £1712)
per person in the CRP POCT arm (n = 301) and £629.72 (SD £1036) per person in the control arm (n = 301).
The number of QALYs gained over the 6-month review period was small in both arms, with a mean of 0.2915
(SD 0.1240) in the control arm and 0.3000 (SD 0.1275) in the CRP POCT arm, giving a marginal QALY
increase of 0.0085 (95% CI –0.0117 to 0.0286; p = 0.760). This results in an ICER of £15,251 (95% CI
£2959 to £22,813) per QALY gained.
Sensitivity analyses
Results remained reasonably robust during deterministic sensitivity analyses when subjected to changes in
the cost inputs with ICERs between £12,519 and £19,063 and health-care cost as the main cost driver.
Owing to the small between-arm differences in QALY gain, results were more sensitive to changes in this
variable (Table 26).
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FIGURE 11 Cost-effectiveness acceptability curve for base-case cost-effectiveness analysis.
TABLE 26 Results of the deterministic sensitivity analyses and scenario analyses on the base-case CUA results
Parameter Change(s) ICER (£)
Deterministic one-way sensitivity analysis
CRP POCT costs Remove GP training cost. Assume machine used for other tests in
routine practice. Assume testing carried out predominantly by nurses,
change cost ±20%
14,980 to 15,521
Medication costs Change costs ±20% 15,195 to 15,304
Health-care costs Change costs ±20% 12,519 to 17,980
QALY gain Change QALY gain ±20% 12,835 to 19,063
Scenario analysis
QALY gain All patients completing EQ-5D-3L excluded 8444a
CRP POCT costs Four unresolved control cases assumed to have received CRP test at
baseline
15,238
Health-care costs COPD-related health-care costs only considered 1054
a Excluding all internal pilot patients reduced costs in the intervention arm, as one excluded patient had a long-term
hospital stay (unrelated to COPD) associated with high cost.
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Scenario analysis showed that the ICER would be reduced to £1054 per QALY gained if COPD-related
health-care costs only were included in the analysis, with a probability of the intervention being
cost-effective at the £20,000 threshold of 72%.
In the probabilistic sensitivity analysis most results found CRP POCT to be more costly but also more effective.
However, results are distributed across all quadrants of the cost-effectiveness plane as a consequence of the
small differences in costs and QALYs between the two arms (Figure 12). Overall, the probability that CRP
testing is cost-effective at a willingness-to-pay threshold of £20,000 is 56% (Figure 13).
Incremental effect
In
cr
em
en
ta
l c
o
st
 (
£)
–0.020 –0.015 –0.010 –0.005 0.000 0.005 0.010 0.015 0.020 0.025 0.030
–400
–200
0
200
400
600
800
FIGURE 12 Cost-effectiveness plane (MITT analysis) for the base-case CUA (incremental cost per QALY gained).
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FIGURE 13 Cost-effectiveness acceptability curve (MITT analysis) for the base-case CUA (incremental cost per
QALY gained).
DOI: 10.3310/hta24150 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 15
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Francis et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
63
Repeating the CUA using the ITT population after multiple imputation resulted in an ICER of £14,334.
Using the lower and upper bounds of the 95% CIs for the cost and QALY differences to conduct
deterministic sensitivity analysis results in ICERs between £7013 and £21,151, with scenarios in which the
intervention is both dominating and dominated (Table 27). This high level of uncertainty is caused by the
small differences in cost and especially the effect of the intervention compared with the control.
This is also illustrated by the cost-effectiveness plane (Figure 14), with point estimates distributed across all four
quadrants. The majority of the point estimates indicate higher costs associated with the intervention, with
most more effective than the control. The cost-effectiveness acceptability curve shows that, at a willingness-
to-pay threshold of £20,000, the probability of the intervention’s cost-effectiveness is 60% (Figure 15).
TABLE 27 Results of the deterministic sensitivity analyses on the ITT CUA results (following multiple imputation)
Analysis
Incremental
ICER (£) QuadrantCost (£) Effect
Base-case multiple
imputation data
129.01
(95% CI
–91.89 to 349.92)
0.009
(95% CI
–0.002 to 0.020)
14,334 North-east quadrant (intervention
more effective and more costly)
95% CI sensitivity analyses
Upper bound cost
Upper bound QALY
349.92 0.020 17,496 North-east quadrant (intervention
more effective and more costly)
Upper bound cost
Lower bound QALY
349.92 –0.002 (Not applicable)
–174,959
North-west quadrant (intervention
more costly and less effective:
dominated)
Lower bound cost
Upper bound QALY
–91.89 0.020 (Not applicable)
–4595
South-east quadrant (intervention
more effective and less costly:
dominant)
Lower bound cost
Lower bound QALY
–91.89 –0.002 45,946 South-west quadrant (intervention
less effective and less costly)
Incremental effect
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FIGURE 14 Cost-effectiveness plane (ITT analysis using multiple imputation) for the secondary CUA (incremental
cost per QALY gained).
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Cost–consequences analysis
Table 28 summarises the results of the cost–consequences analysis.
Budget impact analysis
The estimated budget impact of the use of CRP POCT in primary care is summarised in Table 29. During
the 6-month trial period, the total cost per patient tested with CRP POCT was £126.26 (95% CI –£85.92
to £338.45) per patient higher than in the control arm. Extrapolated to the UK population, the estimated
budget impact over 5 years is £534M (95% CI –£452.8M to £1.52B; see Sensitivity analysis). This is caused
by increased hospitalisation costs in the CRP POCT arm, mostly unrelated to COPD.
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FIGURE 15 Cost-effectiveness acceptability curve (ITT analysis using multiple imputation) for the secondary CUA
(incremental cost per QALY gained).
TABLE 28 Clinical effectiveness and cost-effectiveness outcomes: cost–consequences analysis
Outcome
Trial arm
Difference (95% CI) p-valueCRP POCT Usual care
Cost impact (£)
Total CRP POCT implementation costs 3924 34 3890
Total costs at 4 weeks 46,778 40,935 5843
Total costs at 6 months 238,000 196,358 41,642
CRP POCT implementation costs per person 12.08 0.11 11.97 (11.60 to 12.34) < 0.001
Mean cost at 4 weeks per patient 143.93 126.34 17.59 (–34.80 to 69.98) 0.408
Mean cost at 6 months per patient 732.31 606.04 126.26 (–85.92 to 338.45) 0.680
Mean COPD-related cost at 6 months per
patient
294.14 287.33 6.81 (–116.49 to 130.11) 0.986
Total cost of productivity loss at 4 weeks 6746 13,981 7235
Mean cost of productivity loss at 4 weeks per
patient taking time off work
421.62 932.04 510.42 (–989.56 to –31.28) 0.022
continued
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Sensitivity analysis
There is considerable uncertainty in the budget impact estimates. The 95% CIs around cost estimates are
wide as a result of the general skewness of cost data. Using the 95% CI for secondary care costs as
observed in the trial, the budget impact ranges from –£452.8M to £1.52B. Uptake rates are assumed as
they are impossible to predict and any change will affect the budget impact of CRP testing. Assuming a
stable uptake of 10%, 20%, 30%, 40% or 50% over 5 years results in budget impact estimates between
£169.5M and £847.6M. Increasing the number of acute exacerbations per patient per year to two raises
the budget impact estimate to £558.9M.
Finally, if COPD-related health-care costs only are considered in the budget impact analysis, CRP testing
leads to a cost saving of £10.2M compared with current routine care. This is due to a health-care cost
reduction of £7.98 per patient (95% CI –£138.55 to £122.59 per patient) in the CRP POCT arm as
observed in the trial.
TABLE 28 Clinical effectiveness and cost-effectiveness outcomes: cost–consequences analysis (continued )
Outcome
Trial arm
Difference (95% CI) p-valueCRP POCT Usual care
Health impact
Number (%) of patients consuming antibiotics
for AECOPD in first 4 weeks
150 (57.0) 212 (77.4) –62; AOR 0.31 (0.20 to 0.47) < 0.001
Antibiotic prescribing at index consultation (%) 155 (47.7) 225 (69.7) –70; AOR 0.31 (0.21 to 0.45) < 0.001
Mean CCQ total scores (points) 2.6 2.8 –0.20 (–0.34 to –0.06) 0.005
EQ-5D health score (VAS) 62.9 59.8 3.12 (0.50 to 5.74) 0.019
QALYs in first 6 months 0.3000 0.2915 0.0085 (–0.0117 to 0.0286) 0.760
CRQ-SAS dyspnoea domain 4.3 4.2 0.06 (–0.20 to 0.33) 0.636
CRQ-SAS fatigue domain 3.6 3.5 0.13 (–0.12 to 0.38) 0.295
CRQ-SAS emotional function domain 4.4 4.3 0.15 (–0.04 to 0.34) 0.129
CRQ-SAS mastery domain 4.2 4.3 –0.09 (–0.18 to 0.01) 0.065
Adverse effects of treatment (%) 255 (89.5) 264 (91.3) –9; AOR 0.79 (0.44 to 1.39) 0.410
Pneumonia diagnoses at 6 months (%) 9 (3.0) 12 (4.0) –3; AOR 0.73 (0.29 to 1.82) 0.495
TABLE 29 Estimated costs associated with the use of CRP testing for COPD in primary care in the UK
Parameter
Year
1 2 3 4 5
Number of eligible patients (people
diagnosed with COPD)
1,200,000 1,269,576 1,383,207 1,496,839 1,610,470
Uptake estimate (%) 10 20 30 40 50
CRP-tested patients 120,000 253,915 414,962 598,735 805,235
Yearly cost of CRP testing (£) 1,357,200 2,871,780 4,693,221 6,771,697 9,107,208
Yearly incremental cost of health-care use (£) 27,868,800 58,969,243 96,370,798 139,050,309 187,007,776
Net costs (£) 29,226,000 61,841,023 101,064,019 145,822,007 196,114,984
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Summary
This chapter described, in detail, the methods and results of the health economic evaluation undertaken
as part of the PACE trial. The results suggest that the use of CRP POCT in primary care reduces antibiotic
consumption and costs without significantly affecting other COPD medication costs, health-care resource
use and HRQoL. There were no significant differences in total incremental cost for all causes at 4 weeks or
6 months, or if only COPD-related health-care costs were considered in the analysis. The ICERs were £222
(95% CI –£42.00 to £518.14) per 1% reduction in antibiotic consumption and £15,251 (95% CI £2959 to
£22,813) per QALY gained.
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Chapter 6 Discussion
The PACE randomised controlled clinical trial found that using a CRP POCT to guide antibioticprescribing decisions for patients presenting in primary care with an AECOPD resulted in an absolute
reduction in antibiotic consumption over the 4 weeks after the initial consultation of 20%, and a marginal
improvement in condition-specific health status that was smaller than the published, minimally important
clinical significance for this outcome. Secondary outcomes, including antibiotic prescribing at the index
consultation, antibiotic use for any reason, subsequent consultations in primary and secondary care, and
COPD HRQoL and generic quality of life, were all consistent with the finding that the intervention safely
reduced antibiotic use. Subgroup analyses suggest that the intervention effect was confined to patients
with more than one Anthonisen criteria (the clinical features usually used to guide antibiotic treatment
for AECOPD). There was no evidence of differences between the arms in the use of oral steroids or other
relevant medications. Possible adverse effects from antibiotic consumption were reported by approximately
90% of participants, but there was no evidence of a difference between the trial arms. There was also no
evidence that the intervention led to differences in antibiotic resistance in potential respiratory pathogens
or commensal organisms isolated from sputum and throat swab samples 4 weeks after first consulting for
the AECOPD.
The qualitative process evaluation found evidence that the CRP POCT was seen as broadly acceptable and
useful by patients and primary care clinicians. Technical issues, such as the need to refrigerate cartridges
and calibrate the machine, were seen as potential barriers to use, and concern about costs was a potential
barrier to implementing the POCT in the context of NHS primary care services. Clinicians acknowledged
that using the POCT increased consultation length, but they generally thought that this was offset by the
perceived benefits. These benefits included reducing uncertainty in their prescribing decisions, using the
test result to back up their prescribing decisions in discussions with patients and using the POCT as a tool
to educate patients.
Our health economic evaluation found that the total cost from a NHS perspective at 4 weeks was < £20
more for patients managed with the addition of CRP POCT, and that there were no differences in total
COPD-related costs between the two arms over 6 months.
Strengths and limitations
This pragmatic primary care trial was adequately powered to detect clinically important differences in both
patient-reported antibiotic consumption and COPD health status at 2 weeks post randomisation. This is one
of few studies of an antibiotic stewardship intervention to power on co-primary outcomes involving both a
difference in antibiotic use and no worse (non-inferior) clinical outcomes. Patients were recruited during
routine general practice consultations and from more than 80 UK general practices. Remote allocation was
used and there was no evidence of breaches in allocation concealment. Participant characteristics, including
age, comorbidities, smoking status, COPD health status and clinical features, were well balanced at baseline.
Adherence to intervention allocation was good, with evidence that 97.5% of those allocated to CRP POCT
received the test, and definitely < 3% received a CRP POCT at any point in the 4-week follow-up period.
We ascertained initial antibiotic prescribing data for all but one participant. In addition, we ascertained
patient-reported outcomes for > 80% of participants, with 83% and 87% of patients contributing data to
the antibiotic use and COPD health status primary outcome analyses, respectively. We obtained follow-up
data at 6 months for 68% of participants.
This was an open, pragmatic trial, with no blinding of participants or clinicians, as we aimed to assess the
effects of the intervention in comparison with current usual practice. Introducing sham tests, for example,
would have made comparison with usual care impossible. Open trials allow for a better measurement
of the ‘real-world’ consequences of interventions. They are preferable for studies of cost-effectiveness as
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knowledge of the intervention received may influence patients’ decisions about subsequent help-seeking.
Capturing subsequent resource use is critical to determining costs. However, the antibiotic prescribing
reported by the responsible clinicians and captured from clinical records is consistent with patient-reported
antibiotic use in the trial arms. It is possible that awareness of the intervention contributed to the beneficial
impact we observed on COPD health status (e.g. through patients feeling better because they expected
to feel better); if so, this effect would also occur in real-world clinical practice and, therefore, needed to
be captured.95
We chose patient reports about antibiotic consumption (over the 4 weeks after the baseline appointment
for their AECOPD) to be included in the co-primary outcome, rather than clinician reports or initial antibiotic
prescribing data from the primary care clinical record. Antibiotics that are actually consumed, rather than
prescribed, is the critical measure. ‘Delayed’ or ‘back-up’ antibiotic prescribing is relatively common for
AECOPD, and antibiotics can be obtained from several sources, including hospitals, out-of-hours services
and leftover antibiotics or ‘rescue packs’ of antibiotics stored at home. We captured both antibiotic
prescribing and antibiotic use over 4 weeks to determine whether or not fewer initial prescriptions might
have resulted in more subsequent reconsultations and further antibiotic prescribing.
Generalisability
Participants’ age, gender, comorbidities and GOLD stage are in keeping with those of primary care patients
with COPD,96 and the potential pathogens isolated from baseline sputum samples are in keeping with those
in other studies of AECOPD in the community.89 Although all patients were assessed as having COPD by
their recruiting clinician, and 97.5% of patients had a diagnosis of COPD in their medical records, we were
able to obtain forced expiratory volume in 1 second (FEV1) forced vital capacity (FVC) spirometry data for
only 66% of participants from the primary care medical records and for many of these the spirometry was
carried out many months before or after randomisation. However, clinicians tend to rely on the diagnosis
in the medical records, rather than on a detailed review of spirometry results, when making treatment
decisions for patients with AECOPD, hence the focus on having a COPD diagnosis in the clinical record,
rather than on spirometry criteria, for trial eligibility.
The quality of spirometry is often suboptimal in primary care.97 However, for those who had spirometry,
the vast majority (85%) of patients met the criterion for the diagnosis of COPD. The decision to base
inclusion on the recorded diagnosis and not on spirometry was explicit in the design. It was based on the
already heavy burden of assessment on participating patients and practices and the pragmatic, ‘real-world’
nature of the trial. The low rate of recording of spirometry demonstrates how inappropriate it would have
been to rely on general practice spirometry for the inclusion of patients. Most patients had purulent sputum,
but only a minority (< 4%) had sputum that was rated as having the highest degree of purulence using
the BronkoTest. This may be a reflection of the considerable variation of patients’ interpretations of the
BronkoTest in comparison with that of clinicians. Few participants had very severe underlying COPD in this
study, so the findings may not be applicable to those with very severe COPD. We also excluded patients
who had characteristics that may affect CRP levels (e.g. those with chronic inflammatory diseases) and those
likely to be significantly immunocompromised, so our results cannot be generalised to these groups.
Interpretation and comparison with other literature
We searched MEDLINE using the search terms ‘C-reactive protein/OR crp.mp’ AND ‘Pulmonary Disease,
Chronic Obstructive/OR COPD.mp OR Respiratory Tract Infections/’ AND ‘Anti-Bacterial Agents/or
antibiotic$.mp’ and found three trials that used CRP POCT and included patients with COPD as part of
their population. A Norwegian cluster randomised trial that recruited 179 patients with acute cough/LRTI
comprised 29 patients with COPD or asthma.98 The authors reported an overall reduction in antibiotic
prescribing, but the study was not powered to detect a difference in the COPD/asthma group.
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A Dutch cluster RCT that used a factorial design to randomise patients to CRP POCT or not, and to
communication skills training or not, comprised 31 patients with COPD.33 This study also found a significant
reduction in antibiotic prescribing for LRTI, but it was also not powered for a subgroup analysis of patients
with COPD. A non-randomised Spanish study of a multifaceted intervention consisting of audit and
feedback, education and training in CRP testing for some clinicians found lower antibiotic ‘overprescribing’
for AECOPD (prescribing to patients with ≤ 2 Anthonisen criteria) by primary care clinicians who received
training in CRP testing.99 In the hospital setting, a meta-analysis of eight trials (1062 patients) found
reasonable evidence for using procalcitonin to guide antibiotic initiation and discontinuation for AECOPD,
with the aim of reducing antibiotic exposure without adversely affecting clinical outcomes.100 There is a lack
of similar trial evidence for CRP testing in the hospital setting, but observational studies have shown an
association between higher CRP levels and pneumonia and benefit from antibiotics.28,39 A recent Cochrane
systematic review comprised six trials with > 3000 participants, and confirmed that CRP testing can safely
reduce antibiotic prescribing for respiratory tract infections in the primary care setting.101
Although more than three-quarters of participants in our trial had ≥ 2 Anthonisen criteria, 76% of those
in the intervention arm had a CRP level of < 20 mg/l, suggesting a low probability of significant bacterial
infection and benefit from antibiotics. In the previous trial of antibiotics versus placebo for patients managed
in the community with AECOPD from our group, we found no evidence of a between-arm difference in the
proportions with clinical failure among those with a CRP level of < 40 mg/l.24 Many patients with CRP levels
in the 20–40 mg/l range, in addition to those with a CRP level of < 20 mg/l, could, therefore, probably be
safely managed without antibiotics. We also found a 20% absolute reduction in antibiotic consumption
despite antibiotics being prescribed for 33% of those with a CRP level of < 20 mg/l. These findings suggest,
therefore, that our estimate of the potential reduction in antibiotic use from CRP POCT use is conservative.
Over half of the baseline sputa collected in our study did not yield any potential bacterial respiratory pathogen,
and another one-fifth yielded both viral and bacterial pathogens (possible mixed infections). These findings are
consistent with those of other studies, which have shown that bacterial infection is a likely trigger for AECOPD
in a minority of patients14 and, therefore, antibiotic treatment is unlikely to benefit many of them.
Antimicrobial stewardship is often promoted on the basis of the interests of future generations and society
in general. However, taking fewer antibiotics may also benefit individuals by avoiding disruption of their
microbiome,16–18 including the selection of antimicrobial-resistant organisms that could lead to AECOPD
that are more frequent and/or more difficult to treat. This could be especially important for patients with
COPD who are at greater risk of being colonised with resistant pathogens than patients with normal lungs.
At baseline, sputum sample bacteriology identified > 200 potential pathogens from the overall cohort;
over one-third of the H. influenzae and S. pneumoniae strains cultured were not susceptible to ampicillin.
However, in the trial, a comparison of the prevalence of resistant organisms isolated from patients at
4 weeks and resistance before treatment demonstrated no evidence of any beneficial effect of the
intervention on antimicrobial resistance. Further planned analyses will explore differences in specific
‘antibiotic–bacteria’ combinations, and between those who did and those who did not consume antibiotics.
Antibiotics do benefit many people with AECOPD,24 and the underprescribing of antibiotics needs to be
avoided for patients who are likely to benefit. We included COPD health status in the co-primary outcome
measure to assess whether or not any reduction in antibiotics might have occurred at the expense of
patient recovery and well-being. Despite the important reduction in antibiotic use, we identified a small
beneficial effect on condition-specific health status in the intervention arm. Possible explanations include
a psychological benefit from the perceived benefits of a blood test to guide treatment, a reduction in
adverse effects from antibiotics or beneficial effects from other interventions used instead of antibiotics.
The last of these is unlikely, as we found no evidence of a difference in corticosteroid or inhaler use
between the study arms. Furthermore, we found no evidence of benefits in terms of primary and
secondary care consultations for any reason, or in disease-specific HRQoL during the 6-month follow-up
period. However, a short-term (4 weeks) intervention (and in most cases a single antibiotic prescribing
decision) is unlikely to have a dramatic effect on resistance or longer-term outcomes among patients who
are frequently prescribed antibiotics.
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Our qualitative findings are consistent with those of previous studies on the attitudes towards using CRP
POCTs to manage LRTIs. Clinicians generally have positive views about using CRP POCTs to manage LRTIs,
and feel that they provide an indication of disease severity, help manage patient expectations and increase
their confidence in antibiotic-prescribing decisions.67,102,103 Previous studies have also found similar concerns
about the costs and implementation of CRP POCTs in the management of LRTIs in NHS primary care services.68
Our health economic evaluation identified reduced antibiotic costs at the initial consultation but no significant
differences in the total incremental cost for all causes at 4 weeks or 6 months, or if only COPD-related
health-care costs were considered in the analysis. To our knowledge, this is the first study reporting the
cost-effectiveness of the use of CRP POCT in primary care to guide antibiotic prescribing for patients presenting
with AECOPD based on actual antibiotic consumption. Three studies were identified that previously assessed
the cost-effectiveness of CRP POCT for antibiotic prescribing in patients with LRTIs reporting similarly small cost
and quality-of-life differences between groups.35,36,104 Although these studies were conducted in different
patient populations and settings, the similarities in the direction and magnitude of results confirms the
robustness and accuracy of the cost-effectiveness evidence presented here.
Although we found increased all-cause health-care costs in the CRP POCT arm, these were largely attributed
to a greater number of long-stay hospital patients, most of whom were admitted with conditions not related
to their COPD. This might be an artefact of sampling variation or the low number of events rather than an
indication of an underlying issue related to the intervention itself.
A limitation of the evaluation is the sensitivity of the cost–utility results to changes in patient quality of life.
This is caused by the small differences in utility scores between the two arms. This could be caused by an
insensitivity and lack of responsiveness of the generic EQ-5D instrument to small changes in the health
status of specific conditions. However, EQ-5D-5L utility index values have been shown to correlate well
with established disease-specific HRQoL questionnaires.105 Furthermore, although the QALY difference at
6 months of 0.0085 does not reach the minimum important improvement of 0.05,105 the PACE trial aimed
to prove non-inferiority of health and QoL outcomes despite reduction in antibiotic consumption rather
than superiority. This cost-effectiveness analysis is limited by the short follow-up of the trial, which could
be addressed by long-term decision-analytic modelling based on the high-quality evidence produced by the
PACE trial in the future.
Impact of patient and public involvement
Public contributors were an integral part of the study team from the very beginning of the research
life cycle. Even before the first grant application was submitted, public contributors living with COPD
helped develop the study question, they then contributed to the grant application itself and served on
the Trial Management Group and the Trial Steering Committee. Throughout, they helped refine the study
questions, contributed to critical decisions about the study outcomes, including which measures were
most relevant to COPD patients; and ensured that patient-facing materials were readable and user friendly
(including the CRFs and patient information leaflets) and that the research materials were simplified.
For example, a critically important decision to change the scale used in the co-primary outcome was based
largely on public contributor input. The contributors also helped produce regular study newsletters. Public
contributors have also helped develop the dissemination strategy, and are advising on framing the main
key messages and the implications of the results. After the pilot phase of the study, we met with a GP
and respiratory nurse from one of the best recruiting practices in the pilot study and together identified
items that could be removed from the baseline CRFs and instead included in the patient diary or 6-month
medical record search CRF, to make the initial assessment less burdensome for busy clinicians who were
delivering acute care while also recruiting to PACE. These modifications were fundamental to our ability
to implement the full study, recruit to target and follow up participants so successfully.
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Implications for clinical practice and future research
This pragmatic primary care trial provides clear evidence that using a CRP POCT to guide antibiotic
treatment decisions for AECOPD is both clinically effective and cost-effective in safely reducing antibiotic
use in those patients for whom antibiotics are not indicated. NICE already recommends the use of CRP
testing to predict pneumonia in primary care.86 We believe that our findings provide good evidence to
support the use of a CRP POCT (with the associated guidance for clinicians that we used in this trial)
to guide antibiotic-prescribing decisions for AECOPD in primary care.
Further research, building on our qualitative findings, could help understand how different implementation
approaches affect POCT use and acceptability to both clinicians and patients of a CRP POCT for AECOPD in
primary care. In addition, implementation studies are needed to determine the effect of this intervention on
antibiotic use, clinical outcomes, antibiotic resistance in commensal organisms and help-seeking behaviour
over the longer term. Although we found only small differences in short-term costs and no differences in
long-term costs, there is a need to evaluate the health economic implications of the implementation of this
intervention. Furthermore, the source of funding for any testing would need to be addressed before this test
could be implemented into routine primary care.
Further research is also required to determine the added diagnostic and prognostic value of CRP for
guiding AECOPD management, over and above the diagnostic and prognostic value of clinical features
such as sputum colour, sputum volume, breathlessness and other biomarkers, and how various predictors
are best combined. CRP self-testing is now a realistic possibility and could have a role in directing the
self-management of ‘rescue’ antibiotics for some, but this will require further development and careful
evaluation prior to implementation.
Conclusions
A CRP POCT to help guide antibiotic prescribing decisions for AECOPD in primary care is clinically effective
and cost-effective in safely reducing antibiotic use and prescribing for patients with AECOPD, and is thus a
useful adjunct to both improving outcomes for patients and enhancing antibiotic stewardship.
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Appendix 1 Clinical effectiveness methods
TABLE 30 Summary of outcomes and changes to the outcomes
Outcome measures
Time point(s) of
evaluation of this
outcome measure
Changes to outcome
measures Reason for the change
Primary
Antibiotic consumption (any
consumption of antibiotics for AECOPD
vs. no consumption of antibiotics for
AECOPD)
First 4 weeks post
randomisation
Recovery in terms of COPD health
status as assessed using the CCQ total
scores
2 weeks post
randomisation
Secondary
Prevalence of potentially pathogenic
bacteria [including S. pneumoniae,
Haemophilus species spp and
Enterobacteriaceae] cultured from
sputum at 4 weeks and the proportion
of bacteria that are resistant
4 weeks post
randomisation
Prevalence of commensal organisms
cultured from throat swabs at 4 weeks
and proportion of bacteria that are
resistant
4 weeks post
randomisation
COPD health status over time
measured using the CCQ total score
At weeks 1, 2 and 4
post randomisation
CCQ symptoms domain At weeks 1, 2 and 4
post randomisation
CCQ function state domain At weeks 1, 2 and 4
post randomisation
CCQ mental state domain At weeks 1, 2 and 4
post randomisation
Total antibiotic consumption (number
of days antibiotics consumed for
AECOPD/any reason)
First 4 weeks post
randomisation
Total antibiotic
consumption (number of
days antibiotics consumed
for AECOPD/any reason)
during first 4 weeks post
randomisation was added
in to secondary outcomes
Health utility measured using the EQ-5D At weeks 1, 2 and
4 and at 6 months
post randomisation
EQ-5D was added to the
6-month postal follow-up
Change from the EQ-5D-3L
to the EQ-5D-5L
Owing to the more
sensitive instrument
becoming available at the
time, the EQ-5D-3L used
during the internal pilot
was replaced by the
EQ-5D-5L
All-cause antibiotic consumption During the first
4 weeks post
randomisation
All-cause antibiotic
consumption during the
first 4 weeks was added to
the secondary outcomes
continued
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TABLE 30 Summary of outcomes and changes to the outcomes (continued )
Outcome measures
Time point(s) of
evaluation of this
outcome measure
Changes to outcome
measures Reason for the change
Antibiotic prescribing At the index
consultation
Antibiotic prescribing During the first
4 weeks post
randomisation
Antibiotic prescribing
during the first 4 weeks
post randomisation was
added to secondary
outcomes
Use of other COPD treatments
including oral steroids
During the first
4 weeks post
randomisation
Adverse effects potentially attributable
to antibiotics prescribed for the
exacerbation
During the first
4 weeks post
randomisation
Primary and secondary care
consultations, including hospitalisations
At week 4 and
month 6
Costs (total NHS cost) and
cost-effectiveness
At month 6
Incidence of pneumonia (measured by
patient and GP report)
At week 4 and
month 6
Disease-specific HRQoL over time
measured using CRQ-SAS (dyspnoea,
fatigue, emotion function, mastery and
total scores)
At month 6
TABLE 31 Summary of changes to study inclusion criteria following the internal pilot
Pilot study inclusion/
exclusion criterion Change made following pilot Reason for change
Required spirometry
confirmation of COPD,
very severe (GOLD
grade IV) excluded
Diagnosis of COPD in medical record: all
COPD severities included, but those with a
past history of respiratory failure or requiring
mechanical ventilation excluded
This change occurred after the study had
opened to recruitment in order to minimise
the time taken for the initial assessment during
times of delivering busy acute clinical care
Exclusion of those who
had used systemic
antibiotics in the past
4 weeks
Exclusion of those currently on antibiotics or
who had taken antibiotics previously for the
current AECOPD
Initially, those who had recently taken
antibiotics were excluded as this would have
had an impact on baseline assessments of
antimicrobial resistance. We considered that
the evidence generated by the study should
be applicable to those who have recently
had antibiotics
Exclusion of those with a
life-limiting malignancy
No longer an exclusion criterion We considered that the experimental
intervention should be applicable to these
patients
Exclusion of those who
had taken systemic
corticosteroids in the
past week
No longer an exclusion criterion We considered that the experimental
intervention should be applicable to these
patients
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TABLE 32 Pilot study: eligibility criteria
Inclusion criteria Exclusion criteria
Has spirometry-confirmed (post-bronchodilator
FEV1/FVC of < 0.7) mild, moderate or severe (GOLD
grade I, II or III) COPD (FEV1 of ≥ 30% predicted)
Very severe GOLD grade IV COPD (FEV1 of < 30% predicted) or
has a past history of respiratory failure or mechanical ventilation
Has a current AECOPD with presence of at least one
of the following features: increased dyspnoea,
increased sputum volume, increased sputum
purulence
Has used systemic antibiotics in the last 4 weeks
Has AECOPD that has lasted for at least 24 hours
and at most 21 days
The responsible clinician feels that urgent referral to hospital is
necessary
Is aged ≥ 40 years Has severe illness (e.g. suspected pneumonia, tachypnoea of
> 30 breaths per minute, respiratory failure)
Is able to provide informed consent Has a concurrent infection at another site (e.g. UTI, cellulitis) that
is likely to produce a systemic response
Has a chronic inflammatory condition (e.g. rheumatoid arthritis,
polymyalgia rheumatica)
Has a life-limiting malignancy
Has taken systemic corticosteroids (e.g. oral tablets, injections) in
the past week (not including systemic corticosteroids prescribed at
baseline assessment)
Has cystic fibrosis, a current tracheostomy or bronchiectasis of
origin other than COPD
Is immunocompromised (e.g. AIDS, taking immunosuppressive
therapy or is receiving anticancer radiotherapy or chemotherapy)
Is currently pregnant
Has previously been recruited to the PACE study
AIDS, acquired immunodeficiency syndrome; UTI, urinary tract infection.
TABLE 33 Main study: eligibility criteria
Inclusion criteria Exclusion criteria
Has a current acute exacerbation (presenting with
at least one of the following: increased dyspnoea,
increased sputum volume, increased sputum
purulence) that has lasted for at least 24 hours and
no longer than 21 days
The responsible GP feels that urgent referral to hospital is necessary
Has a diagnosis of COPD in clinical record/on a COPD
practice register
Has severe illness (e.g. suspected pneumonia, tachypnoea of
> 30 breaths per minute, respiratory failure)
Is aged ≥ 40 years Has concurrent infection at another site (e.g. UTI, cellulitis) that is
likely to produce a systemic response
Is able to provide informed consent Has a past history of respiratory failure or mechanical ventilation
Is able to provide the primary outcome data at 2
and 4 weeks within the expected windows
Is currently on antibiotics or has had antibiotics for this acute
exacerbation of COPD
Has an active inflammatory condition (e.g. flare-up of rheumatoid
arthritis, gout or polymyalgia rheumatica)
Has cystic fibrosis, a current tracheostomy or bronchiectasis
Is immunocompromised (e.g. AIDS, taking systemic immunosuppressive
therapy or receiving anticancer radiotherapy or chemotherapy)
Is currently pregnant
AIDS, acquired immunodeficiency syndrome; UTI, urinary tract infection.
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Assessment of sputum purulence
l Patient-reported sputum colour is often not reliable.
l Purulence can be increased in viral infections as well as bacterial infections.
l Try and obtain a sputum sample to objectively assess sputum purulence when possible.
l Ask the patient how much the colour of their sputum has changed from its usual colour. This is
particularly pertinent when it is not possible to objectively assess their sputum.
l The CRP test is particularly useful when the presence of increased purulence is uncertain.
TABLE 34 Interpretation of CRP results
CRP result (mg/l) Interpretation
< 20 Antibiotics are unlikely to be beneficial and usually should not be prescribed
20–40 Antibiotics may be beneficial – mainly if purulent sputum is present. You may decide to prescribe
antibiotics after taking into account the patient’s underlying health status and the features of the
current exacerbation
> 40 Antibiotics are likely to be beneficial. Consider prescribing antibiotics unless the patient is assessed as
being at lower risk of complications and unlikely to have a bacterial infection (no increased sputum
purulence and no features suggesting severe exacerbation)
TABLE 35 Protocol changes
Amendment
number Details of changes made
1 Minor changes and addition of further clarification regarding the future use of the samples and the
disposal of the capillary tube for the finger prick
2 Change of primary outcome measure from CRQ-SAS at 2-week follow-up to CCQ at 2-week follow-up.
Addition of CRQ-SAS at 6-month follow-up
Inclusion/exclusion criteria rephrasing and some additions
Expansion on qualitative evaluation process
Alteration to microbiological analysis
Change to patient information sheet to add that we will collect participant’s address
3 Clarifying and defining which staff at site can assess patient eligibility
Change of wording in one of the inclusion criteria from spirometry-confirmed (post-bronchodilator
FEV1/FVC of < 0.7) mild, moderate or severe COPD (GOLD grade I, II and III) to spirometry-confirmed
mild, moderate or severe (GOLD grade I, II or III) COPD (FEV1 of ≥ 30% predicted)
Clarifying that the primary objective and primary outcome is antibiotic use for AECOPD
All-cause antibiotic consumption during the first 4 weeks has been added to the secondary objectives,
outcomes and analysis sections
EQ-5D-5L has been added to the 6-month postal follow-up
The CRP guidance has been corrected to the following categories: < 20, 20–40, > 40 mg/l
Clarifying the safety reporting procedures
New investigator (Carl Llor) and new administrator (Christian Barlow) have been added
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TABLE 35 Protocol changes (continued )
Amendment
number Details of changes made
4 Clarify that the secondary outcome is prevalence of resistant bacteria in throat swab
Change from the EQ-5D-3L to the EQ-5D-5L
Inclusion/exclusion criteria rephrasing and some additions
Clarification that the randomisation says ‘usual care’ not ‘no POCT’
Amend typographical error on back-up randomisation telephone number
Amend 4-week follow-up window from –3 days to +14 days from +7 days
5 Clarification that Alere will provide training only to those practices using an Alere CRP machine
Demographic data, FEV1, clinical history and smoking status no longer collected at baseline
Clarification around the contacting of patients for their 6-month questionnaire data, telephone
and postal
Qualitative interview topic guides, improved wording and flow, but still focused on the same topics
(e.g. views on the CRP test, research processes and management of COPD)
6 Six-month note review will also include a 12-month note review of antibiotics prescribed prior to the
baseline appointment
The time frame within which the qualitative interviews with participants can be carried out has been
increased from 2 weeks (post 4-week follow-up date) to 4 weeks
7 Rephrasing of the secondary outcome measures
Clarifying the quantitative process evaluation
Clarifying procedures occurring at baseline and at follow-ups
Clarification around statistical analyses
Rephrasing of microbiological analyses
Rephrasing of economic evaluation
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Appendix 2 Clinical effectiveness results
Full intention-to-treat analysis (assuming data are missing at random)
A full ITT analysis was conducted for the co-primary outcomes, with participants with missing outcome
data included using multiple imputation. The imputation models contained variables included in the
original co-primary analyses (i.e. the Anthonisen criteria and, for the CCQ analysis, the baseline CCQ total
score). Twenty imputations were run. For the primary CCQ analysis, 14 missing baseline CCQ scores were
imputed using the mean of the valid responses.
The findings in Tables 36 and 37 demonstrate that the adjustment made little difference to the
intervention effect estimates, and the conclusions remain unaltered on the basis of these analyses.
Further sensitivity analysis adjusting analyses for missing data (assuming that data are
missing not at random)
The observed mean CCQ total score at 2 weeks post randomisation was 2.7 points, with the mean 0.2 points
higher (worse) in the control arm than in the CRP arm (Table 38). Figure 16 demonstrates that the conclusions
that can be drawn from the primary CCQ analysis are robust to all but the most extreme and implausible
assumptions regarding missing participants (i.e. that missing control participants are identical to those observed
and that missing CRP participants were over 3 points worse than those observed).
TABLE 36 Adjusted primary antibiotic analysis for missing data
Analysis set n AOR (95% CI) p-value
MITT 537 0.31 (0.20 to 0.47) < 0.001
Full ITT 649 0.33 (0.21 to 0.52) < 0.001
TABLE 37 Adjusted primary CCQ analysis for missing data
Analysis set n AMD (90% CI) p-value
MITT 563 –0.19 (–0.33 to –0.05) 0.023
MITT with missing baseline CCQ
imputed via mean substitution
577 –0.20 (–0.34 to –0.06) 0.017
Full ITT 649 –0.20 (–0.36 to –0.04) 0.016
TABLE 38 Descriptive statistics for CCQ total score at 2 weeks post randomisation for participants who are included
in the MITT analysisa
Trial arm
TotalUsual care CRP POCT
Observed, n (% total) 289 (89.2) 288 (88.6) 577 (88.9)
Missing, n (% total) 35 (10.8) 37 (11.4) 72 (11.1)
Observed (mean) 2.8 2.6 2.7
Observed (SD) 1.29 1.23 1.26
a Missing baseline CCQ total scores imputed using mean substitution.
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Table 39 demonstrates that, for all but the most extreme and implausible assumptions (i.e. that missing
CRP participants all consumed antibiotics and missing control participants did not), the conclusions drawn
on the primary antibiotic analysis remain robust to various missing data assumptions.
Analysis accounting for change in eligibility criteria
The models presented in Tables 40 and 41 suggest that, although there is a suggestion of a difference in
outcomes before/after the change in eligibility criteria, this is independent of trial arm. The conclusions drawn
regarding differences between trial arms remain unaltered when controlling for this change in eligibility criteria,
and there is insufficient evidence to suggest that the intervention worked differently pre or post change.
Primary analysis on per-protocol population
Excluding participants from the co-primary analyses who were not eligible at the time of recruitment, or
(for the primary CCQ analysis) did not provide data within the specified time window for data collection at
2 weeks post randomisation (–1 day/+7 days), did not appreciably change the intervention effect estimates
and did not alter the conclusions that could be drawn regarding the co-primary outcomes (Tables 42 and 43).
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FIGURE 16 Impact of different missing data assumptions on the findings of the primary CCQ analysis. The figure is
based on a series of pattern mixture models with mean in unobserved outcome minus mean in observed outcome
ranging from 0 (missing at random assumption) to 4 (missing not at random assumption). Black solid line is at y= 0
(no difference between trial arms) and black dashed line is at y = 0.3 (non-inferiority margin).
TABLE 39 Best- and worst-case scenarios for missing primary antibiotic consumption for AECOPD data
Analysis n
Trial arm, antibiotics,
n (%)
AOR (95% CI) p-valueControl CRP POCT
MITT 537 212 (77.4) 150 (57.0) 0.31 (0.20 to 0.47) < 0.001
Sensitivity 1: all non-responders used antibiotics 649 262 (80.9) 212 (65.2) 0.39 (0.27 to 0.58) < 0.001
Sensitivity 2: all non-responders did not use antibiotics 649 212 (65.4) 150 (46.2) 0.39 (0.27 to 0.55) < 0.001
Sensitivity 3: non-responders used antibiotics if
prescribed them at index consultation
649 246 (75.9) 169 (52.0) 0.28 (0.19 to 0.41) < 0.001
Sensitivity 4: non-responders in CRP arm used antibiotics
and those in control arm did not use antibiotics
649 212 (65.4) 212 (65.2) 0.94 (0.66 to 1.33) 0.728
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TABLE 40 Between-arm comparison of antibiotics consumed for AECOPD during the first 4 weeks post
randomisation, adjusting for change in eligibility
Model Variable AOR (95% CI) p-value
Without interaction Before change in eligibility Reference category for change in eligibility 0.065
After change in eligibility 1.97 (0.96 to 4.04)
Control Reference category for trial arm < 0.001
CRP POCT 0.31 (0.20 to 0.47)
With interaction After change in eligibility (main effect) 3.01 (1.19 to 7.59) 0.020
CRP POCT (main effect) 0.67 (0.21 to 2.19) 0.511
CRP POCT × after change in eligibility 0.41 (0.12 to 1.43) 0.162
TABLE 41 Between-arm comparison of CCQ total score at 2 weeks post randomisation, adjusting for change
in eligibility
Model Variable AMD (95% CI) p-value
Without interaction Before change in eligibility Reference category for change in eligibility 0.034
After change in eligibility –0.32 (–0.62 to –0.03)
Control Reference category for trial arm 0.024
CRP POCT –0.19 (–0.35 to –0.03)
With interaction After change in eligibility (main effect) –0.43 (–0.83 to –0.04) 0.032
CRP POCT (main effect) –0.40 (–0.93 to 0.13) 0.137
CRP POCT × after change in eligibility 0.24 (–0.32 to 0.79) 0.406
TABLE 43 Primary CCQ analysis for per-protocol analysis population
Analysis set n AMD (90% CI) p-value
MITT 563 –0.19 (–0.33 to –0.05) 0.023
Per protocol 547 –0.19 (–0.32 to –0.05) 0.028
TABLE 42 Primary antibiotic analysis for per-protocol analysis population
Analysis set n AOR (95% CI) p-value
MITT 537 0.31 (0.20 to 0.47) < 0.001
Per protocol 525 0.27 (0.18 to 0.43) < 0.001
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Medication consumption over time
The models in Table 44 demonstrate that the consumption of antibiotics for AECOPD declines considerably
during the follow-up period and is lower in participants allocated to the CRP arm. There is also some
evidence of a differential intervention effect over time. This is best illustrated in Figure 17, which indicates
a steeper decline in antibiotic consumption for control participants between weeks 1 and 2 (than for CRP
participants), and a further decline between weeks 2 and 4 (whereas the proportion of participants in the
CRP arm consuming antibiotics remains stable). The findings from these models are similar to those from
the models exploring all-cause antibiotic consumption over time (Table 45).
TABLE 44 Antibiotics consumed for AECOPD over timea
Model Variable AOR (95% CI) p-value
Without interaction Week 1 Reference category for time point < 0.001
Week 2 0.10 (0.07 to 0.15)
Week 4 0.07 (0.05 to 0.10)
Control Reference category for trial arm < 0.001
CRP POCT 0.46 (0.33 to 0.65)
With interaction Week 1 Reference category for time point main effect < 0.001
Week 2 0.07 (0.05 to 0.12)
Week 4 0.04 (0.02 to 0.07)
Control Reference category for trial arm main effect < 0.001
CRP POCT 0.29 (0.19 to 0.46)
Week 2 × CRP POCT 1.85 (0.98 to 3.50) 0.005
Week 4 × CRP POCT 3.00 (1.53 to 5.86)
a Analysis based on 1672 responses from 614 participants in 84 practices. Model adjusts for Anthonisen criteria.
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FIGURE 17 Predicted probabilities of antibiotic consumption for AECOPD over time, by trial arm.
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The model estimates presented in Table 46 indicate that, although the use of other COPD medication
declines considerably over the follow-up period, there is no evidence to suggest a difference between arms
and, indeed, no evidence of any differential intervention effect over time (Figure 18).
TABLE 45 Antibiotics consumed for any reason over timea
Model Variable AOR (95% CI) p-value
Without interaction Week 1 Reference category for time point < 0.001
Week 2 0.12 (0.09 to 0.17)
Week 4 0.08 (0.06 to 0.12)
Control Reference category for trial arm < 0.001
CRP POCT 0.48 (0.34 to 0.66)
With interaction Week 1 Reference category for time point main effect < 0.001
Week 2 0.09 (0.06 to 0.14)
Week 4 0.05 (0.03 to 0.08)
Control Reference category for trial arm main effect < 0.001
CRP POCT 0.30 (0.19 to 0.47)
Week 2 × CRP POCT 1.92 (1.04 to 3.52) 0.006
Week 4 × CRP POCT 2.79 (1.46 to 5.32)
a Analysis based on 1696 responses from 615 participants within 84 practices. Model adjusts for Anthonisen criteria.
TABLE 46 Use of other COPD treatments over timea
Model Variable AOR (95% CI) p-value
Without interaction Week 1 Reference category for time point < 0.001
Week 2 0.23 (0.17 to 0.33)
Week 4 0.06 (0.04 to 0.09)
Control Reference category for trial arm 0.301
CRP POCT 0.84 (0.61 to 1.16)
With interaction Week 1 Reference category for time point main effect < 0.001
Week 2 0.24 (0.15 to 0.39)
Week 4 0.05 (0.03 to 0.09)
Control Reference category for trial arm main effect 0.357
CRP POCT 0.77 (0.45 to 1.33)
Week 2 × CRP POCT 0.93 (0.49 to 1.75) 0.405
Week 4 × CRP POCT 1.35 (0.71 to 2.59)
a Analysis based on 1691 responses from 615 participants within 84 practices. Model adjusts for Anthonisen criteria.
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Rates of primary and secondary care consultations during the 6 months
post randomisation
The distributions of primary and secondary care consultations during the first 6 months following
randomisation for each trial arm are displayed in Figures 19 and 20.
The mean number of primary care consultations during the 6 months following randomisation was 6.3
(SE 0.28) for participants allocated to the control arm and 6.6 (SE 0.29) for participants allocated to the
CRP POCT arm. The adjusted incidence rate ratio was 1.04 (95% CI 0.92 to 1.18; p = 0.504). The mean
number of secondary care consultations during the 6 months following randomisation was 1.7 (SE 0.12)
for participants allocated to the control arm and 1.6 (SE 0.11) for participants allocated to the CRP POCT
arm. The adjusted incidence rate ratio was 0.96 (95% CI 0.79 to 1.17; p = 0.719). The mean number of
primary and secondary care consultations combined was, therefore, a combination of the two separate
consultation variables and, similarly, indicated no evidence of a difference between the arms (Table 47).
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FIGURE 19 Distribution of number of primary care consultations by arm. (a) Usual care; and (b) CRP POCT.
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FIGURE 18 Use of other COPD treatments over time.
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Prespecified subgroup analysis for the Clinical COPD Questionnaire primary outcome
There was no evidence of any differential intervention effects for the primary CCQ outcome for any of the
prespecified subgroups (Table 48).
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FIGURE 20 Distribution of number of secondary care consultations by arm. (a) Usual care; and (b) CRP POCT.
TABLE 47 Rates of primary and secondary care consultations during the 6 months post randomisation
Outcome measure Time point
Trial arm
Adjusted
incidence risk
ratioa (95% CI) p-value
Usual care CRP POCT
n
Mean
(SE) n
Mean
(SE)
Primary care
consultations
Six months post
randomisation
301 6.3 (0.28) 304 6.6 (0.29) 1.04 (0.92 to 1.18) 0.504
Secondary care
consultations
Six months post
randomisation
302 1.7 (0.12) 305 1.6 (0.11) 0.96 (0.79 to 1.17) 0.719
Primary and secondary
care consultations
Six months post
randomisation
302 7.9 (0.34) 305 8.2 (0.35) 1.02 (0.91 to 1.15) 0.726
a Ratio is CRP POCT/control. Adjusted for Anthonisen criteria. Clustering of participants within practices was accounted for
by fitting a two-level linear regression model (analysis based on a maximum of 607 participants in 80 practices). For
primary care consultations analysis, a negative binomial regression was fitted to account for overdispersed count data.
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TABLE 48 Subgroup analyses for antibiotic consumption for CCQ total score at 2 weeks post randomisation
(primary outcome)a
Subgroup analysis Variable AMD (95% CI) p-value
COPD severity (GOLD category)
(n = 351)
Usual care Reference category for trial arm main effect
(i.e. effect of trial arm for GOLD I subgroup)
0.140
CRP POCT –0.50 (–1.16 to 0.16)
GOLD I Reference category for COPD severity main
effect (i.e. effect of GOLD subgroup for
participants allocated to usual-care arm)
0.256
GOLD II –0.22 (–0.72 to 0.28)
GOLD III 0.02 (–0.52 to 0.56)
GOLD IV 0.22 (–0.45 to 0.90)
CRP POCT × GOLD I Reference category for trial arm × COPD severity
interaction
0.793
CRP POCT × GOLD II 0.30 (–0.42 to 1.01)
CRP POCT × GOLD III 0.29 (–0.48 to 1.06)
CRP POCT × GOLD IV 0.00 (–1.05 to 1.05)
Severity of COPD exacerbation
(Anthonisen criteria) (n = 563)
Usual care Reference category for trial arm main effect
(i.e. effect of trial arm for 1/3 features subgroup)
0.737
CRP POCT –0.06 (–0.39 to 0.28)
1/3 features Reference category for severity of COPD
exacerbation main effect (i.e. effect of severity of
COPD exacerbation for participants allocated to
the usual-care arm)
0.564
2/3 features 0.16 (–0.15 to 0.48)
3/3 features 0.13 (–0.16 to 0.43)
CRP POCT × 1/3 features Reference category for trial arm × severity of
COPD exacerbation interaction
0.627
CRP POCT × 2/3 feature –0.22 (–0.66 to 0.23)
CRP POCT × 3/3 feature –0.15 (–0.56 to 0.27)
Presence of potentially
pathogenic bacteria cultured
from sputum at baseline
(n = 353)
Usual care Reference category for trial arm main effect
(i.e. effect of trial arm for no potential
pathogenic bacteria subgroup)
0.263
CRP POCT –0.16 (–0.43 to 0.12)
No potential pathogenic
bacteria
Reference category for the presence of
potentially pathogenic bacteria cultured from
sputum at baseline main effect (i.e. effect of
presence of potential pathogenic bacteria for
participants allocated to the usual-care arm)
0.286
Potential pathogenic
bacteria
0.16 (–0.14 to 0.46)
CRP POCT × no potential
pathogenic bacteria
Reference category for trial arm presence of
potential pathogenic bacteria interaction
0.538
CRP POCT × potential
pathogenic bacteria
–0.13 (–0.55 to 0.29)
a Models adjust for Anthonisen criteria (when it is not the subgroup of interest) and CCQ total score at baseline.
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Appendix 3 Health economics
Unit costs
TABLE 49 Unit costs of antibiotics and oral corticosteroids included in costing for the health economic evaluation
Medication Dose (mg) Pack size Unit cost (£)
Antibiotics
Amoxicillin 250 14 0.69
Amoxicillin 250 21 0.97
Amoxicillin 500 14 0.90
Amoxicillin 500 21 1.26
Azithromycin 250 4 1.25
Azithromycin 500 3 1.07
Cefalexin 250 28 1.44
Cefalexin 500 21 1.64
Ciprofloxacin 100 6 1.97
Ciprofloxacin 250 10 0.68
Ciprofloxacin 500 10 0.89
Ciprofloxacin 750 10 8.00
Ciprofloxacin Eye drops 5 ml 4.70
Ciprofloxacin/dexamethasone Ear drops 5 ml 6.12
Clarithromycin 250 14 1.20
Clarithromycin 500 14 2.01
Clarithromycin suspension 250mg/5 ml 70 ml 4.66
Co-amoxiclav 375 21 1.66
Co-amoxiclav 625 21 1.73
Doxycycline 50 28 1.22
Doxycycline 100 8 0.78
Erythromycin 250 28 1.30
Flucloxacillin 250 28 1.25
Flucloxacillin 500 28 1.69
Macrobid 100 14 9.50
Metronidazole 200 21 1.49
Metronidazole 400 21 4.10
Metronidazole 500 21 37.82
Nitrofurantoin 50 28 13.43
Nitrofurantoin 100 28 8.57
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TABLE 49 Unit costs of antibiotics and oral corticosteroids included in costing for the health economic evaluation
(continued )
Medication Dose (mg) Pack size Unit cost (£)
Oxytetracycline 250 28 0.84
Phenoxymethylpenicillin 250 28 0.97
Trimethoprim 100 28 0.85
Trimethoprim 200 6 0.40
Trimethoprim 200 14 0.93
Oral corticosteroids
Dexamethasone 2 50 16.41
Prednisolone 1 28 0.68
Prednisolone 5 28 0.74
Prednisolone 25 56 75.00
Source of unit costs: Monthly Index of Medical Specialities 201779 and British National Formulary.80
TABLE 50 Unit costs of inhaled medication included in costing for the health economic evaluation
Medication Inhaler type
Dose per
puff (mg)
Pack size
(puffs)
Unit
cost (£)
Aclidinium Eklira Genuair (AstraZeneca UK Limited, Luton, UK) 322 60 28.60
Beclometasone Clenil Modulite 50 (Chiesi Limited, Manchester, UK) 50 200 3.70
Clenil Modulite 100 100 200 7.42
Clenil Modulite 200 200 200 16.17
Clenil Modulite 250 250 200 16.29
Formoterol Atimos Modulite (Chiesi Limited, Manchester, UK) 12 100 30.06
Formoterol Easyhaler [Orion Pharma (UK) Limited, Newbury, UK] 12 120 23.75
Foradil (Novartis Pharmaceuticals UK Ltd, Camberley, UK) 12 60 28.06
Oxis Turbohaler 6 (AstraZeneca UK Limited, Luton, UK) 6 60 24.80
Oxis Turbohaler 12 12 60 24.80
Formoterol/
aclidinium
Duaklir Genuair (AstraZeneca UK Limited, Luton, UK) 12/340 60 32.50
Formoterol/
beclametasone
Fostair 100/6 (Chiesi Limited, Manchester, UK) 6/100 120 29.32
Fostair 200/6 6/200 120 29.32
Fostair NEXThaler 100/6 6/100 120 29.32
Fostair NEXThaler 200/6 6/200 120 29.32
Formoterol/
budesonide
Symbicort 100/6 Turbohaler (AstraZeneca UK Limited, Luton, UK) 6/100 120 33.00
Symbicort 200/6 Turbohaler 6/200 120 38.00
Symbicort 400/12 Turbohaler 12/400 60 38.00
Symbicort pMDI 6/200 120 28.00
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TABLE 50 Unit costs of inhaled medication included in costing for the health economic evaluation (continued )
Medication Inhaler type
Dose per
puff (mg)
Pack size
(puffs)
Unit
cost (£)
Formoterol/
budesonide
DuoResp Spiromax 160/4.5 (Teva Pharma B.V., Swensweg,
the Netherlands)
6/200 120 29.97
DuoResp Spiromax 320/9 12/400 60 29.97
Formoterol/
fluticasone
Flutiform (Napp Pharmaceuticals Limited, Cambridge, UK) 5/50 120 14.40
Flutiform 5/125 120 28.00
Flutiform 10/250 120 45.56
Fluticasone Flixotide Accuhaler 50 (GlaxoSmithKline UK, Uxbridge, UK) 50 60 4.00
Flixotide Accuhaler 100 100 60 8.00
Flixotide Accuhaler 250 250 60 25.51
Flixotide Accuhaler 500 500 60 43.37
Flixotide Evohaler 50 50 120 5.44
Flixotide Evohaler 125 125 120 12.50
Flixotide Evohaler 250 250 120 20.00
Glycopyrronium Seebri Breezhaler (Novartis Pharmaceuticals Ltd, Dublin, Ireland) 50 30 27.50
Indacaterol Onbrez Breezhaler (Novartis Pharmaceuticals Ltd, Dublin, Ireland) 150 30 32.19
Onbrez Breezhaler 300 30 32.19
Indacaterol/
glycopyrronium
Ultibro Breezhaler (Novartis Pharmaceuticals Ltd, Dublin, Ireland) 110 10 10.83
Ultibro Breezhaler 110 30 32.50
Ipratropium
bromide
Atrovent (Boehringer Ingelheim Limited, Bracknell, UK) 20 200 5.56
Ipratropium Steri-Neb (Teva UK Ltd, Harlow, UK) 250 ml 1 ml 4.71
Ipratropium Steri-Neb 250ml 2 ml 5.61
Olodaterol/
tiotropium
Spiolto Respimat (Boehringer Ingelheim Limited, Bracknell, UK) 2.5/2.5 60 32.50
Salbutamol Airomir (Teva UK Ltd, Harlow, UK) 100 200 1.97
Airomir Autohaler 100 200 6.02
Easyhaler 100 200 3.31
Salamol Easi-Breathe (Teva UK Ltd, Harlow, UK) 100 200 6.30
Easyhaler 200 200 6.63
Salbutamol
nebulised
Salamol Steri-Neb 2.5 mg/2.5 ml 20 1.91
Salamol Steri-Neb 5mg/2.5 ml 20 3.82
Ventolin® Evohaler® (Glaxo Wellcome UK Limited, Uxbridge, UK) 100 200 1.50
Ventolin® Accuhaler® (Glaxo Wellcome UK Limited, Uxbridge, UK) 200 60 3.60
Ventolin
nebulised
Ventolin® Nebules® (Glaxo Wellcome UK Limited, Uxbridge, UK) 2.5 mg/2.5 ml 20 1.65
Ventolin® Nebules® 5 mg/2.5 ml 20 2.78
Salmeterol Neovent™ [Fannin (UK) Limited, Wellingborough, UK] 25 120 29.26
Serevent® Evohaler® (Glaxo Wellcome UK Limited, Uxbridge, UK) 25 120 29.26
Serevent® Accuhaler® (Glaxo Wellcome UK Limited, Uxbridge, UK) 50 60 35.11
Vertine 25 120 23.40
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TABLE 50 Unit costs of inhaled medication included in costing for the health economic evaluation (continued )
Medication Inhaler type
Dose per
puff (mg)
Pack size
(puffs)
Unit
cost (£)
Salmeterol/
fluticasone
Seretide 100 Accuhaler (Glaxo Wellcome UK Limited, Uxbridge, UK) 50/100 60 18.00
Seretide 250 Accuhaler 50/250 60 35.00
Seretide 500 Accuhaler 50/500 60 40.92
Seretide 100 Evohaler (Glaxo Wellcome UK Limited, Uxbridge, UK) 25/100 120 18.00
Seretide 250 Evohaler 25/250 120 35.00
Seretide 500 Evohaler 25/500 120 59.48
Sirdupla [Generics (UK) Limited t/a Mylan, Potters Bar, UK] 25/125 120 26.25
Sirdupla 25/250 120 44.61
AirFluSal Forspiro (Sandoz Limited, Camberley, UK) 50/500 60 29.97
Terbutaline Bricanyl® Turbohaler® (AstraZeneca UK Ltd, Luton, UK) 500 100 8.30
Tiotropium Braltus (Teva UK Limited, Eastbourne, UK) 13 30 25.80
Spiriva® (Boehringer Ingelheim International GmbH, Ingelheim am
Rhein, Germany)
18 30 34.87
Spiriva Respimat 2.5 60 23.00
Umeclidinium Incruse Ellipta [GlaxoSmithKline (Ireland) Limited, Dublin, Ireland] 55 30 27.50
Vilanterol/
umeclidinium
Anoro Ellipta [GlaxoSmithKline (Ireland) Limited, Dublin, Ireland] 22/55 30 32.50
Vilanterol/
fluticasone
Relvar Ellipta [GlaxoSmithKline (Ireland) Limited, Dublin, Ireland] 22/92 30 22.00
Vilanterol/
fluticasone
Relvar Ellipta 22/184 30 29.50
Aerochamber
Plus
Device 4.90
Source of unit costs: Monthly Index of Medical Specialties 201779 and British National Formulary 2017.80
TABLE 51 Unit costs of health-care resources included in costing for the health economic evaluationa,b
Resource
Currency
code
Unit
cost (£) Notes
Primary care
GP consultation at surgery N/A 36.00 9.22 minutes’ duration including direct care staff and qualifications
GP consultation at home N/A 85.00 GP home visit (9.22 minutes) plus 20 minutes’ travel time (indirect,
£147 per hour)
GP consultation by
telephone
N/A 27.36 7.1 minutes’ duration
Nurse consultation at
surgery
N/A 9.46 £56.74 per hour (including qualifications), 10-minute appointment
assumed
Nurse consultation at home N/A 23.79 10 minutes at £56.74 per hour plus 20 minutes’ travel time
(indirect, £43 per hour)
Nurse consultation by
telephone
N/A 6.71 7.1 minutes’ duration
NHS Direct consultation N/A 14.60 Costed as telephone triage (GP led)
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TABLE 51 Unit costs of health-care resources included in costing for the health economic evaluationa,b (continued )
Resource
Currency
code
Unit
cost (£) Notes
Secondary care
A&E attendances
Unspecified (all) N/A 137.74 Weighted across all specialties according to frequency (number of
attendances)
Discharged N/A 115.10
Admitted N/A 194.12
Outpatient attendances
Addiction services 721 21.30
Anticoagulant service 324 26.26
Audiology 840 58.33
Breast surgery 103 141.86
Cardiology 320 127.67
Chemical pathology 822 89.11
Colorectal surgery 104 130.32
Dermatology 330 101.63
Diabetic medicine 307 159.31
Diagnostic imaging 812 37.30 Assumed as X-ray
Endocrinology 302 157.74
ENT 120 96.87
Gastroenterology 301 136.57
General medicine 300 167.05
General surgery 100 130.06
Geriatric medicine 430 220.29
Gynaecology 502 133.01
Haematology 303 160.58
Hepatology 306 255.35
Maxillofacial surgery 144 118.90
Medical oncology 370 151.12
Mental illness 710 287.57
Nephrology 361 150.78
Neurology 400 175.60
Neurosurgery 150 205.98
Old-age psychiatry 715 171.41
Ophthalmology 460 63.46
Oral surgery 140 111.47
Pain management 191 139.12
Plastic surgery 160 99.95
Pharmacology 305 114.04
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TABLE 51 Unit costs of health-care resources included in costing for the health economic evaluationa,b (continued )
Resource
Currency
code
Unit
cost (£) Notes
Physiotherapy 650 48.33
Palliative medicine 315 207.43
Podiatry 653 42.84
Programmed pulmonary
rehabilitation
342 58.69
Radiology 811 84.52
Respiratory medicine 340 154.77
Rheumatology 410 142.74
Speech and language
therapy
652 116.05
Spinal surgery service 108 134.83
Stroke medicine 328 170.60
Thoracic surgery 173 194.31
Transient ischaemic attack 329 179.57
Trauma and orthopaedics 110 117.01
Upper gastrointestinal
surgery
106 131.80
Urology 101 105.19
Vascular surgery 107 153.01
Inpatient stays
Non-elective inpatient stay
(no further information)
3058.19 Weighted across all specialties according to frequency (number of
episodes), mean length of stay 7.87 days
Non-elective excess
bed-day
298.41 Weighted, added per day for stays of > 8 days
Elective inpatient stay
(no further information)
3749.81 Weighted across all specialties according to frequency (number of
episodes), mean length of stay 4.72 days
Elective excess bed-day 361.67 Weighted, added per day for stays of > 5 days
Non-elective short stay
(no further information)
615.83 Weighted across all specialties according to frequency (number of
episodes), mean length of stay 1 overnight stay
ENT, ear, nose and throat surgery; N/A, not applicable.
a Curtis and Burns (Personal Social Services Research Unit) 2016.78
b Curtis and Burns (Personal Social Services Research Unit) 2015106 (inflated).
All inpatient stays with reason/description were costed according to the indication using appropriate currency codes.
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Results
TABLE 52 Total medication costs recorded for the CRP POCT and control arms during the trial follow-up period
Medication
Trial arm, total cost (£)
Difference (£)CRP POCT (n= 325) Usual care (n= 324)
Antibiotics
Cost at index consultation 203.29 292.34 –89.05
Cost at 6-month review 668.33 617.80 50.53
Oral steroids
Cost at index consultation 244.02 236.68 7.34
Cost at 6-month review 335.37 380.09 –44.72
Inhaled medications
Cost at index consultation 1017.50 993.50 24.00
Cost at 6-month review 3053.75 2338.51 715.24
Total medication cost
Cost at index consultation 1464.81 1522.52 –57.71
Cost at 6-month review 4057.45 3336.39 721.05
TABLE 53 Total primary care costs recorded for the CRP POCT and control arms for any reason during the trial
follow-up period
Health-care resource
Trial arm (£)
Difference (£)CRP POCT (n= 275) Usual care (n= 280)
Primary care: total cost in 4-week follow-up period
GP visits at surgery in 4 weeks’ follow-up 3960.00 5076.00 –1116.00
Nurse visits at surgery in 4 weeks’ follow-up 765.99 690.34 75.65
GP visits at home in 4 weeks’ follow-up 340.00 425.00 –85.00
Nurse visits at home in 4 weeks’ follow-up 23.79 47.58 –23.79
GP telephone consultations in 4 weeks’ follow-up 820.80 1121.76 –300.96
Nurse telephone consultations in 4 weeks’ follow-up 60.43 53.71 6.71
Other health-care contacts in 4 weeks’ follow-up 511.00 467.20 43.80
Total cost of primary care use in 4 weeks’ follow-up 6482.01 7881.59 –1399.58
Primary care: total cost in 6-month review period for any reason
n = 304 n = 302
GP visits at surgery 35,748.00 34,524.00 1224.00
Nurse visits at surgery 5484.87 5049.86 435.01
GP visits at home 2125.00 2890.00 –765.00
Nurse visits at home 547.17 428.22 118.95
GP telephone consultations 8481.60 7633.44 848.16
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TABLE 53 Total primary care costs recorded for the CRP POCT and control arms for any reason during the trial
follow-up period (continued )
Health-care resource
Trial arm (£)
Difference (£)CRP POCT (n= 275) Usual care (n= 280)
Nurse telephone consultations 423.00 396.14 26.86
Other contacts 85.14 66.22 18.92
Total cost of primary care use 52,894.77 50,987.88 1906.89
Primary care related to COPD: total cost in 6-month review period for COPD-related reasons
GP visits at surgery 13,968.00 15,120.00 –1152.00
Nurse visits at surgery 2222.32 2014.27 208.05
GP visits at home 935.00 1360.00 –425.00
Nurse visits at home 0.00 333.06 –333.06
GP telephone consultations 3310.56 3392.64 –82.08
Nurse telephone consultations 248.43 228.28 20.14
Other contacts 28.38 47.30 –18.92
Total cost of primary care use 20,712.68 22,495.55 –1782.87
TABLE 54 Total secondary care costs recorded for the CRP POCT and control arms during the trial follow-up period
Health-care resource
Trial arm (£)
Difference (£)CRP POCT (n= 275) Usual care (n= 280)
Secondary care: total cost during the 4-week follow-up period
A&E visits 1903.38 1433.78 469.60
Outpatient appointments 3988.74 5874.06 –1885.32
Inpatient stays 14,389.09 8804.48 5584.62
Other secondary care use 2212.75 2942.83 –730.08
Total cost of secondary care use 22,493.96 19,055.14 3438.82
Secondary care: total cost in the 6-month review period for any reason
n = 305 n = 302
A&E visits 11,294.68 10,468.24 826.44
Outpatient appointments 46,356.10 47,568.97 –1212.87
Inpatient stays 106,046.95 70,106.45 35,940.50
Total cost of secondary care use 163,697.73 128,143.66 35,554.07
Secondary care related to COPD: total cost in the 6-month review period for COPD-related reasons
A&E visits 4958.64 4407.68 550.96
Outpatient appointments 7337.58 11,127.03 –3789.45
Inpatient stays 40,919.04 37,317.07 3601.97
Total cost of secondary care use 53,215.26 52,851.78 363.48
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